

STORAGES

# Clinical Research

## PROCEEDINGS

Official Publication of The American Federation for Clinical Research

VOL. IV, NO. 4

NOVEMBER, 1956

### IN THIS ISSUE

REFERENCE SET  
NON-CIRCULATING

---

STATISTICS AND THE INDIVIDUAL PATIENT, *page 225*

MEDICAL RESEARCH IN THE AREA OF THE SOUTHERN SECTION  
OF THE AMERICAN FEDERATION FOR CLINICAL RESEARCH, *page 227*

NOTICES, *page 229*

PROGRAM, MIDWESTERN SECTION, *page 230*

ADVANCE RESEARCH REPORTS SUBMITTED TO THE ANNUAL MEET-  
ING OF THE MIDWESTERN SECTION, AMERICAN FEDERATION FOR  
CLINICAL RESEARCH, CHICAGO, NOVEMBER 1956, *page 232*

ANNUAL AUTHOR INDEX, *page 259*

ANNUAL SUBJECT INDEX, *page 263*

---

Published by Grune & Stratton, Inc.

V

=

=

err  
ful  
ap  
an  
to  
by  
pri  
cis  
sts  
jud  
an  
his  
ran  
of  
the

vic  
vic

jud  
ica  
of  
tai  
ap  
see  
pa  
po  
dis  
wa  
les  
log  
na  
ste

me  
t-t  
can  
is  
am  
rel  
sid  
ga  
me

ver

### Statistics and the Individual Patient

By Eric Reiss\*

AMONG THE MOST astonishing features of modern science of statistics is the ease with which powerful statistical methods can be employed. This ease of application has invited widespread use in research, and it has become customary for editors and readers to frown upon data whose validity is not sanctified by some statistical manipulation, however inappropriate it may be. It is therefore surprising that clinicians feel compelled to apologize whenever they use statistical reasoning in arriving at a diagnostic judgment, as though this sort of reasoning were an admission of utter failure. If the clinician bases his judgment in part on statistical information, he rarely does so without quickly stating his recognition of the fact that "statistics don't mean anything in the individual case."

In order to examine the validity of this point of view, a few basic statistical concepts must be reviewed.

In the final analysis, all diagnoses are statistical judgments. This is true of histologic as well as clinical diagnoses. One is reminded, in this connection, of a pathologist who diagnosed carcinoma of a certain organ on the basis of the characteristic histologic appearance. When, 15 years later, the patient was seen again, apparently in excellent health, the pathologist unhesitatingly obtained his original report and changed its wording to indicate a benign diagnosis. His concept of carcinoma of this organ was sufficiently rigid that he could not conceive of lesions having similar appearance but varying biologic behavior. It is the remarkable variation in the natural history of many diseases that invites a statistical orientation.

When an investigator compares two sample means by the appropriate statistical arithmetic, say a *t*-test, and concludes that the means differ significantly at a stated level of probability, his conclusion is based on *individual* samples. These are generally small in an absolute sense, and very small indeed in relation to the population of which they are considered to be random representatives. The investigator always recognizes that his particular sample may have been unusual, and the possibility of error

due to sampling is quantitatively expressed by the probability statement. If statistics were useless when applied to individual samples, the investigator would have to test the entire population. This is generally impossible. The overwhelming value of statistical technics is due to the fact that their intelligent application makes possible inductive reasoning from individual to population. Whatever the reasons for the difficulties in applying statistics in clinical diagnosis may be, they certainly have nothing to do with the clinician's concern with individual patients.

By a comparison of statistics as applied in the laboratory and the clinic, it is possible to bring the clinical difficulties into sharper focus. In the example given in the preceding paragraph, the test of significance could not prove that the samples were different. The test indicated only that differences as great as those observed would occur owing to chance variation in only rare samples. If chance is an unlikely explanation for the observed differences, other factors presumably produced them. The test of significance yields absolutely no information about what these factors may be. Such information is obtained only from the actual conduct of the experiment: if treatments *X* and *Y* were assigned at random to individuals drawn from a population, and uniform experimental procedure was observed throughout, some of the difference in effect between the *X*-treated and *Y*-treated individuals is probably due to differences between *X* and *Y*.

The investigator's advantages over the clinician may now be noted: (1) He can test an exact hypothesis. This is generally the so-called null hypothesis, which states that samples are random representatives of the same population, with factors *X* and *Y* having no real effect. This hypothesis can never be proved, but may be rendered very unlikely. (2) Having rejected the null hypothesis, the investigator possesses a knowledge about the cause or causes of observed differences from the way in which the experiment was conducted.

By contrast, the clinician generally obtains little diagnostic help from a test comparable to the test of the null hypothesis. He is interested in the causes of certain effects, and testing the null hypothesis—as the investigator's example illustrates—yields no information whatever about these. Suppose that

\* Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.

factor  $Z$  has been measured in the serum of many normal persons, and that its distribution has been carefully determined. If a patient's serum is now tested for this factor, one may calculate the probability that the patient's serum could be a random sample of the population of normal sera. If this probability is very small, it may be concluded that the patient is abnormal as regards this factor. But if abnormal, what disease entity is suggested by the measured abnormality? To answer this question, information is required about all possible disease populations. The population of which the patient's serum is most likely to be a random sample is more strongly suggested than others. In practice, such reasoning is rarely helpful because abnormal populations tend to be rather alike, and, in general, too little is known about the distributional characteristics of abnormal populations. It should be noted that the present example is analogous to the preceding one; we are dealing here with a single serum, which is simply the mean of one serum. The investigator dealt with a single sample composed of several individuals, but the logical problem is the same in both instances: testing whether an individual could be considered to belong to a specified population.

These arguments may be summarized as follows: Both investigator and clinician deal with individuals chosen from very large populations. Having performed a well-designed experiment, the investigator can determine the probability that his samples came from a specified population. If this probability is very small, he rejects the null hypothesis and concludes that the samples probably belong to different populations. With this conclusion, he immediately knows from what populations the samples were probably derived. The clinician, on the other hand, knows little about the population to which his patient may belong after rejecting the null hypothesis. Probability-testing alone restricts both investigator and clinician to the negative conclusions that the individual sample or individual person is unlikely to belong to a specified population, though the degree of unlikelihood may be quantitatively assessed. The positive proposition that an individual does belong to a specified population defies quantitation.

The actual application of statistical reasoning in clinical medicine is not as difficult as these remarks may imply. In general, the diagnosis can usually be narrowed down to two or three major diagnostic possibilities, and it is the choice between them that taxes the clinician's skill and judgment. Consider a simple, idealized example: In a particular patient, all diagnostic aids point towards a choice between two diseases, but there are no clues to aid in the differentiation. If one of these diseases is known to occur twice as frequently as the other, the clinician has twice as good a chance of being right when he decides in favor of the more common disease. Of course, this sort of reasoning is correct only if (1)

the frequency of occurrence of the diseases is actually known, and (2) there really are no discernible distinguishing features between the diseases. The essential point of the argument is that, given these conditions, the probability considerations can be definitely applied to an individual patient. The probability that the patient has one or the other disease cannot be estimated, but the relative probability can be obtained, at least in this idealized case. In practice, the true frequencies may be known only within rather wide ranges, and powerful diagnostic hints are often overlooked. The good clinician assiduously searches for these hints. Textbooks and the literature abound with data that partially characterize disease populations, and these data are extremely useful for the physician dealing with an individual patient. Documented experience thus supplies the valid basis for inductive inferences that result in a diagnosis. Insofar as such experience is properly obtained, it permits some quantitative probability estimates, and therefore comes within the proper domain of statistics.

There is an unfortunate tendency toward careless collection and interpretation of clinical statistical data. Clinical papers are often deplorably vague about the method of patient selection used. Patient populations vary widely between various localities.\* Since reported data usually deal with small samples, population estimates derived from such samples are subject to large variation.

All these difficulties call for more, and not less, good statistics. Many excellent volumes have been written about the features of good statistics (which is the basis of proper induction) and the features of bad statistics (which is the basis of confusion and error). All that needs to be said here is that unbiased sampling from well defined populations is one of the most important features of good statistics.

The good, experienced clinician, of course, uses his own past acquaintance with disease as a statistical yardstick, even if he has never heard of samples, populations, induction and null hypotheses. However much one may resent it, diagnoses are statistical judgments. If these judgments are formulated purposefully and based on the experience of a large number of competent observers, so much the better and an apology is hardly in order.

---

\* The difference between populations is particularly striking in diagnostic exercises like clinicopathologic conferences. Here very unusual populations are sampled—difficult or unusual problems. Institutions vary in their preference for different kinds of cases. A physician is well justified in making a diagnosis at such a conference that he would not make at a bedside. After all, he is sampling an entirely different population, and a most unusual one at that.



---

---

## Medical Research in the Area of the Southern Section of the American Federation for Clinical Research\*

By John H. Moyer†

---

---

WITH THE DEVELOPMENT of new schools and the expansion of older ones throughout the south, many opportunities have become available for enterprising young men interested in medical research. Since I originated from an old traditional school—the University of Pennsylvania—and later moved to a relatively new medical center in Houston, I felt that a worthwhile topic for my discussion today would be medical research as seen through the eyes of a young investigator in the Southern Section of the AMERICAN FEDERATION FOR CLINICAL RESEARCH. Furthermore, I should like to make a few suggestions as to how I think this organization now serves, and might better serve, the younger clinical investigators throughout the South. The latter proposal is particularly pertinent since the AMERICAN FEDERATION FOR CLINICAL RESEARCH was conceived and organized for the purpose of stimulating research among young investigators in the clinical and allied medical sciences.

Medical research is a relatively new experience in many areas in this section of the country, and, therefore, the medical investigator is faced with problems which are entirely different in comparison to those present in established traditional institutions. The investigator, even though a novice, must develop his own program and pattern of activity, a responsibility usually entrusted only to the wise, mature and well-seasoned men in the traditional atmosphere. In many areas of the South the clinical investigator cannot depend on fixed administrative channels and old established rituals to support his activities. Usually he finds a shortage of medical personnel, rather than three teams for every job. He must adapt his program so that his research is not only investigative, but that it also offers something toward the medical care of heavy patient loads.

As a clinical investigator born and trained in the atmosphere of tradition, the following observations based on experience in a relatively new medical school stand out in my mind:

(1) The academician may easily find himself completely occupied with routine patient care. To achieve a better work balance requires organization, persistence, tenacity and drive toward maintaining the kinetics of a research program; otherwise, re-

search is sacrificed and the academic clinician becomes a slave to full-time routine care of patients—a position which continues to be fostered by many medical school and hospital administrators.

(2) To keep a research program going requires adaptability on the part of the clinician. If obstacles arise in one area, it is necessary for the investigator to take the next avenue of approach, but he must keep driving continually. Although the program may at times move forward in a somewhat tangential course, at least it will move forward. One cannot afford to become frustrated and beaten, for, if this occurs, the program disintegrates in short order due to the absence of "traditional administrative channels and support." The same circumstances which foster opportunities for the young investigator in the untraditional centers become liabilities if the investigator loses his drive and kinetic approach.

(3) At the same time the investigator cannot afford to subjugate all efforts to his research aims. In the over-all program, patient care must exist if the investigator is to obtain cooperation from medical school and hospital administrators, as well as from the allied services. When there is a shortage in medical personnel, the investigator must give at the same time that he takes. It is not often possible for the clinician in this area to isolate himself to gadgeteering in the field of so-called "pure research."

(4) It seems to me that the best clinical research program is the one which combines research, patient care and teaching in a well-organized manner. The research program should be integrated into the over-all academic program. This program should include students, residents and staff men, not merely as props, but as "active characters in the play." In the research program, residents and students, when possible, should enter into the experimental design and the conduct of the experiment, and not simply act as the "guinea pigs" or subjects. This allows for stimulation and greater motivation of men who subsequently will form a reservoir of academicians and medical investigators. The AMERICAN FEDERATION FOR CLINICAL RESEARCH has most to offer to this latter group of investigators. Of necessity, numerous research projects will have to be designed for all levels of research experience. This will include projects which require high degrees of technical skill and experience, along with some well-designed, but not overly complicated experiments, so that the inexperienced investigators may develop insight into the problems under study.

---

\* Chairman's Address, annual meeting of the Southern Section, American Federation for Clinical Research, New Orleans, January 1956.

† Baylor University College of Medicine, Houston, Texas.

(5) Finally, the responsible investigator should be cognizant of the fact that a research program is composed of men and women. One of the outstanding reasons for failure of research programs is our occasional inability to live with one another and appreciate our fellow-man. Research might better be looked on as a privilege. Let us be honest with our peers, and with ourselves, and use research in the quest for scientific truth rather than as an end to personal gain. If this quest be the prime motivating force, animosities among collaborators and contemporaries in research programs will be less in evidence. When research is a team enterprise, let each member obtain his just due, irrespective of his station in life, school appointment, rank, or what have you. When these principles are followed, team-mates in a research organization rarely strike out!

This brings me to the second point in this discussion. How can the AMERICAN FEDERATION FOR CLINICAL RESEARCH help the young investigator in the Southern Section?

Let me begin by outlining a brief background of this organization. The AMERICAN FEDERATION FOR CLINICAL RESEARCH was founded in May, 1940, but the first constitution was not adopted until 1947. A brief outline of the history of the organization is presented in the September 1955 issue of CLINICAL RESEARCH PROCEEDINGS by Dr. Beierwaltes, who was President at that time. The purpose of the organization is to provide a medium in which young investigators may get together and present and discuss the results of their research activities. The organization for such exchanges has been developed at three levels: (1) local research clubs, (2) four sectional groups (Eastern, Midwestern, Western and Southern) and (3) the annual (National) meeting. The total membership, which now exceeds 2500, is not to be limited. The national organization supports the publication of CLINICAL RESEARCH PROCEEDINGS, which is distributed to all members at a nominal cost.

Although the national organization has moved along rather rapidly, the Southern Section has not kept pace. This is owing largely to the fact that *lack of activity and responsibility among officers and members* has predominated, rather than organization, kinetics and activity. The latter, not the former, makes for a strong organization. This criticism I can apply without malice toward former officers of the section, since I am open to the same criticism, having been an officer of this Section for four years. How can we improve this situation? I believe that the following points are worthy of consideration, not only for the Southern Section but for other sections as well:

(1) *Program of the Southern Section:* papers for presentation should be selected on the basis of the following considerations:

- (a) Excellence of research projects.
- (b) Preference to young investigators for the

presentation of papers. The members should keep this in mind when preparing abstracts. An individual should present only one paper at a meeting, and the paper should be presented by one of the younger authors whenever possible.

(c) A geographic distribution for selection of abstracts, in order to stimulate areas which are less active. If papers from one or two areas completely dominate the program, members from other areas which are new and less well-established become discouraged. Furthermore, the various areas which have many members have the option of setting up FEDERATION research clubs which will permit all of the investigators to present papers in those areas which have a large number of members. A number of such clubs has already been established in the Southern Section. When all areas have become strong and well-established, then excellence of the research project alone can be the sole consideration.

(d) A broad spectrum of papers, representing a variety of subject matter.

(e) Expanded meeting facilities. When the number of abstracts submitted for the annual meeting of the section exceeds by three times the number on the program, then two simultaneous panels should be set up or the meeting extended to two days.

(2) *A Policy and Membership Committee should be established with the Secretary-Treasurer of the Section acting as Chairman.* This should be a semi-permanent committee with each appointee serving several years on a staggered system. A replacement should be appointed each year by joint action of the Chairman and Secretary of the Section. A minimum of one member from each state should be on the committee. The members should be active throughout the year and should meet at the annual meeting of the Section. The Chairman of the committee should make a formal report each year at the business meeting. The purpose would be to develop policies and keep in contact with all geographic areas within the section in regard to ideas for improving the function of the organization, developing research clubs, and maintaining communication with active investigators and prospective members.

(3) *Improve liaison with the national organization.* It has become essential that the liaison and administrative channels be improved between the various sections of the AMERICAN FEDERATION FOR CLINICAL RESEARCH and the national organization. Let's make this a two-way organization! Presently, there is not much in common between the administrations of the national organization and the sections. There is a minimum of communication between the two. The sectional officers receive no reports from the annual council meeting or the business meeting of the national organization. There are no officers in common. The sectional chairmen attend one national council

meeting, but then retire, and there is no continuity of thought relative to organizational procedures and activities. The Chairman and Secretary-Treasurer of the national organization are selected from the national council members who are not selected by the section. Consequently, the officers are chosen by acquaintances rather than by sectional distribution, since the national officers are selected by a nominating committee, the members of which may have little if any relationship to or knowledge of the various geographic sections.

I would suggest that the council of the Southern Section consist of seven members: the Chairman, past Chairman, Secretary-Treasurer, the National Councillor of the Southern Section, and three Sectional Councillors. The Southern Section should select three sectional councillors to serve a term of

three years, and one National Councillor to serve a term of five years. The national councillor should also serve as a fourth sectional councillor. An amendment should be made to the national constitution that national councillors must be elected from among the sectional councillors of the section. This will always mean that at least one individual will be serving at both the sectional and national levels. National councillors would serve a term of five years.

Reports of both the annual (National) council meeting and the annual business meeting should be made available to the officers of the various sections well in advance of the sectional meetings. This will allow items of business to be discussed which were brought before the national meeting and which are of importance to the sections.

## NOTICES

### Members Lost to the National Office

It would be appreciated if each member would review the following list and notify Dr. William W. Stead (V. A. Hospital, Minneapolis 17, Minnesota) of the current address of anyone on the list whom he recognizes:

W. J. Butt	John F. Gillespie
Ronald T. Cape	Marvin M. Hirsch
Roy C. Crosby	Erwin Huston
Vincent J. Fontana	Robert L. Johnson
George L. Forbes, Jr.	Donald F. Marion
Goffredo G. Gensini	Mary L. Scholl
Michele Gerundo	John R. Sheehan

Santos Silva  
Bernard M. Wagner

Walter S. Wiggins  
Irvin Zeavin

### Forthcoming Meeting

The tenth annual meeting of the Western Society for Clinical Research will be held Thursday afternoon, Friday morning and Saturday morning, January 31st through February 2nd, 1957, at Carmel-by-the-Sea, California.

Information regarding the meeting may be obtained from Dr. Arthur J. Seaman, Secretary-Treasurer, Western Society for Clinical Research, University of Oregon Medical School, Portland 1, Oregon.

---

---

## PROGRAM, MIDWESTERN SECTION

---

---

American Federation for Clinical Research

Thursday, November 8, 1956

Thorne Hall, Northwestern University, Chicago, Illinois

**Dr. Harper K. Hellems, Presiding**

*Presentations will be limited to ten minutes*

---

---

9:00 a.m.

1. Nephrotic Syndrome in Adults.  
*Victor E. Pollak, Robert M. Kark,† Conrad L. Pirani\* and Robert C. Muehrcke.* Chicago  
page 250
2. Changes in Body Water Compartments During the Course of Acute Renal Insufficiency.  
*Alexander P. Remenchik, James A. Schoenberger and Josephine M. Dyniewicz.\** Chicago.  
page 252
3. The Ratio  $\frac{Tm}{\text{Renal Weight}}$ : An Index of Renal Scarring.  
*A. P. Crosley, Jr., J. F. Brown,\* B. Schuster,\* D. A. Emanuel,\* H. Tuchman, C. Castillo\* and G. G. Rowe.* Madison, Wisc. page 252
4. Relation of Renal Vein Pressure to Renal Vascular Resistance and Urine Flow Rate.  
*Francis J. Haddy, Malcolm Fleishman\* and Jerry Scott.\** Fort Knox. page 252
5. Cutaneous Necrosis Due to Norepinephrine: Mechanism and Prevention.  
*A. Stephen Close\* and Ross C. Kory.* Wood, Wisc. page 241
6. Mechanism of Increased Serum Activity of the Enzymes, Glutamic-Oxaloacetic Transaminase (SGO-T), Glutamic-Pyruvic Transaminase (SGP-T), and Lactic Dehydrogenase (SLD), Following Myocardial Infarction in the Dog.  
*Irwin Nydick, Paul Ruegsegger,\* Felix Wroblewski and John S. LaDue.†* New York.  
page 240

### INTERMISSION (10 Minutes)

*Refreshments courtesy of G. D. Searle & Co.*

7. Nitrogen Clearance Rates of Right and Left Lungs in Different Postures.  
*Glen A. Lillington,\* R. Drew Miller, Ward S. Fowler† and H. Frederic Helmholtz, Jr.†* Rochester, Minn. page 256

\* By Invitation

† Senior Member

8. A Rapid Colorimetric Method for the Determination of Oxygen Saturation of Whole Blood by Reflectance.  
*William Meltzer\* and George A. Saxton, Jr.* Chicago. page 255
9. Endobronchial Involvement in Systemic Sarcoidosis.  
*Gordon L. Snider and S. Allen Mackler.\** Chicago. page 257
10. Probable Mechanism of Ventricular Fibrillation and Cardiac Arrest Following Hypercapnia.  
*Ananda S. Prasad, E. B. Brown, Jr.\* and Edmund B. Flink.†* Minneapolis. page 239
11. The Neutralizing Antibody Response to Adenovirus Infection.  
*J. Thomas Grayston, Clayton G. Loosli,\* Paul B. Johnston,\* Mabel E. Smith\* and Robert L. Woolridge.\** Chicago. page 250
12. Metabolic Interrelations of Calcium and Magnesium in Patients With and Without Osteolytic Disease.  
*William O. Smith\* and Leonard P. Eliel.* Oklahoma City. page 245

1:00 p.m.

### LUNCHEON AND BUSINESS MEETING

Abbott Hall Dining Room

*Courtesy of Eli Lilly and Company*

2:00 p.m.

13. The Effect of Bromine Ion on  $I^{131}$  Thyroid Function Studies.  
*Richard E. Peterson and Masa Yamamoto.\** Iowa City. page 242
14. The Hyperglycemic Response as a Measure of Glucocorticoid Potency.  
*Kelly M. West and James A. Hagans.* Oklahoma City. page 244

15. Comparative Effects of Insulin and Orinase on Blood Levels of Pyruvate and Alpha Ketoglutarate in Normal Subjects.  
*Allen R. Hennes,\* Bernardo L. Wajchenberg, Stefan S. Fajans and Jerome W. Conn.\** Ann Arbor. *page 242*
16. The Effect of the Administration of an Intravenous Fat Emulsion Upon the Blood Lipids of Normal and Hospitalized Subjects.  
*Jack M. Iacono,\* William W. Cleland,\* Lucille Palm\* and John F. Mueller.* Denver. *page 245*
17. 5-Nucleotidase Activity of Human Serum.  
*Irving I. Young.* Detroit. *page 246*
18. Percutaneous Transhepatic Cholangiography.  
*William T. Fitzgerald,\* James C. Redington\* and William A. Knight, Jr.* St. Louis. *page 248*
- INTERMISSION (10 Minutes)
19. Hepatic Function and Morphology in Chlorpromazine Jaundice as Affected by Continued Administration of Chlorpromazine.  
*Edward M. Schneider, Charles Daugherty\* and James K. DeVore.\** Oklahoma City. *page 248*
20. Significance of Increased Urinary Pepsinogen (Uropepsin) Excretion in Duodenal Ulcer and During ACTH Administration.  
*B. I. Hirschowitz, D. H. P. Streeten and H. M. Pollard.†* Ann Arbor. *page 247*
21. C.I.B.H.A. Infuscusuria: A New Clinical Syndrome.  
*Robert D. Lange and Joseph H. Akeroyd.\** Washington, D. C. *page 234*
22. Homozygous Hemoglobin-D Disease.  
*Amos I. Chernoff, George Smith\* and Ruth Steinkamp.* St. Louis. *page 233*
23. Cobalt-60 Labeled Vitamin B-12 Absorption and Excretion Studies Using Timed Release Capsules.  
*Philip C. Johnson and E. Stanley Berger.\** Oklahoma City. *page 234*
24. Erythrocyte Radioiron Uptake in the Rat and the Effects of Cobalt Administration.  
*Donald R. Korst and Frank H. Bethell.†* Ann Arbor. *page 232*

### Officers of the Midwestern Section

#### CHAIRMAN

Harper K. Hellemis, M.D.  
Detroit, Michigan

#### SECRETARY

James F. Hammarsten, M.D.  
Oklahoma City, Oklahoma

#### COUNCILLORS

Robert P. Gilbert, M.D., *St. Paul, Minnesota*  
William Harrington, M.D., *St. Louis, Missouri*  
Walter Kirkendall, M.D., *Iowa City, Iowa*

John F. Mueller, M.D., *Denver, Colorado*  
Robert J. Rohn, M.D., *Indianapolis, Indiana*  
Richard Westcott, M.D., *Cleveland, Ohio*



---

---

Advance Reports Submitted to the Annual Meeting of the  
**Midwestern Section**  
of the  
American Federation for Clinical Research

---

---

Thorne Hall, Chicago, Illinois • Thursday, November 8, 1956

---

---

BLOOD, 232

CARDIOVASCULAR SYSTEM, 238

ENDOCRINES AND METABOLISM, 241

GASTROINTESTINAL SYSTEM, 247

INFECTIOUS DISEASES, 249

KIDNEY, 252

NERVOUS SYSTEM, 253

RESEARCH METHODS, 254

RESPIRATORY SYSTEM, 256

---

---

## BLOOD

### Long-Term Studies of Iron Overload in Dogs

By *Elmer B. Brown, Jr., David E. Smith, Reubenia Dubach, César Reynafarje and Carl V. Moore.*  
Department of Medicine, Washington University  
School of Medicine, St. Louis.

Large amounts of iron as saccharated iron oxide or as hemoglobin from transfused red blood cells were given to 6 dogs to determine the effects of prolonged iron-overload and in an attempt to produce hemochromatosis. Intravenously administered saccharated iron oxide was given in 100 to 200 mg. daily doses to a total iron concentration of 0.5 Gm./Kg. in 2 dogs and 1.0 Gm./Kg. in 2 others. Transfusions of whole blood totalling more than 12 L. were given to each of 2 dogs to yield concentrations of 0.5 Gm./Kg. hemoglobin iron. At intervals during a 7-year period of observation, blood counts, serum iron, fasting blood sugar, serum bilirubin, bromsulfalein retention and serum protein determinations were done. Tissue samples for iron analysis and histologic study were obtained by biopsy initially, at 6 months and 3 years after beginning iron administration, and at autopsy.

Despite concentrations of iron chosen to be comparable to those found in human hemochromatosis, there were no findings in the dogs suggestive of hemochromatosis. Acute toxicity was minimal in spite of greatly elevated serum iron levels, and no laboratory evidence of cirrhosis or diabetes was obtained. Blindness due to retinal degeneration of unknown pathogenesis was the only long-term abnormality noted. Major tissue iron deposits were

confined to the liver, spleen, mesenteric lymph nodes and bone marrow, with only a slight sprinkling of hemosiderin in the pancreas and other organs. Although parenchymal iron deposition was seen, the predominant distribution was in the reticuloendothelial cells whether the iron came from hemoglobin catabolism or from saccharated iron oxide. No fibrosis or cirrhosis was produced by the iron deposits in the liver or elsewhere.

One of the principal problems in the pathogenesis of hemochromatosis is whether increased tissue iron deposits by themselves eventually produce cirrhosis and pancreatic fibrosis, or whether additional factors must be present. The results of these studies suggest that prolonged tissue iron-overload in concentrations comparable to those of human hemochromatosis is well tolerated, and in a 7-year period of observation does not of itself produce hemochromatosis in the dog.

### Erythrocyte Radioiron Uptake in the Rat and the Effects of Cobalt Administration

By *Donald R. Korst and Frank H. Bethell.* Radioisotope Service, Ann Arbor V.A. Hospital, and the Department of Medicine, University of Michigan School of Medicine, Ann Arbor.

Twenty groups of 4 to 6 each of normal or hypophysectomized white (Sprague-Dawley) rats weighing 150-360 Gm. were given radioiron, and the response observed over a 3- to 5-day period. Several strengths of cobalt were given for 3 and 25 days prior

to the i.v. injection of  $\text{Fe}^{59}$ . Splenectomy did not alter the responses.

The methods used are patterned after those of Plzak et al. It has been found that minimal blood loss is important in this test, and that the best-suited rats are in the 150 to 200 Gm. weight range. Large rats have too high an uptake to be good test animals. The normal rats have an average % radioiron utilization, 1 day after injection, of  $36 \pm 10\%$  (1 s.d.) the second day of  $51 \pm 9\%$ , the third day of  $48 \pm 7\%$  and the fifth day of  $55 \pm 11\%$ . The fifth day determination was always on the uptake plateau, and therefore was eliminated. Hypophysectomized rats (10 days or more post-operatively) have the following average radioiron uptakes: first day,  $12 \pm 4\%$ ; second day,  $19 \pm 9\%$ ; third day,  $32 \pm 10\%$  and fifth day,  $28 \pm 9\%$ . The method entails i.v. injection of ferrous citrate ( $\text{Fe}^{59}$ ) and withdrawal of .02-ml. blood specimens from which hemoglobin is determined and radioactively counted in 2-ml. aliquots. A standard to represent total injection radioactivity (about 2  $\mu\text{c.}$ ) is made up in the same syringe. Using these values plus the average weights (4.59% body weight, after Berlin et al.) and average hemoglobins of each rat, the following formula is applied:

$$\frac{\% \text{ RBC } \text{Fe}^{59} \text{ Uptake}}{\frac{\text{c/m (2 ml. of sample)} \times \text{Wt. (Gm.)} \times \text{Hgb. (Gm./100 ml.)} \times .306}{\text{c/m (2 ml. of Std.)}}}$$

The results are expressed as the average of each group of 4 rats.

Cobalt administration causes an increased radioiron utilization in the 70-100% range for normal rats, and in the 40-50% range for the hypophysectomized rat. The rate of red cell uptake is accelerated to a comparable degree whether the cobalt is given for 3 or 25 days. The effects of cysteine, histidine, and methylene blue on the effect of cobalt changes in ferrokinesics are being studied. Protein-free extracts of human plasma are also being tested using the rat radioiron uptake as an assay method.

#### Identification of Sick Cell-Hemoglobin D Disease by Solubility Studies in Phosphate Buffer

By Jerome L. Silverman and Amos I. Chernoff.  
Department of Internal Medicine, Washington University School of Medicine, St. Louis.

The identical electrophoretic mobility of hemoglobins S and D makes it impossible to differentiate the heterozygous combination, sickle cell-hemoglobin D disease, from homozygous hemoglobin S disease by electrophoretic technic alone. Furthermore, no method has been available to quantitate the percentages of hemoglobin S or D in a mixture of these 2 pigments. The discovery of a Negro female patient with homozygous hemoglobin D disease has made it possible to determine the solubility of reduced hemoglobin D in phosphate buffer using a slight modification of the method of Itano. In addition,

a standardization curve has been constructed by using various combinations of hemoglobins S and D and plotting the percentage of each component against the solubility of the mixture.

The solubility of a specimen of reduced hemoglobin D was found to be  $1.43 \pm 0.01$  (s.d.) Gm./L. in 2.58 M phosphate buffer at  $25^\circ \text{C}$ . Serial dilution of this specimen (90% hemoglobin D-10% S, 75% D-25% S, 50% D-50% S, 25% D-75% S, 10% D-90% S) was made with reduced hemoglobin solutions from 2 patients with homozygous hemoglobin S disease, the solubilities of which were  $0.23 \pm 0.01$  Gm./L. and  $0.30 \pm 0.02$  Gm./L. Both homozygous patients had approximately 2% hemoglobin F as shown by the alkali denaturation technic. Determination of the solubilities of the mixtures so prepared indicated a curvilinear relationship between the solubilities for 100% hemoglobin D and 100% hemoglobin S.

Since the solubility of a 50-50 mixture of D and S in both cases was more than twice that of S alone, this technic may be utilized to differentiate the 2 conditions, thus allowing further study of sickle cell-hemoglobin D disease. Also, use of the standardization curves allows the approximate percentages of D and S to be determined, once this disease is distinguished from homozygous S disease by the greater solubility of its hemoglobins.

#### Homozygous Hemoglobin D Disease

By Amos I. Chernoff, George Smith and Ruth Steinkamp. Department of Internal Medicine, Washington University School of Medicine, St. Louis.

The prevalence of the heterozygous form of hemoglobin D (D trait) in the Negro has been established to be 0.4%. It may be calculated that the homozygous state for hemoglobin D should occur in 1 out of 250,000 Negroes. One such individual has been observed, and the syndrome of homozygous hemoglobin D disease has been characterized.

The patient, a 40-year-old Negro, had always been in good health except for some easy fatigability for 10 or more years. Physical examination was within normal limits. She has a light complexion and features are not typically negroid. Hematologic studies were as follows: red cells, 5,500,000 to 6,500,000 per mm.<sup>3</sup>; hemoglobin, 12.5-13.5 Gm. %; hematocrit, 38%; MCV 67  $\mu^3$ ; MCH, 23  $\gamma\gamma$ ; MCHC, 35%. Leukocyte and platelet counts were normal; reticulocytes, 1.8%. The erythrocytes appeared somewhat hypochromic and microcytic with slight anisocytosis and poikilocytosis. Target cells comprised 60-70% of the red cells. The bone marrow revealed a moderate erythrocytic hyperplasia. The osmotic fragility curve was shifted symmetrically to the right with 10% hemolysis occurring at 0.34% saline and 90% hemolysis at 0.20% saline. Coombs' test was negative. Van den Bergh and liver

function tests were normal. Serum iron and iron-binding capacity were normal. The hemolytic index was 12. Cr<sup>51</sup>-tagged red cells disappeared somewhat more rapidly than normal, half-time being 21 days. Paper electrophoresis studies of the patient's hemoglobin indicated a single component moving in the position of hemoglobin S. Sickling of the red cells was absent, and gelling could not be induced in a concentrated reduced solution of hemoglobin. Hemoglobin solubility in 2.58 M phosphate buffer at 25°C was 1.3 Gm./L. The alkali denaturation test for hemoglobin F was normal.

Family studies revealed that the patient's 3 sisters have hemoglobin D trait, while none of 3 half-brothers has hemoglobin D. Neither parent is living, but several of their relatives also lack hemoglobin D. In addition to Negro blood, white English and American Indian ancestry are present in the kinship. Although the genetic criteria for homozygosity for hemoglobin D cannot be proved, it seems likely that this patient represents an instance of homozygous hemoglobin D disease.

#### CIBHA Infuscuria: A New Clinical Syndrome

By Robert D. Lange and Joseph H. Akeroyd. Department of Hematology, Walter Reed Army Institute of Research, Walter Reed Army Medical Center, Washington, D.C.

A 12-year-old girl who presented a clinical syndrome of a hemolytic anemia with hitherto undescribed inclusion bodies in her erythrocytes has been studied at Walter Reed Army Institute of Research. The patient has been anemic since the age of 18 months and, in addition, has always passed dark brown to blackish colored urine. A splenectomy was performed at the age of 4, but transfusions were still required. From the age of 8 until recently she was maintained on cortisone.

The red cell inclusion bodies are refractile, irregular in shape and vary in size up to 2  $\mu$ . They are present in mature erythrocytes and reticulocytes but not in normoblasts of the bone marrow. The inclusion bodies have some of the characteristics of Heinz bodies, but are not identical. They are best demonstrated by use of the vital dyes. Electron microscopy reveals them to be relatively dense. The inclusion bodies examined spectroscopically demonstrated peaks of maximum absorption at 265 and 420  $\text{\AA}$  suggesting the presence of an abnormal hemoglobin or porphyrin-nucleoprotein complex. They are Feulgen negative.

Transfusion studies show a shortened survival of the patient's own cells and a normal survival of normal cells in the patient. The patient's cells disappeared rapidly when transfused into an infant with an intact spleen. These studies indicate the presence of an intracorporeal defect of the red cells. Coombs' tests have been negative.

The urinary pigment is probably bilifuscin or a

mesobilifuscin, but we have proposed the term infuscuria until such time as the pigment is definitely identified.

This is believed to represent a new clinical syndrome: congenital inclusion body hemolytic anemia (CIBHA) associated with the passage of dark colored urine (infuscuria). It is suggested that the disease may be due to an inborn error in nucleoprotein synthesis or maturation.

#### Nonaddisonian Megaloblastic Anemia

By Norman A. Nelson and Ronald C. Bishop. Department of Medicine, Wayne County General Hospital, Eloise, Michigan.

The recent introduction of radioactive vitamin B<sub>12</sub> studies has provided a means for establishing the diagnosis of pernicious anemia in patients not presenting the classic hematologic findings. Pernicious anemia, either in relapse or remission, may now be diagnosed by demonstrating the absence of intrinsic factor activity by means of radioactive vitamin B<sub>12</sub> studies. Conley has emphasized their value in patients with neurologic disease resembling subacute combined degeneration without anemia, or in those who have received inadequate therapy. Such studies may also be of help in excluding the diagnosis of pernicious anemia.

We have recently had the occasion to study 2 patients, both of whom had a macrocytic megaloblastic anemia with histamine-fast achlorhydria. One had a history of dietary insufficiency and purpuric skin lesions suggesting scurvy. He improved without definitive therapy other than diet. The Schilling test effectively excluded the diagnosis of pernicious anemia. The other patient was an epileptic on dilantin. It is interesting to note several recent reports from England on dilantin-induced megaloblastic anemia. An adequate hematologic response occurred in this patient during a trial with investigational material. The Schilling test, performed on 2 occasions, however, demonstrated normal urinary excretion of radioactive vitamin B<sub>12</sub>, again eliminating the diagnosis of addisonian pernicious anemia and the need for continued vitamin B<sub>12</sub> therapy.

In addition, a third patient with nutritional megaloblastic anemia was studied. Free hydrochloric acid was present in the gastric juice. A radioactive vitamin B<sub>12</sub> excretion test was done, confirming the presence of intrinsic factor activity.

#### Cobalt<sup>60</sup>-Labeled Vitamin B<sub>12</sub> Absorption and Excretion Studies Using Timed Release Capsules

By Philip C. Johnson and E. Stanley Berger. Radioisotope Service V.A. Hospital, and the Department of Medicine, University of Oklahoma, Oklahoma City.

An attempt was made to investigate the site of vitamin B<sub>12</sub> absorption in man by giving patients

without known neurologic or hematologic diseases an oral dose of 4  $\mu$ g. of vitamin B<sub>12</sub> labeled with 0.2  $\mu$ c. of Co<sup>60</sup>. The control group (*group 1*) was given the B<sub>12</sub> as a water solution. A similar amount of vitamin B<sub>12</sub> was given in spansules having 4 different release times. In *group 2* the spansules were designed to dissolve after entering the small intestine; in *group 3*, 1 hour release, in the upper small intestine; in *group 4*, 4½ hour release, in the middle small intestine; and in *group 5*, 7 hour release, in the lower small intestine. Each group contained at least 10 patients. Fecal excretion of the Co<sup>60</sup> B<sub>12</sub> showed: for *group 1*, 61.0  $\pm$  6.01%; for *group 2*, 57.3  $\pm$  4.76%; for *group 3*, 50.9  $\pm$  4.30%; for *group 4*, 49.4  $\pm$  5.11%; for *group 5*, 59.7  $\pm$  4.23%. There is no statistically significant difference in these values (*p* greater than 0.10).

Simultaneous urinary clearance tests were performed on these patients. Two loading doses of 1.0 mg. each of vitamin B<sub>12</sub> were given intramuscularly: the first simultaneously with the oral dose, the second, 24 hours later. The urinary excretion as % of the oral dose for the 0-24-hour collection period was: for *group 1*, 3.74  $\pm$  0.65; for *group 2*, 4.62  $\pm$  0.69 (*p* = 0.4), for *group 3*, 6.57  $\pm$  1.29 (*p* = 0.1), for *group 4*, 6.16  $\pm$  0.53 (*p* = 0.05), for *group 5*, 7.14  $\pm$  1.03 (*p* = 0.02). For the 24-48-hour collection period it was: for *group 1*, 1.58  $\pm$  0.01; for *group 2*, 4.17  $\pm$  0.61 (*p* = 0.001); for *group 3*, 3.99  $\pm$  1.34 (*p* = 0.2); for *group 4*, 5.15  $\pm$  0.96 (*p* = 0.005); for *group 5*, 8.75  $\pm$  1.99 (*p* = 0.005). In *groups 4* and *5* the urinary excretion during both collection periods was greater than those of the control *group 1*. These differences are statistically significant.

Based on the work of others, the previous binding by gastric juice, the site of absorption and the concentration of intrinsic factor are all thought to be related to vitamin B<sub>12</sub> absorption. On the other hand, urinary clearance of vitamin B<sub>12</sub> has been shown to be related to serum binding. Our data would suggest that the rate of release of vitamin B<sub>12</sub> in the gastrointestinal tract influences both vitamin B<sub>12</sub> absorption and urinary excretion. Furthermore, in the face of equal fecal excretion, the variable urinary clearance of vitamin B<sub>12</sub> suggests that the site of absorption and the contact with gastric juice influences serum and liver binding of the vitamin.

#### Differentiation of Primary and Secondary Polycythemia by Pulmonary Function Studies

By June M. Fisher, George N. Bedell and Paul M. Seeborn. Department of Internal Medicine, State University of Iowa College of Medicine, Iowa City.

The purpose of this paper is to present the findings of pulmonary function tests in patients with polycythemia—both primary and secondary—and to evaluate the place of these tests in studying such patients. Pulmonary function tests were done in 15

patients with polycythemia (hemoglobin 17.0 Gm. or greater and hematocrit 55% or greater). Measurements including lung volumes, maximal breathing capacity, maximal expiratory flow rate, evenness of alveolar ventilation, and arterial blood studies performed while the patient was breathing room air and after 100% oxygen breathing for at least 10 minutes.

Eight patients diagnosed as having polycythemia vera by hematologic criteria had essentially normal function studies. Arterial oxygen saturation exceeded 94% when the patients were breathing room air. One patient diagnosed polycythemia vera by hematologic criteria had abnormal pulmonary function tests and arterial oxygen saturation of 93% while breathing room air. He was found to have a pulmonary infarct. Six patients had significant abnormalities in pulmonary function and arterial oxygen saturation below 91% while breathing room air. The eventual clinical diagnoses in these patients were emphysema (3), pulmonary fibrosis (2) and pulmonary hypertension, cause not determined (1).

We conclude that if a patient has polycythemia and normal arterial oxygen saturation at rest, the diagnosis is polycythemia vera. Patients with polycythemia vera may have anoxemia at rest if they also have lung disease, venous to arterial shunt, medullary center depression or other cause for arterial anoxemia. Patients with secondary polycythemia do have anoxemia at rest. Pulmonary function tests are useful in the study of patients with polycythemia of unknown cause as they may reveal evidence to support a diagnosis of polycythemia vera, or an unsuspected cause for secondary polycythemia.

#### Mean Leukocyte Corpuscular Volume in Leukemia

By William R. Best and Louis R. Limarzi. Department of Medicine, University of Illinois College of Medicine, Chicago. (Aided by a grant from the U.S. P. H. S.)

Metabolic studies of leukocytes are often done in suspensions containing some erythrocytes. An approximate adjustment of data on the basis of gross protein weight may be made utilizing mean erythrocyte and leukocyte corpuscular volumes, relative numbers of the 2 cell types, and metabolic activity of erythrocytes alone.

Bloods were allowed to settle in Wintrobe hematocrit tubes for 1 hour and centrifuged at 3000 r.p.m. for 30 minutes. The buffy layer (BL) in per cent was noted. Simultaneous white blood counts (WBC) in cells/cm. were obtained. The mean leukocyte corpuscular volume (MLCV) in  $\mu^3$  was calculated.

$$MLCV = 10^7 \times BL/WBC$$

With WBC's less than 75,000 falsely high MLCV's were often obtained. Only bloods with WBC greater than 75,000 and with characteristic cells greater than 70% are analyzed below. Mean and standard deviation



tion of MLCV for various leukemias were: chronic lymphocytic (CLL, 29 cases),  $246 \pm 74$ ; chronic granulocytic (CGL, 51 cases),  $552 \pm 140$ ; acute granulocytic including acute exacerbation of chronic (AGL, 12 cases),  $448 \pm 119$ ; and acute lymphocytic and unclassified (ALL, 10 cases),  $260 \pm 82$ . Except for ALL minus CLL, the differences between the various means are all statistically significant. No relationship could be established between MLCV and the differential count in CGL. Erythrocyte mean corpuscular volume in 360 leukemias of all types was  $90.3 \pm 9.5 \mu^3$ .

These mean values have been helpful in correcting metabolic studies for erythrocyte contamination. In addition, these values permit a crude estimate of WBC when BL exceeds 4%. WBC is approximately 40,000 for each % of BL in ALL and CLL and, approximately 20,000 for each % in AGL and CGL.

#### Hodgkin's Disease of the Bone Marrow

By William H. Bond and Robert J. Rohm. Department of Medicine, Indiana University Medical Center, Indianapolis.

Hodgkin's disease, a malignant granulomatous disorder of the reticuloendothelial system, is frequently associated with nonspecific alterations in marrow constituents and, on autopsy examination, may show patchy invasion of the bone marrow cavity.

Because of the syncytial nature of the pathologic process, the attendant fibrosis or other unexplained causes, it is extremely rare to be able to demonstrate Reed-Sternberg cells on random needle aspiration of the marrow cavity.

Of the 80 patients with Hodgkin's disease seen in this clinic, 3 who had been diagnosed by standard fixed tissue techniques, lymph node biopsy, etc., demonstrated numerous abnormal reticulum cells of the Reed-Sternberg type during the course of their disease.

The clinical features of these patients and their response to treatment are outlined. Photomicrographs of tissues prepared with hematoxylin and eosin and Wright's stain were made to determine the comparative cytologic characteristics of these cells, and time-lapse phase contrast microcinematographic studies were undertaken to show the motility behavior of these cells and, in one patient, the effect of CB-1348 upon the behavior of such cells.

#### A Coagulation Defect in Thrombocythemia Located in the Serum and Plasma

By Irving A. Friedman, Arthur B. Dupee, Joseph H. Robbins and Frank C. Higgins. Hektoen Institute for Medical Research, Cook County Hospital, Chicago.

Two cases of thrombocythemia associated with hemorrhagic diatheses, splenomegaly, leukocytosis,

and marrow megakaryocytosis were studied. The coagulation profiles, including prothrombin consumption tests, were normal. However, the bleeding time was prolonged in both cases and thromboplastin generation was abnormal. The addition of normal serum or barium sulfate-treated plasma to the thromboplastin generation tests corrected this defect in 1 patient whose platelets behaved normally. The second patient showed partial correction of thromboplastin generation by either serum, barium sulfate-treated plasma or normal platelets. Therefore, both patients demonstrated a plasma and serum deficiency (simulating plasma thromboplastin antecedent [PTA] deficiency), and in 1 patient this defect was combined with a platelet thromboplastin deficiency.

The first patient developed marked thrombocytosis, bleeding and thrombotic episodes following splenectomy. After administration of  $P^{32}$  there was a simultaneous decrease in the number of platelets and bleeding time, with a disappearance of clinical symptoms. Repeat thromboplastin generation studies at this time were normal.

The common denominators of these 2 cases include prolonged bleeding times with normal prothrombin consumption tests. There was a definite correlation between the thrombocytosis, bleeding time and presence of a serum or plasma defect in 1 patient, which suggests association of the increased numbers of platelets with the serum-plasma defect.

#### Studies on the Heparin-Like Effect of Dextran Sulfate

By Donald R. Griffith, Ricardo H. Landaburu, Josiah A. Polhemus, Park W. Willis, III and Ivan F. Duff. Department of Internal Medicine, University of Michigan Medical School, Ann Arbor.

We have had occasion to investigate the anticoagulant effect of dextran sulfate, (Dexulate-Glaxo, London, England) a synthetic sulfated polysaccharide. The material (supplied in 5 cc. ampuls, 1000 U/cc.) was administered to a total of 12 patients. Eight had normal clotting mechanisms and received a single intravenous dose of 5000 U. Four patients who had thromboembolic disease (3 deep femoral thrombophlebitis and 1 probably pulmonary infarct) were given the drug in a constant intravenous infusion. Subsequent determinations were made of the Lee-White clotting time in all cases, the Quick 1-stage prothrombin time in 9 cases, the 2-stage prothrombin time (Ware-Seegers method) in 1 case, the modified Owren (Ware) prothrombin time in 2 cases, factor V (proaccelerin) in 3 cases, factor VII (proconvertin) in 1 case and fibrinogen in 1 case.

The clotting time was uniformly prolonged. This effect was marked (from  $1\frac{1}{2}$  to 10 times the control value) during the first hour after the single dose and persisted into the second hour on only 2



occasions. When the drug was administered by continuous infusion it was possible to control the clotting time by regulating the speed of infusion. The Quick 1-stage prothrombin time was promptly and significantly prolonged. This effect would last from 6-12 hours following the single dose. Factor V activity was markedly reduced in all 3 cases; this paralleled the effect on the Quick 1-stage prothrombin time. The modified Owren (Ware) prothrombin time, 2-stage prothrombin time, factor VII activity and fibrinogen levels were unaffected by the drug. No hemorrhagic or other toxic effects were noted in these short-term studies.

#### Some Observations on Hyperglobulinemic Purpura (Waldenström's Syndrome)

By William E. Symon, Robert J. Rohn and William H. Bond. Department of Medicine, Indiana University Medical Center, Indianapolis.

Abnormal capillary bleeding and chronic, recurrent purpuric states may be associated with, and the result of, previous formation of various abnormal serum proteins.

The abnormal serum proteins are globulins, and usually migrate with, or near, the  $\gamma$  globulin on electrophoretic migration. These abnormal globulins are roughly divided into 3 categories: (1) macroglobulins, (2) cryoglobulins and (3) hyperglobulins. All 3 may be associated with bleeding abnormalities.

Three cases have been studied manifesting hyperglobulinemic purpura. In 1, the disease is well advanced, demonstrating the classic clinical and laboratory alterations which have been outlined in the previous 18 published cases of this type. In the second, a shorter clinical course is associated with variability in clinical and laboratory manifestations, whereas the third is unique in being the first reported case of this disorder associated with, and possibly due to, a disseminated reticulum cell sarcoma.

Our investigations utilized hematological studies, hepatic function tests, clinical photographs, photomicrographs, representative free boundary electrophoretic and paper electrophoretic patterns and ultracentrifugal patterns.

#### S-Agammaglobulinemia and F-Gammaglobulinuria in an Unusual Myeloma Patient

By Donald L. Howie, William Q. Wolfson and Joseph Weiner. Department of Medicine and the Laboratory Service, U.S. Army Hospital, Fort Riley; and the Office of the Regimental Surgeon, Headquarters 18th Infantry Regiment, Fort Riley, Kansas.

A 49-year-old Negro woman first had pain in November 1954, diagnosed in May 1955 by clinical course, x-ray and marrow studies. P<sup>32</sup> was followed by almost 1 year of complete symptomatic remission, including disappearance of azotemia. In May 1956 an acute relapse occurred with a periph-

eral blood and marrow picture of plasmablastic leukemia, with recurrence of renal failure and azotemia, and with hepatic impairment of urea synthesis (low blood urea/NPN, and, eventually, with sepsis which was fatal despite vigorous antibiotic, hormonal and supportive measures.

While the clinical course was consistent with myelomatosis, histopathology was not unequivocal: one opinion suggested acute monocytic leukemia. Serum electropherograms showed elevated  $\alpha_2$  globulin (common and probably nonspecific in myeloma), markedly reduced  $\beta_2$  globulin and absence of slow  $\gamma_2$  globulin. Schiff staining was increased in all fractions except the fast  $\gamma$  globulin which also stained subnormally with toluidine blue, but not with mucicarmine. Both serum and urine were negative for cryoglobulin, pyroglobulin, macroglobulin and Bence-Jones protein. There was marked proteinuria without albuminuria. Its cause was an apparently homogeneous protein which migrated as a fast  $\gamma$  globulin and could not be even partially resolved from that of serum in mixtures.

Possible interpretations are: (1) only a partial agammaglobulinemia existed, or (2) there was complete agammaglobulinemia, and the fast  $\gamma$  globulin in serum actually was a myeloma component. Recent immunologic studies suggest the latter to be usually correct in apparent s-agammaglobulinemia. It seems probable in this patient because of an apparently identical urine protein with renal clearance greater than albumin, because of anomalous staining of the serum fast  $\gamma$  proteins, and because of the reduced  $\beta_2$  globulin, which is largely immunoglobulin. The second view also clarifies the patient's refractoriness to antibiotic treatment.

#### Hemorrhagic Skin Lesions in Steroid-Treated Patients

By Gunter M. Nashelsky, Charley J. Smyth, Glenn M. Clark and Kurt N. von Kaula. Department of Medicine, University of Colorado Medical Center, Denver.

This report concerns findings in a number of patients who have been on rather long-term steroid therapy. All have developed areas of painless subcutaneous hemorrhage, varying from petechiae to extensive ecchymoses. We have studied 10 patients (rheumatoid arthritis, 8; lupus erythematosus disseminatus, 1; intestinal lipodystrophy [Whipple's disease], 1). In each instance, "continuous" therapy with ACTH, cortisone, hydrocortisone or prednisone had been administered for not less than 3 years, and prednisone for not less than 13 months of this time. The most frequent site of involvement was the forearm and hand, occasionally the lower extremity—all areas subject to frequent trauma. In most instances, the skin lesions developed or became much more extensive during the period of prednisone therapy in doses ranging from 10 to 15 mg./day. No patient developed generalized symptoms.

It is considered most likely that these skin hemorrhages are the result of some effect upon the wall and/or supporting tissues of the blood vessels brought on by steroid treatment, and are not due to any abnormality in the coagulation system. Minor trauma appears to be a major contributing factor in these vascular lesions.

#### "Gelatinous" Bone Marrow

By *Norman A. Nelson and Leo P. Cawley*. Department of Medicine and Pathology, Wayne County General Hospital, Eloise, Michigan.

In addition to the usual red and yellow bone marrow, a gelatinous form was recognized through its characteristic consistency by Bichat in 1812. It was believed to represent an abnormality occurring primarily in cachexia. Although this alteration of the marrow has been recognized for over 100 years, and in spite of considerable investigation into its nature by the early hematologists and pathologists, there is a paucity of related clinical studies.

Recent observations of 2 patients with grossly gelatinous marrow, noted upon aspiration, prompted further study. In both instances the appearance of

marrow particle sections, stained with hematoxylin and eosin were identical. Only scattered hematopoietic islands were present. The fat cells appeared small and were widely separated by large sheets of amorphous pink-staining material. Both patients suffered from severe normocytic anemia.

The first patient presented with the nephrotic syndrome and carcinoma of the prostate. The amorphous material in the marrow failed to give a positive reaction with the periodic acid-Schiff (PAS) reagent. The second patient was first seen with typical pernicious anemia in relapse, at which time the marrow was megaloblastic and of normal cellularity. In spite of continued vitamin B<sub>12</sub> therapy, the patient returned with severe normocytic anemia, active pulmonary tuberculosis and cachexia. The amorphous intercellular marrow material in this instance gave a strongly positive PAS reaction. Serial studies have demonstrated improvement.

In summary, an accumulation of PAS-positive intercellular material normally present in minute amounts in the bone marrow may occur under certain circumstances. This should probably be differentiated from PAS-negative material which might represent simple edema fluid.

## CARDIOVASCULAR SYSTEM

### Primary Pulmonary Hypertension

By *Roy Behnke, James Carpentier and Dallas Fouts*. Department of Medicine, Indiana University School of Medicine, Indianapolis.

The principal physical findings in increased pulmonary blood flow are an accentuated pulmonary second sound, a diastolic left parasternal shock, a systolic and/or diastolic murmur, and right ventricular hypertrophy. When these are "paradoxically combined" with the roentgen features of scanty lung vasculature, which usually indicates diminished pulmonary blood flow, the diagnosis of primary pulmonary hypertension should be suspected.

The symptoms, although disabling, are paroxysmal and evanescent, so that the patient is often considered neurotic. Dyspnea of a severity disproportionate to the effort which produces it is a nearly invariable feature of the syndrome, but it may be accompanied by effort syncope and effort angina.

The three young adult women studied were symptomless at rest but incapacitated by dyspnea with slight exertion; 2 had effort syncope and 1 effort angina. Right heart catheterization revealed resting pulmonary artery pressures of 102/42, 72/34 and 70/27; the latter 2 pressures rose sharply to

91/42 and 106/49 with exercise. The highest resting cardiac output was 3.14 L./min., and the greatest exercise output was only 4.17 L./min. No left-to-right shunt was found, but in 1 patient the foramen ovale was traversed with the catheter. The left atrial pressure was -1.4 mm. Hg, while the right was -2.7 mm. Hg. That cyanosis can be produced through such a foramen was demonstrated during exercise, at which time the right atrial pressure rose to 3.5 mm. Hg, and there was prompt arterial oxygen undersaturation uncorrected by the administration of oxygen.

No adverse effects were noted during catheterization even with exercise, contrary to the experience of others. Diagnostic right ventricular hypertrophy was present on all electrocardiograms.

A necessary factor in the correct final diagnosis of the syndrome is the absence of lung disease. No evidence of such was found in these cases, and complete pulmonary function tests revealed no physiologic deviation from the normal.

### Stenosis of a Branch of the Pulmonary Artery: A Cause for Continuous Murmurs over the Chest

By *Frederic L. Eldridge, Arthus Selzer and Herbert N. Hultgren*. Department of Medicine, Stanford University School of Medicine, San Francisco.

There have been rare reports of stenosis of a branch of the pulmonary artery, but no one has clearly pointed out its association with continuous murmurs heard over the chest.

Three patients, aged 5 to 7 years, all with other congenital cardiac malformations, have been shown by cardiac catheterization to have pressure gradients in a main branch of the pulmonary artery, indicating the presence of 1 or more stenoses of these branches. Two of the 3 patients exhibited continuous ductus-like murmurs heard at the chest wall over the site of the stenosis.

Both patients with continuous murmurs had pressure gradients across the area of stenosis throughout the cardiac cycle, whereas the patient with only a systolic murmur exhibited a pressure gradient only in systole. This finding indicates that the stenosis was the site of origin of the continuous murmur. Further proof has been provided by the experimental production of a continuous murmur in dogs in which partial constriction of a pulmonary artery branch was accomplished.

The finding of these stenoses in either right or left pulmonary arteries suggests that during cardiac catheterization pressure measurements should be made distally in both pulmonary arteries. This anomaly may not be as rare as the paucity of reports would indicate. Of real importance is the fact that these murmurs may mimic the murmur of patent ductus arteriosus.

#### Susceptibility of Dogs with Aortic Insufficiency to Endocarditis: Effect of the Hufnagel Valve

By Joseph Roshe, Benjamin Highman and Paul D. Altland. Clinic of Surgery, National Heart Institute, and the National Institute of Arthritis and Metabolic Diseases, Bethesda, Maryland.

Dogs with aortic insufficiency have proved highly susceptible to experimental endocarditis. Infections resembling acute and subacute bacterial endocarditis were produced consistently in 30 dogs by single and multiple intravenous injection of cultures of *Staphylococcus aureus* and *Streptococcus mitis* JH26, respectively. In addition to mitral and aortic vegetations, visceral infarcts and hemorrhagic and inflammatory lesions were seen in various organs. Dogs receiving *S. mitis* often developed, in addition, an acute diffuse glomerulonephritis, and occasionally focal glomerular lesions. No endocarditis was noted in 10 injected control dogs, including 2 with sham operations.

Hufnagel valves were inserted in 10 additional dogs with aortic insufficiency to determine if a reduction in cardiac work-load would reduce susceptibility to endocarditis. Three dogs were given *Staph. aureus* and seven *S. mitis*. Survivors were killed at 7-14 days. All dogs developed endocarditis. The severity of the endocarditis and other lesions was

comparable to that seen in dogs without Hufnagel valves. The valve did not prevent diffuse and focal glomerulonephritis in dogs given *S. mitis*.

The data indicate that although the Hufnagel valve improves the altered hemodynamics of aortic insufficiency, it does not significantly lower the marked susceptibility of dogs with aortic insufficiency to endocarditis and glomerulonephritis. It is felt that the Hufnagel valve in patients does not lower their susceptibility to endocarditis.

#### Probable Mechanism of Ventricular Fibrillation and Cardiac Arrest Following Hypercapnia

By Ananda S. Prasad, E. B. Brown, Jr. and Edmund F. Flink. Medical Service, Minneapolis V. A. Hospital, Department of Internal Medicine and the Department of Physiology, University of Minnesota, Minneapolis.

Severe arrhythmias, including ventricular fibrillation, often occur during the first few minutes after return to air breathing following high CO<sub>2</sub> breathing. In previous work with dogs, plasma potassium concentration rose during high CO<sub>2</sub> breathing and increased further when the dogs returned to air breathing. However, the concentration of plasma potassium following 4 hours of high CO<sub>2</sub> breathing is not increased sufficiently to account for fibrillation or arrest by itself. The following experiments were carried out to determine changes in ultrafiltrable calcium and phosphorus.

Femoral artery blood samples were collected under oil from dogs anesthetized with sodium Pentothal. Several samples were obtained before, during 4 hours of 30% CO<sub>2</sub> breathing and during the recovery phase. Blood pressure and electrocardiogram were recorded simultaneously and continuously. The plasma was separated under oil. Ultrafiltrate of plasma was obtained by using a standard centrifuge, as previously reported. The ultrafiltrable calcium during respiratory acidosis increased slightly (0.4 to 0.6 mg./100 ml.) following 20 minutes of 30% CO<sub>2</sub> breathing. A marked decrease from the control concentration (1.6 to 3.3 mg./100 ml.) occurred at the end of 4 hours, and a further slight decrease occurred at the 5-minute recovery time. These changes occurred without significant changes in the total calcium. Both potassium and phosphorus increased.

The mechanism of cardiac arrest under these circumstances seems to depend upon the simultaneous reduction in plasma ionic calcium and the rise in plasma potassium concentration. A phenomenon similar to that exhibited by dogs has been noted in man by Miller et al. Certain unexplained postsurgical deaths may be due to rapid reduction in CO<sub>2</sub> tension, which had become elevated during anesthesia.

### Lactic Dehydrogenase and Glutamic Oxalacetic Transaminase Levels in the Serum of Patients with Acute Myocardial Infarction

By *H. J. Zimmerman, C. G. Pilz and William Rock.*  
Department of Medicine, V. A. Hospital, Chicago.

The diagnostic value of serum transaminase levels in patients with myocardial infarction has been demonstrated by a number of recent studies. This highly sensitive index of myocardial infarctions, however, is helpful for only the first several days after the occurrence of the infarction, and almost always returns to normal by the 5th day.

In the present study of 25 patients with acute myocardial infarction, serum lactic dehydrogenase and transaminase levels were estimated serially. In all of these patients elevated levels of both enzymes were demonstrated. Lactic dehydrogenase levels, however, remained elevated for 6 to 12 days, while transaminase levels had returned to normal by 5 days or sooner. Patients with coronary pain, but without diagnosable infarction, had normal levels of transaminase and usually of lactic dehydrogenase. Patients in this category with congestive heart failure had mild lactic dehydrogenase elevations.

The degree of lactic dehydrogenase elevation was less marked than that of transaminase in patients with acute myocardial infarction, but there was a high degree of correlation between the relative degree of elevation of these enzyme levels.

Lactic dehydrogenase levels of the serum, while less specific and less sensitive than glutamic oxalacetic transaminase levels, remain clinically helpful for a longer period after an episode of myocardial infarction.

### Mechanism of Increased Serum Activity of the Enzymes, Glutamic Oxalacetic Transaminase (SGO-T), Glutamic Pyruvic Transaminase (SGP-T) and Lactic Dehydrogenase (SLD), following Myocardial Infarction in the Dog

By *Irwin Nydick, Paul Rueggesser, Felix Wroblewski and John S. LaDue.* Memorial Center for Cancer and Allied Diseases, New York City.

It has been previously demonstrated that increases in serum activity of the enzymes, glutamic oxalacetic transaminase (SGO-T), glutamic pyruvic transaminase (SGP-T) and lactic dehydrogenase (SLD) occur following myocardial infarction in the dog and man. The hypothesis was advanced that the mechanism of these rises was one of release of these enzymes into the blood stream from the necrotic myocardium. The present series of experiments was designed to study this hypothesis in more detail in man and in the dog.

That these increases are the result of leakage from necrotic myocardium is verified by the following findings: (1) The relative rises of serum enzyme

activity are proportional to the original concentration gradients between the myocardium and the serum for each enzyme as well as to the size of the infarct. (2) The enzyme concentration in the infarcted muscle diminishes proportionally to the age of the infarct. (3) The most rapid rises in serum enzyme activity correspond to the period during which there is the most precipitous decrease in enzyme concentration in the infarcted myocardium. (4) Simultaneous samples of coronary sinus and peripheral venous blood show enzyme concentrations 10-15% richer in the samples from the coronary sinus. (5) In man, only 16 of 50 patients with coronary insufficiency and electrocardiographic abnormalities confined to the ST segments and T waves demonstrated any abnormalities in serum enzyme activity, whereas SGO-T and SLD increases are seen consistently following myocardial infarction. The low initial concentration of glutamic pyruvic transaminase in the heart muscle of man explains the irregular pattern of SGP-T variation following infarction. In the dog, experimental coronary insufficiency does not alter the serum enzyme patterns.

### Progesterone and Alpha-Tocopherol in Experimental Epinephrine-Thyroxine Arteriosclerosis and in Cholesterol-Induced Atherosclerosis

By *Oscar F. Davis, Y. T. Oester and Bernard Friedman.* Department of Pharmacology and Experimental Therapeutics and the Graduate School, Stritch School of Medicine of Loyola University, Chicago.

A high incidence (89.5%) of a severe degenerative aortic sclerosis, essentially of the tunica media, is produced in rabbits by using epinephrine and thyroxine following the method previously reported by us. The lesions are rapidly induced in 15 days or less. Similarly, an essentially intimal atherosclerosis is induced in rabbits treated for 20 days or less with intravenous and subcutaneous injections of cholesterol suspensions. Alpha-tocopherol was studied in these scleroses because reports from Canadian and European sources have indicated that alpha-tocopherol produces improvement in clinical atherosclerosis. The reports of low  $\beta$  lipoprotein blood levels in young females, as well as low SF 10-30 Gofman fractions in pregnancy, led to the investigation of the effects of progesterone on these scleroses.

Five different groups of rabbits (8-19 per group) were given the epinephrine-thyroxine regime which produces the medial arteriosclerosis. In addition, each group received 1 of the following agents by subcutaneous injection: (1) progesterone, 50 mg./day; (2) progesterone, 75 mg./day; (3) alpha-tocopherol, 100 mg./day; (4) alpha-tocopherol, 200 mg./day; (5) alpha-tocopherol, 600 mg./day. None of these groups of animals demonstrated any signifi-



cant differences in incidence or severity of the induced medial sclerosis when compared to the control group of epinephrine-thyroxine alone.

Three different groups of rabbits (6-14 per group) were given the cholesterol regime which produces the intimal atherosclerosis. In addition, each group received 1 of the following agents by subcutaneous injection: (1) progesterone, 75 mg./day; (2) alpha-tocopherol, 200 mg./day; (3) alpha-tocopherol, 600 mg./day.

The group of animals receiving 75 mg./day of progesterone exhibited a much lower incidence of the intimal aortic sclerosis than the other 2 groups or the control group receiving only cholesterol. The incidence in the progesterone group was 46%, 6 animals in a total of 13 animals, while the control group had an incidence of 71.8%, 23 animals in a total of 32 animals.

#### Comparison of Reserpine and Deserpidine in Hypertensive Patients

By A. S. Ridolfo, S. M. Chernish and B. L. Martz.  
Lilly Laboratory for Clinical Research, General Hospital, Indianapolis.

Reserpine, Deserpidine (desmethoxyreserpine) and placebo were administered in a double blind study, each for a 6-weeks period in random order, to 11 patients with moderate primary hypertension. Dosage of reserpine and Deserpidine was 1 mg./day in 9, 0.5 mg./day in 2. Blood pressure and pulse were recorded in supine (after 5-minute rest) and standing positions at 2-week intervals.

Group averages of supine blood pressure readings were as follows: *lying*, placebo 182/112, reserpine 166/102, Deserpidine 169/103; *standing*, placebo 166/113, reserpine 155/107, Deserpidine 155/109.

Nasal congestion and dreams were reported more frequently during both drug periods than during placebo administration.

#### Cutaneous Necrosis due to Norepinephrine: Mechanism and Prevention

By A. Stephen Close and Ross C. Kory. Surgical and Investigative Medicine Service, V. A. Hospital,

Wood, the Departments of Surgery and Medicine, Marquette University School of Medicine, Milwaukee, Wisconsin.

The increasing use of intravenous norepinephrine has been accompanied by frequent reports of cutaneous necrosis. The mechanisms involved in the production and prevention of this necrosis were investigated.

Leg veins were exposed in 7 dogs and norepinephrine was infused through polyethylene catheters. In 6 dogs, intense venospasm promptly appeared at the catheter tip. As the infusion continued, the spastic areas showed progressive and persistent blanching associated with disappearance of previously visible vasa vasorum. Tissue ischemia appeared to parallel the infusion vein rather than the tributary veins. Thrombosis did not occur cephalad to the catheter.

Four dogs received a standard series of subcutaneous norepinephrine injections into all 4 extremities. Slough resulted in 31% of these legs. In 16 dogs the incidence of slough was increased to 88% by inducing hemorrhagic hypotension prior to norepinephrine injections. In this series, 1 hindleg and 1 foreleg of each dog were utilized as controls (32 legs). The legs paired with the control legs received the same 4-6-hour exposure to norepinephrine, and were then infiltrated with either Regitine or Priscoline in saline solutions with or without hyaluronidase. Treated legs were not included in the results unless paired control legs developed sloughs. In 16 legs infiltrated with Regitine (12 in combination with hyaluronidase), no sloughs occurred. In 7 legs infiltrated with Priscoline (4 in combination with hyaluronidase), no sloughs occurred. In contrast, 5 legs were infiltrated with hyaluronidase alone; all 5 developed sloughs.

These observations strongly suggest that ischemia of the vein wall permits diffusion of norepinephrine into adjacent tissues. Increased sensitivity to norepinephrine induced by hypotension augments the vasoconstriction resulting from this diffusion. The resulting prolonged tissue anoxia leads to slough. Early local infiltration of adrenergic blocking agents is an effective means of preventing this complication.

## ENDOCRINES AND METABOLISM

#### The Evaluation of Thyroid Function in Patients Receiving Carbutamide (Substance BZ-55)

By G. W. Irwin, G. T. Lukemeyer, H. A. Soper and C. E. Test. Department of Medicine, Indiana University Medical Center, Indianapolis.

Recently several new sulfonamides which cause hypoglycemia have been introduced and used in the

treatment of diabetes mellitus. The possibility of side effects with long-term administration of these compounds has caused concern. It seemed important to determine if any antithyroid effect occurred with the administration of these sulfonamides. A few preliminary reports indicate depression of  $I^{131}$  thyroidal uptake following carbutamide.

In an attempt to compare any antithyroid ef-



fect of carbutamide with other known antithyroid drugs,  $I^{131}$  accumulation gradients were determined. A single dose of 2.5 Gm. of carbutamide caused no antithyroid effect such as that noted with methimazole.

Thyroid function was also studied before and at varying periods during carbutamide therapy. This report concerns a group of cases receiving 1 to 3 Gm. of carbutamide daily for 4 to 7 months. In this series there has been only slight fluctuation of the values for the BMR, PBI, 24-hour  $I^{131}$  thyroidal uptake and cholesterol determinations. In general, these tests have been within the normal range. There has been no thyroid enlargement or clinical features of hypothyroidism in these patients receiving carbutamide.

#### The Effect of Bromine Ion on $I^{131}$ Thyroid Function Studies

By *Richard E. Peterson and Masa Yamamoto*. Radioisotope and Medical Services of the Iowa City V. A. Hospital, and the Department of Medicine, College of Medicine, State University of Iowa, Iowa City.

The observation that a clinically hyperthyroid patient had normal  $I^{131}$  tracer studies when first studied after 6 weeks of 3 Gm. daily of elixir triple bromides (ETB) aroused interest in the possibility of a bromine effect on radioiodine diagnostic studies.

Another hyperthyroid patient was studied with a tracer dose of  $Br^{82}$ . The thyroid concentrated 17-20% of the  $Br^{82}$  tracer dose and 55-70% of  $I^{131}$  tracer doses. At 24 hours, this patient had 57% of the serum  $I^{131}$  organically bound (butanol extractable), while an insignificant amount (less than 0.4%) of the serum  $Br^{82}$  was butanol extractable.

Twenty-five euthyroid patients were studied with  $I^{131}$  tracer studies before and on the third day of receiving ETB, 1 Gm. q.i.d. The PBI was not altered significantly. At 1 hour, the thyroid uptake of iodine was depressed by 2% of the dose ( $p < 0.01$ ) and the 24th hour thyroid uptake was decreased 4.8% of the dose ( $p < 0.1$ ). The 24-hour urine excretion of  $I^{131}$  was decreased 7% of the dose, with  $p < 0.05$ .  $I^{131}$  counts over the calf (body background) were increased following the ETB, averaging 35% increase at 6 hours and 18% increase at 24 hours. The total serum level of  $I^{131}$  and of butanol-extractable  $I^{131}$  were slightly, but insignificantly, decreased.

These data imply that the thyroid significantly concentrates but does not organically bind the bromine ion. Bromide, in the dosage given, depresses thyroid  $I^{131}$  uptake probably through competition in the halogen trapping mechanism. The decrease in urinary excretion of  $I^{131}$ , without change in the serum level of  $I^{131}$ , is compatible with the increased extrathyroidal  $I^{131}$  concentration indicated by the increased counts over the calf following bromide administration. The possibility of ETB administration interfering with  $I^{131}$  thyroid diagnostic studies must be kept in mind.

#### The Scintigram in Thyroid Disease Diagnosis

By *Robert E. Mack and Charles R. Carson*. Walter Reed Army Medical Center, Washington, D. C.

A study was made of the preoperative scintigram and the pathologic findings of 87 patients undergoing thyroidectomy. Interpretation of the scintigram was based upon a comparison of the scanning outline with the thyroid gland size as determined by physical examination. Any area with a reduction in the amount of normally functioning thyroid tissue appeared as a relative void in the radioactivity pattern.

The distribution of radioiodine was diffuse in all but one of 33 patients with adenomatous goiter. In an additional group of 33 patients having adenomatous goiter with hemorrhage or cyst formation, 26 exhibited a diminution of radioactivity in the area of disease. The finding of a normal scintigram in the remaining seven suggests that uniform involvement of the thyroid gland in the disease process may result in a parallel decrease in the iodine-concentrating ability. A similar explanation may be applicable to chronic thyroiditis, since 4 of 8 patients with this disease had normal scintigrams.

Of the 5 patients with papillary adenocarcinoma, 3 had normal scintigrams. The scanning abnormality in the other 2 appeared to be related to a coexisting colloid cyst rather than the carcinoma. Five of 8 patients with follicular adenoma or adenocarcinoma had apparently normal scintigrams. The failure of localization in these 5 patients may be related to the size of the lesion, since with one exception the diameter of the nodule did not exceed 1.5 cm. Radioautographs in 2 of these patients revealed a halo of functioning thyroid tissue surrounding the nodule.

The results of this study indicate that the value of the scintigram is limited by the sensitivity of the counter system for changes in distribution produced by small lesions, and the relative inaccuracy of visual estimates of radioiodine concentration. Serial scintigrams may be helpful in the evaluation of questionable changes.

#### Comparative Effects of Insulin and Orinase on Blood Levels of Pyruvate and Alpha-Ketoglutarate in Normal Subjects

By *Allen R. Hennes, Bernardo L. Wajchenberg, Stefan S. Fajans and Jerome W. Conn*. Metabolism Research Unit, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor.

In an effort to elucidate the mode of action of arylsulfonylurea compounds, a group of acute experiments have been performed on normal subjects to determine the effects of intravenous administration of insulin and of intravenous and oral administration of Orinase upon blood levels of glucose, pyruvate and alpha-ketoglutarate.

In 7 of 8 experiments an increase in the level of blood pyruvate was the earliest change associated with hypoglycemia produced by administration of insulin. In no instance did the level of pyruvate decrease before or during the time that blood sugar was falling. In contrast, following administration of Orinase, a decrease in the level of blood pyruvate was the earliest change associated with hypoglycemia in 7 of 9 experiments. This fall in the level of pyruvate preceded the fall in blood sugar in 3 subjects. In only 1 experiment was the earliest change in blood pyruvate an increase. There was no definite pattern of change in blood levels of alpha-ketoglutarate following intravenous administration of either insulin or Orinase.

Thus, the acute hypoglycemia following administration of insulin is usually associated with production of pyruvate in excess of its removal. Acute hypoglycemia following intravenous or oral administration of Orinase is usually associated with removal of pyruvate in excess of its production. These differences suggest that the immediate hypoglycemia induced by administration of insulin, on the one hand, and of Orinase, on the other, occurs via different mechanisms.

These results do not support a current concept that the sulfonylurea compounds produce acute hypoglycemia by stimulating rapid release of endogenous insulin.

#### Clinical Evaluation of Tolbutamide (1-butyl-3-p-tolylsulfonylurea) in the Treatment of Diabetes Mellitus

By *Robert H. Unger*. University of Texas Southwestern Medical School and the V. A. Hospital, Dallas.

A clinical evaluation of tolbutamide (1-butyl-3-p-tolylsulfonylurea) was undertaken in 20 diabetic patients who were classified into three groups: (1) severe labile diabetics, (2) moderately severe stable diabetics in whom insulin had been required for adequate control, (3) milder stable diabetics controllable with varying degrees of carbohydrate restriction without insulin.

Base-line studies were conducted for at least 7 days prior to beginning therapy. During this control period, and throughout the study, labile diabetics were maintained on suboptimal doses of insulin, while all stable diabetics were fed constant, calorically adequate, regular diets and received no insulin. After adequate base-line studies, tolbutamide therapy was begun with daily oral doses of 3 Gm. In unresponsive patients dosages were gradually raised to as high as 12 Gm./day.

Group 1 (3 patients): In no case was improvement observed during tolbutamide therapy. Profound insulin reactions occurred in 1 patient despite progressive deterioration in control of diabetes. Group 2 (8 patients): Decrease in fasting hyperglycemia and suppression of glycosuria was observed in

only 3 patients. Group 3 (9 patients): Decrease in fasting hyperglycemia and suppression of glycosuria occurred in all 9 patients.

Untoward effects were encountered in 2 subjects. One patient developed urticaria, and generalized erythema occurred in another. In both, spontaneous clearing took place without termination of therapy. Liver function tests, urinalyses, complete blood counts and  $I^{131}$  uptake studies failed to reveal significant alterations.

The results confirm the effectiveness of tolbutamide in regulating many patients with mild and moderately severe stable diabetes, particularly the milder cases controllable with diet alone. Among the labile diabetics, not only was no benefit observed, but the concomitant administration of tolbutamide and insulin may possibly have been a factor in inducing hypoglycemic episodes.

#### Rapid Estimation of the Blood Glucose Concentration using Ordinary "Tes-Tape"

By *Holbrooke S. Seltzer*. Metabolic Service, V. A. Hospital, and the Department of Internal Medicine, University of Texas Southwestern Medical School, Dallas.

Previous methods for the rapid estimation of the blood sugar concentration have not met widespread acceptance because they require special equipment and are cumbersome to operate. In contrast, the increasing utilization of Tes-Tape, the indicator paper containing glucose-oxidase which is used to detect urinary glucose, now makes available to everyone a fast and simple procedure for approximating the blood glucose level. The technic is based on the Tes-Tape color response either to undiluted plasma or to serial dilutions of plasma.

Whole blood glucose values (Somogyi) of 130 specimens of oxalated venous blood ranged from 16 to 760 mg. %. Corresponding plasma glucose levels were usually slightly higher, with a mean increase of 12 mg. %. The Tes-Tape response to plasma glucose always reflected the respective blood glucose level.

Simple determination of the Tes-Tape reaction to undiluted plasma enabled severe hypoglycemia or frank hyperglycemia to be distinguished from normoglycemia within 3 minutes after venipuncture.

More precise information, obtainable within another few minutes, was provided by the color responses of serial dilutions of plasma. The "end-point" was the weakest dilution of a plasma sample, showing a faint green tint on the yellow Tes-Tape one minute after application. Reading accuracy was proportional to the blood sugar concentration. At each plasma dilution representing an end-point, 90% or more of the corresponding blood glucose values fell within the parenthesized range: Plasma dilution (blood glucose): 0 (15-20 mg. %), 1:2 (20-40 mg. %), 1:4 (35-65 mg. %), 1:8 (45-95 mg. %), 1:16 (75-165 mg. %), 1:32 (145-355 mg. %), 1:64 (225-450 mg. %), 1:128 (500-760 mg. %).

The method described constitutes a valuable diagnostic aid and therapeutic guide in: (1) distinguishing hypoglycemic coma from other causes of unconsciousness, (2) evaluating the glycemic status of diabetic patients, and (3) following the blood glucose level during treatment of diabetic coma.

#### The Hyperglycemic Response as a Measure of Glucocorticoid Potency

By *Kelly M. West and James A. Hagans*. Department of Medicine, University of Oklahoma School of Medicine, and the V.A. Hospital, Oklahoma City.

The purpose of this report is to show that the hyperglycemic responses of human subjects are a reliable indication of glucocorticoid potency if a technic which includes glucose loading is used, and if the drugs tested have similar characteristics of time-action.

Twenty-one healthy ambulant young adults with no family history of diabetes were given 1.75 Gm./Kg. ideal body weight of glucose orally, 2 hours after which the venous blood glucose was determined. Subjects were given, on 5 subsequent occasions, the same simplified glucose tolerance test 2 hours after ingestion of cortisone acetate, prednisone, prednisolone, 9- $\alpha$ -fluorohydrocortisone and hydrocortisone.

Using a method of sequential analysis, only 3 cortisone-modified tests were required to establish the hyperglycemic effect of 50 mg. cortisone acetate after the results of the control tests of the group were known. Only 2 tests were required to establish the hyperglycemic effect of 10 mg. of prednisone, and 2 tests to establish the effect of 10 mg. prednisolone. Four tests established that 2 mg. 9- $\alpha$ -fluorohydrocortisone was ineffective, indicating by inference that it was less than 25 times as potent as cortisone acetate. The very subtle difference between the hyperglycemic potency of 40 mg. hydrocortisone and 50 mg. cortisone acetate was identified (hydrocortisone greater) after 12 tests by comparing the responses of the first 6 subjects tested. In each instance  $p = < .01$ . Forty-two tests in 21 subjects failed to identify any difference between the potency of prednisone and prednisolone.

The ability of a test requiring only 1 blood glucose determination to indicate glucocorticoid potency has been evaluated. This simple method yielded results which were in every instance comparable to those which have been previously established by more elaborate methods utilizing indices of "glucocorticoid" potency other than hyperglycemia. Furthermore, this type of testing seems capable of reliably identifying very small differences in potency.

#### Sodium Deficiency and Adrenocortical Hormone Secretion

By *Albert B. Eisenstein and Phyllis Hartoft*. Departments of Preventive Medicine and Pathology, Washington University School of Medicine, St. Louis.

Although sodium deprivation evokes hypertrophy of the zona glomerulosa and increased aldosterone secretion, it is not known whether production of other adrenocortical hormones is altered. The effects of sustained sodium restriction on adrenal steroid secretion have, therefore, been investigated.

Young male Wistar rats were placed on a synthetic diet deficient in sodium. Pair-fed controls received the same diet to which 0.6% sodium chloride was added. Animals from both groups were killed 2, 4, 7, 9, 14, 30 and 60 days after beginning the diets, and serum sodium, potassium, blood hematocrit and adrenal weights were determined. One adrenal from each rat was incubated aerobically at 37°C. in a buffered medium containing ACTH. After 2 hours incubation, steroids secreted were recovered and quantitatively determined by a spectrophotometric technic. This procedure measures all biologically active steroids secreted by the rat adrenal, and thus represents total hormone production of this gland. In addition, the secretion of individual adrenocortical hormones was determined by paper chromatographic analysis. The remaining adrenal from each rat was used for histologic study.

The results demonstrate that total steroid secretion by the adrenals of control rats increased progressively as the animals grew. Total adrenal steroid production by sodium-deficient animals remained constant throughout the experiment and was significantly ( $p = < 0.01$ ) lower than in controls.

Chromatograms revealed increased secretion of aldosterone by the adrenals of sodium depleted rats, but synthesis of corticosterone and other hormones was reduced. These changes were correlated with diminished serum sodium concentration and increased size of the zona glomerulosa.

It is concluded from these observations that prolonged sodium depletion results in increased synthesis of aldosterone, but the secretion of other adrenocortical hormones is greatly diminished. It is suggested that these changes may interfere with the ability of the animals to withstand stress of other types.

#### Importance of Anemia in Artificially-Induced Metabolic Acidosis

By *Edwin G. Olmstead, Donald A. Roth and John H. Lunseth*. Departments of Medicine and Pathology, Milwaukee County General Hospital and Marquette University School of Medicine.

Three patients with severe blood loss anemia were studied in an attempt to assay the importance

of red blood cell and hemoglobin buffers in overcoming metabolic acidosis. After initial blood pH, nonprotein nitrogen, bicarbonate, chloride, sodium and potassium were obtained, these patients were given 50 mEq. of ammonium chloride intravenously per hour for a 4-hour period. At hourly intervals a blood pH, blood bicarbonate, urinary pH, and total titratable acidity were determined. Two hours after the end of the infusion, 233 mEq. of sodium bicarbonate were administered intravenously, and blood and urinary studies were continued as above.

Following this, patients were transfused with red cell mass to normal hemoglobin levels and red blood counts, and the procedure was again carried out exactly as above.

The study showed no significant change in range of blood pH, bicarbonate, urinary pH or titratable acidity during and following ammonium chloride infusion in this period of anemia, as compared with a period of normal red blood count and hemoglobin levels. No difference in response to infusion of sodium bicarbonate during the state of compensated metabolic acidosis was noted when patients were anemic, as compared with when they had a normal red blood count and hemoglobin level. It was concluded that correction of severe anemia is not an important factor in overcoming ammonium chloride-induced metabolic acidosis nor in correction of this acidosis with sodium bicarbonate.

#### **The Effect of the Administration of an Intravenous Fat Emulsion upon the Blood Lipids of Normal and Hospitalized Subjects**

By *Jack M. Iacono, William W. Cleland, Lucille Palm and John F. Mueller.* Army Medical Nutrition Laboratory, Fitzsimons Army Hospital, Denver.

A study was made of the effect of an intravenous infusion of a fat emulsion on the various serum lipid fractions in 9 healthy volunteer laboratory workers and 9 patients selected at random from a surgical ward of a general hospital. Blood samples were obtained before, at the end and 2 and 4 hours after the end of a single infusion of 600 ml. of a 15% cotton-seed oil emulsion. The whole serum and its subnatant, recovered after centrifugation at 28,000 g for 1 hour, were analyzed for total fatty acid, free and total cholesterol, phospholipid and unesterified fatty acid. It is a reasonable assumption that the subnatant contains most of the soluble lipoprotein, and the supernatant the chylomicron fat.

The concentrations of various lipid components were highest at the end of the infusion, and gradually declined toward normal thereafter. Although there was some individual variation, the hospitalized subjects showed lower concentrations of all fractions than the volunteer subjects, indicating more rapid "clearing" of the infused fat by the former. The con-

centrations in the whole serum and subnatant paralleled one another in the phospholipids, while minor variations occurred in total fatty acids. The most interesting variation occurred in cholesterol, wherein the values in the whole serum followed the expected rise and fall but the subnatant value progressively diminished.

The results of these studies suggest that the transfer of cholesterol from soluble lipoprotein to the chylomicron fraction may be important in fat transport. Cholesterol may function as an actual fat carrier or as a simple emulsifier.

#### **Metabolic Interrelations of Calcium and Magnesium in Patients With and Without Osteolytic Disease**

By *William O. Smith and Leonard P. Etzel.* Oklahoma Medical Research Foundation and V.A. Hospital, Oklahoma City.

Hypomagnesemia of 0.9 to 1.1 mEq./L. with convulsions occurred in 3 patients with osteolytic disease in association with episodes of hypercalciuria, hypercalcemia and renal impairment. Urine excretion of calcium and magnesium was followed daily for a prolonged period. Urine magnesium was found to vary directly with urine calcium, and in a greater amount than could be accounted for on the basis of bone destruction alone; when urine calcium increased by 100 mg. daily, magnesium increased by 6 mEq. daily. When a hypercalciuria of related calcium was produced in 1 of the patients with intravenous EDTA, however, no increase occurred in urinary magnesium.

Two patients without osteolytic disease and with normal renal function were studied with daily intravenous calcium loading while on metabolic balance. Here an inverse relationship was noted: the urine magnesium decreased to 25% of the control values, while urine calcium increased by 700%. However, the serum magnesium declined from 1.9 mEq./L. to 0.8 mEq./L. in 1 patient and from 1.6 mEq./L. to 1.2 mEq./L. in the other. Stool magnesium showed no change. A diuresis of sodium, chloride and water occurred in both patients. It is postulated that the magnesium moved intracellularly. Neither of these patients developed symptoms of hypomagnesemia. No changes in serum or urine magnesium were seen with infusions of an equivalent amount of sodium.

It appears that the normal metabolic response to intravenous calcium loading is an intracellular shift of magnesium with a resultant decrease in extracellular concentration and in renal excretion of this ion. Patients with osteolytic disease show increased renal loss and extracellular depletion of magnesium during hypercalciuria of ionized calcium, possibly due to tubular damage from the intermittent hypercalcemia occurring in such patients.



### 5-Nucleotidase Activity of Human Serum

By *Irving I. Young*. Department of Medicine, Wayne State University College of Medicine, and City of Detroit Receiving Hospital, Detroit.

5-Nucleotidase, a phosphatase specific for nucleotides containing a phosphate esterified at carbon 5 of the pentose, is widely distributed in human tissues. In serum, this enzyme has at pH optimum of 7.5 to 8.0 and is strongly activated by magnesium ion.

Quantitation of 5-nucleotidase activity in serum by determining the rate of hydrolysis of 5-nucleotides is unsatisfactory because of the presence of nonspecific alkaline phosphatase. Selective inhibition of alkaline phosphatase is possible by preincubation of serum with 0.0015 M ethylenediaminetetraacetic acid. At this concentration of ethylenediaminetetraacetic acid 5-nucleotidase is either unaffected or somewhat activated. A unit of 5-nucleotidase activity has been established as equivalent to the liberation of 1 mg. of phosphorus as the phosphate ion during 1 hour of incubation at 37° and pH 7.5 with a substrate containing adenosine-5-phosphate and magnesium ion.

Normal values for adults range from 0.3 to 3.0 U/100 ml. serum. Significant elevations are observed in the presence of biliary tract obstruction, frequently but not invariably parallel to serum alkaline phosphatase activity.

In agreement with the findings of Dixon and Purdom, serum 5-nucleotidase activity is not elevated in diseases of bone associated with high alkaline phosphatase values.

### The Effect of Ether Anesthesia on Pyruvate and Lactate Metabolism

By *William R. Drucker, Christine Costley, Robert Stults, William Holden, Maz Miller, James Craig and Hiram Woodward*. Departments of Surgery and Medicine, University Hospitals and Highland View Hospital, Cleveland, Ohio.

Inhibition of carbohydrate metabolism in the cell may be responsible for ether narcosis. This possibility has been extensively investigated in tissue slices, but relatively few studies have been conducted in man. Our previous studies in man revealed that ether anesthesia caused a marked decrease in glucose tolerance but relatively little change in fructose tolerance. This was interpreted as indicating that ether inhibits specific enzymatic processes.

The present study was designed to determine the effect of ether on pyruvate and lactate metabolism, since pyruvate is the final step in the anaerobic scheme of glycolysis, and it supplies, via acetyl CoA, a main source of fuel for the citric acid cycle.

Ten volunteers were given 2 pyruvate or lactate tolerance tests, 1 as a control and 1 during ether anesthesia. The sodium pyruvate (0.12 Gm./Kg.) or

sodium lactate (0.11 Gm./Kg.) was given intravenously for 1 hour by a constant infusion pump. Arterial blood oxygen was followed by an oximeter and serial measurements of blood gases. The results revealed a marked disturbance in tolerance for both pyruvate and lactate during ether anesthesia despite adequate arterial oxygenation. The average rise during the initial 30 minutes of infusion was: 1.33 mg.% (control) and 3.13 mg.% (anesthesia) for pyruvate; and 8.8 mg.% (control) and 21.4 mg.% (anesthesia) for lactate. The results are of interest in regard to the possibility that decreased energy production due to impaired pyruvate and lactate metabolism may result in narcosis.

### Effects of Pyrazinamide on Serum and Urine Uric Acid

By *Donald F. Gleason, John P. Street and Kenneth A. Kahn*. Department of Medicine, V.A. Hospital, Minneapolis.

Patients being treated with pyrazinamide (3 Gm./day) for tuberculosis were found to exhibit hyperuricemia. Serial 24-hour urine and serum urates were measured in patients and controls, using a uricase ultraviolet spectrophotometric method. Pyrazinamide itself did not interfere with this method.

In 6 male patients, serum urate ranged from 9.4 to 13.6 mg.% (10 controls, 3.6 to 6.1 mg.%) and urine excretion ranged from 140 to 395 mg./day (ten controls, 400 to 740 mg./day) on ordinary hospital diet. Serum urate was 8.2 mg.% and excretion 220 mg./day in 1 female patient.

Pyrazinamide was administered to 3 males after control periods. Urinary excretion decreased precipitously to extremely low levels and then rose slowly into the above subnormal ranges. Serum urate rose rapidly and remained elevated. Simultaneous creatinine determinations and other clinical renal function tests revealed no abnormality, except that PSP excretion ability was depressed in some patients. On discontinuing pyrazinamide, the urate abnormalities reversed promptly, but an excess of urates was excreted for about 1 week.

One patient with no previous gout developed acute gouty arthritis shortly after pyrazinamide was discontinued. However, his serum urate remained elevated. Pretreatment levels were not available. It appears probable that he had asymptomatic gout and the induced abnormalities simply precipitated his first attack.

Increased tubular reabsorption of urates appears to be involved, but alternatives, such as altered ultrafiltrability of urates, are not excluded. Decreased urate excretion persisted after many months of pyrazinamide therapy, apparently reflecting decreased production. This may be a physiologic response to elevated serum levels, but may represent more fundamental disturbance in urate metabolism. The observed phenomena present potential tools for further study of uric acid metabolism and gout.



## GASTROINTESTINAL SYSTEM

### Significance of Increased Urinary Pepsinogen (Uropepsin) Excretion in Duodenal Ulcer and During ACTH Administration

By *B. I. Hirschowitz, D. H. Streeten and H. M. Pollard*. University Hospital, Ann Arbor, Michigan.

To determine whether the mechanisms of increased uropepsin excretion due to ACTH were the same as those responsible for the increases in patients with duodenal ulcer, pepsinogen clearances were measured simultaneously with gastric pepsin secretion in 5 normal males before and during 6 days of ACTH-gel administration, as well as in 6 ulcer subjects with high uropepsin excretion.

In the normal controls and in the ulcer subjects good linear correlation ( $r = +.92$ ) existed between urinary and plasma pepsinogen. The mean pepsinogen clearance in ulcer patients ( $36 \pm 19$  L./24 hr.) did not differ significantly from that in normals ( $44 \pm 14$  L./24 hr.). ACTH administration, however, invariably produced a steep sustained rise in urinary pepsinogen excretion without change in plasma pepsinogen, the mean clearance increasing to  $65 \pm 29$  L./24 hours. Thus, the increased uropepsin excretion in ulcers resulted from elevated blood levels of pepsinogen with a normal renal clearance, whereas the increased uropepsin excretion during ACTH occurred with a fixed plasma pepsinogen and was due to an increased renal clearance of pepsinogen.

The differences between pepsinogen clearances and GFR probably imply some glomerular impediment to excretion, as well as some tubular resorption of pepsinogen (Mol. Wt. 44,000), as is the case with albumin (Mol. Wt. 47,000). The positive correlation between endogenous creatinine and pepsinogen clearances in the normals ( $r = +.68$ ), and increases in both by ACTH ( $p < .01$ ), though proportionately different, (13 and 48%, respectively), suggested that the increases of uropepsin by ACTH may partly be due to increased glomerular filtration of pepsinogen. The uropepsinuric effect of phloridzin (Peczenik) suggests, however, that tubular resorption plays some part in regulating uropepsin excretion.

The relation between gastric pepsin secretion and uropepsin excretion is erratic—ratios vary from 100:1 to 3000:1—even in the same subject, and various substances may affect one independently of the other. This is not surprising, since at least 3 factors may be responsible for elevation of uropepsin excretion: (1) increased peptic cell mass (e.g., longstanding duodenal ulcer), (2) reversal of secretion gradient of peptic cells resulting in elevation of plasma pepsinogen, and (3) increased renal clearance of pepsinogen as produced by ACTH.

### The Effect of Serotonin and Lysergic Acid Diethylamide on the Secretory Response to Reserpine

By *James B. Hammond*. Lilly Laboratory for Clinical Research, Indianapolis General Hospital, Indianapolis.

Because Shore, Silver and Brodie have demonstrated an inhibition of serotonin- and reserpine-potentiated effects of certain hypnotics by lysergic acid diethylamide, it seemed of interest to study the effects of these agents on gastric secretion.

In dogs receiving serotonin intravenously in doses which stimulated intestinal motility, no gastric secretion ensued. Likewise, there was no gastric secretion following the intravenous injection of LSD at a dose producing generalized muscular rigidity. As has been previously demonstrated, the injection of reserpine was followed by a consistent and pronounced gastric secretion. This response was not affected by the simultaneous injection of serotonin but was reduced by the administration of LSD.

These data suggest that peripheral as well as central actions of reserpine may be inhibited by LSD, but not by serotonin.

### The Use of Alcohol as a Liver Function Test

By *David G. Pietz, B. D. Rosenak and R. N. Harger*. Gastrointestinal Clinic, Indianapolis General Hospital, Indianapolis.

Ninety-five % ethyl alcohol, diluted to 25%, was ingested in a dosage of 0.5 Gm./Kg. by 75 subjects as a test for liver function. This is patterned after tests devised by European workers who found that cirrhotics had a higher 4-hour alcohol blood level than normals. Similarly, 3- and 4-hour determinations (the former as a check of the procedure) were obtained using instead, however, a modified Harger Drunkometer rather than blood analysis per se. Four-hour levels of 0-10 mg. %, 10.1-20, and 20.1+ were considered normal, borderline and abnormal respectively. Modifications of the Drunkometer procedure include using the rebreathing technic outlined by Harger, an incubator for maintenance of breath sample at 28°C., 0.25 ml. of  $K_2MnO_4$  in the reagent, and an alteration of the color standards. One standard employs 2 ml. of 5%  $CoSO_4$  with 13 ml. of water. The other uses 1 ml. of 5%  $CoSO_4$ , 1 ml. of 0.1%  $K_2Cr_2O_7$  and 18 ml. of water.

The alcohol test was compared to the 45-min. bromsulfalein determination, which in turn has been classified into normal, borderline and abnormal categories. Each was subdivided into presence or absence of corroborative evidence of liver disease. The latter included clinical history and findings, cephalin flocculation, thymol turbidity, bilirubin and alkaline phosphatase tests.

In the normal bromsulfalein range (37 subjects) there were 2 (5.4%) unexpected results. The inci-

dence of borderline alcohol levels was high when there was other evidence for liver disease. In the borderline bromsulfalein category (5.1-10%), no discrepancies were found. In the abnormal bromsulfalein range (25 patients), the unexpected results were 28%, though they may be as high as 40%.

The alcohol test is most useful in diagnosing mild liver disease in contrast to determining prognosis and differential diagnosis of jaundice. An abnormal value appears to be highly significant.

#### **Hepatic Function and Morphology in Chlorpromazine Jaundice as Affected by Continued Administration of Chlorpromazine**

By *Edward M. Schneider, Charles Daugherty and James K. DeVore*. Department of Medicine, University of Oklahoma School of Medicine, Oklahoma City.

Four patients who developed jaundice while receiving chlorpromazine were studied throughout the course of jaundice while administration of the offending agent was continued in unchanged dosage.

In all 4 patients a group of laboratory tests including liver function studies, serum electrophoresis and lipid phosphorus determinations were done on at least 3 occasions during the periods of observation. In three of the 4 subjects a liver biopsy specimen was obtained at the time of onset of icterus, and again after all clinical and laboratory evidence of jaundice had cleared.

Elevation of serum bilirubin and alkaline phosphatase was noted in every subject at the time of onset of clinical jaundice. In all patients the initial lipid phosphorus was greater than the final determination at completion of the study. The total cholesterol levels paralleled these findings in every patient. In 2 subjects the first liver biopsy revealed periportal infiltration and bile canaliculi plugging. The biopsy on the third subject demonstrated only slight vacuolar fatty change. Repeat biopsies (63-78 days later) in all 3 patients were normal except for persistent slight fatty change in 1.

In three of the four subjects all evidence of jaundice disappeared within 10-21 days. In the fourth subject normal serum bilirubin levels were not obtained until 78 days after onset of jaundice.

The complete return to normal of hepatic function and morphology while chlorpromazine administration was continued effectively dispels the notion that this drug is a specific hepatotoxin. However, the findings herein reported could well find their etiology in one of two other theoretic mechanisms: (1) a hypersensitivity to chlorpromazine, or (2) a combination of biliary dysergias and water diuresis (with resulting dehydration) leading to bile stasis and canaliculi plugging.

#### **The Effect of Oral Ethanol on the Hepatic Glutamic Pyruvic and Glutamic Oxalacetic Transaminase in the Rat**

By *Keith S. Henley, Hugh S. Wiggins and H. M. Pollard*. Department of Medicine, University Hospital, University of Michigan, Ann Arbor.

The effect of alcohol was tested on 4 groups of rats: (1) those receiving 20% alcohol as the sole source of fluid, and on an ad lib diet (10 rats); (2) those receiving water, and pair-fed with those from group 1 (10 rats); (3) those receiving water, pair-fed with group 1, and isocaloric by means of fat supplements (10 rats); (4) those receiving water and fed ad lib (12 rats).

The diet was adequate with respect to lipotropic factors and vitamins, which also were present in the drinking fluid. One-half the animals were killed after 8 weeks, and the remainder after a further 17 days of halved food intake and consequent weight loss. Glutamic pyruvic (GPT) and glutamic oxalacetic (GOT) transaminase determinations were carried out in duplicate on the livers and brains.

After 8 weeks, the mean hepatic GPT activity was significantly lower in group 1 than in group 3 in terms of dry weight, and than group 4 in terms of dry weight and nitrogens. This difference was enhanced by starvation, becoming significant between groups 1 and 2 also. It was significant between group 1 and any of the other 3 groups in the starved and nonstarved animals taken together, in terms both of dry weights and nitrogens. Upon starvation, there was also a significant increase in hepatic GOT activity in groups 1 and 2.

These changes were not reflected in the transaminase determinations on the brains. As the nitrogen contents of the livers were similar in the various groups, the differences were independent of the extent of any fatty changes.

The results show that alcohol causes a reduction in hepatic GPT activity that is enhanced by starvation and is indicative of a direct action of alcohol on the liver.

#### **Percutaneous Transhepatic Cholangiography**

By *William T. Fitzgerald, James C. Redington and William A. Knight, Jr.* Department of Internal Medicine, St. Louis University School of Medicine, St. Louis.

A method of cholangiography by direct instillation of radiopaque dye into the biliary system has been investigated. Results obtained in the study of 14 patients revealed the following lesions of the biliary system: 2 benign obstructions, 11 malignant obstructions and 1 case unsatisfactory for interpretation.

The procedure was performed under local anes-

thetia, following Demerol and atropine premedication. In all cases a transthoracic approach was utilized. The site selected was between the anterior axillary and midclavicular lines, one or two intercostal spaces below the superior border of liver dullness. A 6-inch, 20 gage needle was inserted at this site and directed toward the hilum of the liver. Continuous suction was maintained during insertion of the needle. When a major biliary duct or radicle was encountered, 20 to 40 cc. of the hepatic bile was

aspirated and saved for analysis. Twenty to 30 cc. of 50% Hypaque was then injected into the biliary system, following which appropriate x-rays were made.

With this technic we obtained cholangiograms in 13 of the 14 cases. The findings demonstrated obstruction of the biliary system ranging in location from the ampulla of Vater to the porta hepatis. We encountered bile leakage in 2 cases but no fatalities.

## INFECTIOUS DISEASES

### Penicillinase Formation and Penicillin Resistance in Neomycin-Resistant Staphylococci

By Paul R. Finley and Wendell H. Hall. Laboratory Service, V. A. Hospital, Minneapolis.

While testing the effect in vitro of combinations of neomycin and penicillin against strains of staphylococcus, a phenomenon was observed which has not been reported heretofore. Two strains of hemolytic, coagulase-positive *Staphylococcus aureus* (#9 and #14), obtained from the blood of patients, were exposed separately to neomycin and penicillin. Both strains were highly susceptible to both antibiotics as determined by tube-dilution and disc techniques prior to exposure.

A moderate degree of resistance to the drugs was established by serially transferring the organisms into progressively higher concentrations of the antibiotics. It was observed that the two strains which were rendered resistant to penicillin alone (#P9 and #P14) were effectively inhibited by neomycin. On the other hand, the same two strains exposed to neomycin alone (#N9 and #N14), showed definite resistance to both penicillin and neomycin, especially with a large inoculum. This fact led to the suspicion that the 2 strains (#N9 and #N14) exposed solely to neomycin were able to fabricate a substance capable of negating the effect of penicillin on the staphylococcus in vitro.

From the 2 strains of *Staphylococcus aureus* (#N9 and #N14) that had been exposed to increasing amounts of neomycin, an extract containing a penicillin-inhibiting substance was prepared according to the method of Harper. The extract was able to nullify the bactericidal action of penicillin on a susceptible staphylococcus to a significant degree. The larger the amount of extract added, the more effective was the inhibition. The 2 strains (#N9 and #N14) grown in neomycin alone retained the ability to produce the inhibiting substance after repeated subculture on antibiotic-free media.

The 2 strains of staphylococcus (#P9 and

#P14) grown solely with increasing amounts of penicillin, did not produce an inhibitor to penicillin, albeit they became somewhat more resistant to penicillin than the parent strains, #9 and #14. Large populations of the parent strains contained no demonstrable penicillin-resistant variants nor penicillinase producers.

Strains of staphylococcus in which penicillin resistance has been induced by repeated exposures to penicillin in vitro seldom produce penicillinase, and the resistance is only temporary. Neomycin therapy seldom leads to resistance in the staphylococcus to either neomycin or penicillin, but the present experiments suggest that individuals treated with neomycin might harbor staphylococci resistant to penicillin even though there has been no administration of penicillin. The mechanism of cross-resistance to neomycin and penicillin may be on the basis of the ability of neomycin to induce penicillinase production in the staphylococcus.

### Long-Term Follow-up of Patients with Healed Bacterial Endocarditis

By Buford Hall. Department of Medicine, University of Illinois College of Medicine, Chicago

This study was undertaken to determine the long-term prognosis of healed bacterial endocarditis and to note factors which influence the prognosis. The present status of all 17 patients who were discharged from the hospital cured of bacterial endocarditis 6 or more years ago was determined. During the first year after antibiotic treatment, 5 patients died—3 of congestive heart failure and 2 of noncardiac causes. Two additional patients died 26 months and 6 years after penicillin therapy, of coronary heart disease and congestive failure, respectively.

Of 10 living patients, followed 6 to 10 years, 4 are in Class I (functional capacity, A.H.A.), 5 are in Class II, and 1 is in Class III. The patient followed for the longest time has had 2 children and no cardiac symptoms whatever.

The total dosage of penicillin administered, the duration of therapy and the presence of previous treatment had no demonstrable effect on the prognosis in these patients.

The mean ages at the time of the infection of the 10 survivors and of the 5 who died of heart disease were 31.5 and 40.8 years, respectively. Four of the latter group had aortic regurgitation (3 with cardiomegaly), while only 3 of the 10 survivors had aortic regurgitation (1 with cardiomegaly) at the time of hospitalization. Of 7 patients with aortic regurgitation, 4 are now dead and the other 3 have shown a decrease in functional capacity. Of 9 patients having only mitral valve disease, 2 are dead (1 of tuberculosis), 3 have worsened symptomatically, and 4 are unchanged. A patient with the tetralogy of Fallot died following thoracotomy.

This study shows that some patients may remain well 6 to 10 years after recovery from bacterial endocarditis, especially if aortic regurgitation is not present after therapy.

#### The Neutralizing Antibody Response to Adenovirus Infection

By *J. Thomas Grayston, Clayton G. Loosli, Paul B. Johnston, Mabel E. Smith and Robert L. Woolridge.* University of Chicago School of Medicine, Chicago; the Naval Medical Research Unit No. 4, USNTC, Great Lakes, Illinois.

Studies were performed on 53 paired sera from patients suffering upper respiratory illness and having an adenovirus isolated from their throat washing. Adenovirus types 1 through 10 as antigen were run against each serum pair in a newly developed simplified tissue culture neutralization technique. The test procedure consisted of adding the viral antigen, the serum and a HeLa cell suspension at one time to culture tubes. Neutralization of virus by serum allowed normal HeLa cell growth, while excess virus caused cytopathogenic changes that could be read at 1 or 2 days. Neutralization tests with rabbit type specific antisera failed to show any significant cross-reactions among the 10 types.

Of the 53 persons studied, adenovirus type 3 was isolated from five; type 4 from 25; and type 7 from 23. Four-fold serum neutralizing titer rises were found with the homologous antigen type in all but 2 paired sera. Heterologous rises were found in approximately 20% of the tests with the 10 antigen types. The percentages of heterologous rises with each antigen type ranged from 13 to 44. The most frequent heterologous rises were observed with antigen types 3, 4 and 6.

The presence of neutralizing antibody in the acute serum sample apparently did not predispose to a heterotypic rise. No clear pattern of cross-

reactions emerged from the study. It is concluded that there exist immunologic relationships of adenovirus types 1 through 10, as demonstrated by neutralization tests, which are not apparent in rabbit type specific antisera.

#### Nephrotic Syndrome in Adults

By *Victor E. Pollak, Robert M. Kark, Conrad L. Pirani and Robert C. Muehrcke.* Departments of Medicine, Presbyterian Hospital, Research and Educational Hospital, and Cook County Hospital; Department of Pathology, University of Illinois College of Medicine, Chicago.

In adults the nephrotic syndrome is the clinical expression of many different disease states. It may result from damage primarily to glomeruli, from damage primarily to tubules, or from increased pressure in renal veins, as in renal vein thrombosis and constrictive pericarditis. Clinical differentiation of these causes is difficult. We have studied by percutaneous renal biopsy 67 adult nephrotics, and these studies have reflected a wide range in pathology and etiology.

Subacute or chronic glomerulonephritis was found 26 times. The lesions were membranous in some and proliferative in others, but mixed lesions were frequently found. Diffuse glomerulosclerosis was found in 3 of 16 patients with diabetes mellitus; diffuse and nodular lesions in 7; diffuse, nodular and exudative lesions in 6. Eight patients with SLE had the nephrotic syndrome, and 3 others had the pseudonephrotic syndrome. The lesions of lupus nephritis were more severe in the pseudonephrotics. Primary renal amyloidosis was found once, bilateral renal vein thromboses twice, and once the lesion was undiagnosed. The kidneys were normal in 4 patients studied only after diuresis. With increasing experience it was possible to make exact histologic diagnoses in over 90% of cases, and to forecast, on the degree and type of glomerular damage, the prognosis and the response to treatment with ACTH or corticosteroids.

The histologic appearance of the kidneys was unique in 6 patients. The glomerular capillaries contained an unusually large number of erythrocytes, but the basement membrane and epithelial and endothelial cells of the glomerulus were normal. Severe tubular degeneration and edema of the interstitial tissue were observed. ACTH or corticosteroid administration resulted in an excellent diuresis. During diuresis the tubular epithelium was taller and less degenerated, and the glomerular capillaries contained few erythrocytes. These 6 patients are alive; 3 enjoy excellent health; and none has developed evidence of progressive renal disease.

### Nephron Function in Elderly Men Following Bladder Neck Obstruction

By John B. Wild and Walter M. Kirkendall. Renal Laboratory, Department of Internal Medicine, and the Department of Urology, State University of Iowa and the Medical Service, V. A. Hospital, Iowa City.

We studied the clearance of sodium para-aminohippurate ( $C_{PAH}$ ), inulin ( $C_I$ ), sodium ( $C_{Na}$ ), potassium ( $C_K$ ) and chloride ( $C_{Cl}$ ) in 9 men with prostatism whose ages varied from 65 to 86 (average 75). A total of 19 studies were done. Each patient was tested immediately after decompression. In 3 of them, studies were repeated in the following year to gain information about the functional renal defect and the manner and degree of recovery.

Clearance values are expressed as ml./min./1.73 M<sup>2</sup>.  $C_{PAH}$  varied from 9 to 307,  $C_I$  from 8 to 105 shortly after decompression. Filtration fraction (FF) was high (.23 to .9) in 7 patients, low in 2 (.17, .14), suggesting that proximal tubular function was relatively more impaired than glomerular filtration. This was supported by the fact that renal extraction of PAH in 2 patients was found to be 50% in 1 with  $C_{PAH}$  of 44 and 86% in the other with  $C_{PAH}$  of 297.  $C_{Na}$ ,  $C_K$  and  $C_{Cl}$  were within normal limits in all patients. Three patients were given aminometradine (Mictine), 6 acetazolamide (Diamox) intravenously, and in each electrolyte excretion changed as acutely as in normal persons. This suggests that distal tubular function in the remaining nephrons was adequate to maintain these electrolytes in balance in our patients.

Our results reinforce the knowledge that severe depressions of  $C_{PAH}$  and  $C_I$  may result from urinary obstruction. They also show that, although these clearances do not improve greatly after relief of obstruction, kidney function was compatible with tolerable health and stationary but slightly elevated blood urea nitrogen levels.

The role of infection, undoubtedly great, could not be separated from those of obstruction and secondary hydronephrosis. Practically all patients on admission had leukocytosis, fever and infected urine and were treated by antibiotics before or after the kidney studies.

### Enterodialysis in the Management of Renal Failure: A Metabolic Balance Study with Consideration of the Exchange Rates of Electrolytes and Non-protein Nitrogen

By Paul R. Schloerb. Department of Surgery, University of Kansas School of Medicine, Kansas City; the Research Laboratory and Radioisotope Service, Kansas City V. A. Hospital, Kansas City. (Aided by a grant from the U.S. P. H. S.).

In an attempt to combine the relative merits of intestinal perfusion and extracorporeal hemodialysis for the removal of accumulated toxic metabolites in uremia, a method using perfusion of a closed cellophane tube within the intestinal tract is being developed. An interim evaluation of this method in the normal human, and one terminally uremic patient with correlative findings in nephrectomized dogs, is described in this preliminary report.

A closed cellophane tube is introduced into the intestine. By means of suitable connections, a dialyzing fluid of appropriate electrolyte and osmolar concentration is perfused through the lumen of the cellophane tubing. Exchange rates of radio-sodium, radiopotassium and heavy water have been measured between the blood and the lumen of the cellophane tube in both directions in dogs. Metabolic balance studies have included analyses of serum and dialysate fluids for Na, K, Ca, Mg, Cl, P,  $HCO_3$ , NPN, BUN, Glucose and pH.

One uremic patient, a 46-year-old man with arteriolonephrosclerosis and malignant hypertension, was terminal despite the usual medical supportive measures and was treated by enterodialysis using 7 feet of  $2\frac{7}{32}$ " diameter cellophane, introduced into the intestine by jejunostomy under local anesthesia. Intermittent perfusion-aspiration was done, averaging every 150 minutes with a mean volume of perfusate of 400 ml. Six hours after beginning enterodialysis, reorientation and arousal from coma occurred. During the period of 63 hours, when death occurred from myocardial infarction, 50 mEq. of potassium and 14.7 Gm. of nonprotein nitrogen were removed without significant change in other electrolytes. At the shorter perfusion times (60-75 min.), the rates of removal of potassium and nitrogen were double the over-all average, corresponding to daily rates of removal of 36 mEq. of potassium and 12 Gm. of nitrogen, amounts which are in excess of the minimum daily dietary requirement.



# KIDNEY

## Changes in Body Water Compartments during the Course of Acute Renal Insufficiency

By *Alexander P. Remenchik, James A. Schoenberger and Josephine M. Dyniewicz.* Department of Medicine, University of Illinois College of Medicine, Chicago.

Although changes in body water compartments in acute renal insufficiency have been extensively studied in experimental animals, only a limited number of observations on man has been published. From 1 to 3 simultaneous studies of antipyrine space (AS) and radiosulfate space (RSS) were made in 8 patients with acute renal insufficiency. All patients, after diagnosis, were managed during the oliguric phase by continuous intravenous administration of hypertonic dextrose in water in amounts less than 600 cc./24 hours. In 6 of the patients the initial AS was greater than 60% of the body weight. In 3 patients, who recovered from acute renal insufficiency, there was a marked fall in AS to values within normal limits. In 1 patient studied frequently during the period of oliguria, the initial AS was in the normal range and subsequent changes in AS correlated with changes in body weight. The remaining 4 patients expired before additional studies were done.

The initial RSS was greater than 20% in all of the patients. In the 3 patients who survived, the RSS fell to normal in 2 and to near normal in the other. In contrast to other types of patients, there was no significant loss of radiosulfate from the RSS into sinks other than the urine during the oliguric phase.

The results are in agreement with the conclusions of other investigators that there is an accelerated net catabolic rate in acute renal insufficiency. This increased catabolism of body tissue produces a quantity of water larger than had been previously realized, and the diuretic phase in part represents the excretion of excess quantities of water and electrolytes accumulated during the catabolism of this tissue. If this interpretation is correct, then the therapy of acute renal failure should be modified accordingly.

## The Ratio TM/Renal Weight: An Index of Renal Scarring

By *A. P. Crosley, Jr., J. F. Brown, B. Schuster, D. A. Emanuel, H. Tuchman, C. Castillo and G. G. Rowe.* Department of Medicine and Cardiovascular Laboratory, University of Wisconsin Medical School, Madison.

The ratio of the functional tubular mass of the kidney ( $Tm_{PAR}$ ) to in vivo determined renal weight has been conceived in this laboratory as an index

of renal scarring. The following evidence, based on studies of this function in 5 normal subjects and 12 patients with renal disease, is presented in support of this thesis. The normal range for the ratio was 0.16 to 0.26. Patients with chronic glomerulonephritis, where  $Tm_{PAR}$  is reduced in proportion to weight as nephrons are destroyed by glomerular damage, had normal values. In contrast, individuals with chronic pyelonephritis, where damage is primarily parenchymal and followed by scar formation, showed a reduction of the ratio in all cases. Diabetics, with nephropathy, where damage may be primarily glomerular and/or parenchymal, had values which were either within normal limits or reduced. Patients with benign nephrosclerosis showed an elevation of this relationship.

These findings, with the exception of benign nephrosclerosis, are therefore in accord with the changes which might be expected from the pathologic findings in these entities. In all types of kidney diseases these observations are in agreement with previous results relating renal oxygen consumption to  $Tm_{PAR}$ .

## Relation of Renal Vein Pressure to Renal Vascular Resistance and Urine Flow Rate

By *F. J. Haddy, M. Fleishman and J. Scott.* Army Medical Research Laboratory, Ft. Knox, Kentucky.

The role of the absolute level of venous pressure in determining vascular resistance and urine flow rate has been studied in 101 pentobarbitalized laparotomized dogs. In 58 instances, renal blood flow was controlled by interposing a pump in the renal artery. With blood flow rate constant, elevation of renal vein and artery pressures by venous obstruction resulted in an immediate elevation of renal vascular resistance but no change in urine flow rate. Neither value changed in denervated kidneys. During renal artery infusion of acetyl- $\beta$ -methylcholine and phentolamine, the maneuver resulted in a resistance decrease. The resistance decrease was of borderline significance with phentolamine alone. Progressive elevation of artery pressure and blood flow rate resulted in equal resistance decreases in innervated and denervated kidneys as long as vein pressure was maintained at a low constant value. However, with vein pressure elevated, resistance increased with artery pressure and blood flow rate. In the absence of the pump, urine flow rate immediately decreased upon elevation of vein pressure in both innervated and denervated kidneys. Vein pressure elevation during renal artery infusion of histamine, acetyl- $\beta$ -methylcholine, phentolamine plus acetyl- $\beta$ -methylcholine and phentolamine plus physostigmine was associated with urine flow rates

which were well above those with vein pressure normal or elevated in the absence of drugs. The results with phentolamine alone were equivocal.

These findings are interpreted as demonstrating a renal venous-arteriolar reflex having both local and nonlocal components. The urine flow rate decrease induced by vein hypertension may be related to the resistance increase induced by the local component of the reflex. These data also suggest that the apparent "autoregulation" of renal blood flow described by Pappenheimer and others may be more related to activation of the venous-arteriolar reflex than to changes in blood viscosity.

#### **Studies of the Functional Capacity of Autotransplanted Kidneys in Dogs with Comparative Data on the Contralateral (Control) Kidneys**

By *Neal S. Bricker, Ralph Straffon, Ed Mahoney and John P. Merrill.* Department of Medicine, Peter Bent Brigham Hospital; the Harvard Medical School, Boston.

Progress in homotransplantation of human kidneys emphasizes the need to thoroughly assess the functional capacity of transplanted kidneys. Moreover, electrolyte excretion data from transplanted (therefore denervated) kidneys may aid in clarifying the disputed role of renal nerves in electrolyte transport. In an experimental approach to this problem, simultaneous functions of the separate kidneys of unanesthetized dogs with divided urinary bladders were measured serially. After control studies, 1 kidney in each animal was autotransplanted (5 dogs) or denervated in situ (2 dogs). Contralateral kidneys served as controls. Follow-up

clearances were obtained up to 6 months after surgery.

GFR in all transplanted kidneys decreased markedly initially and thereafter increased, ultimately equalling control (contralateral) values in 2 animals. Regardless of level, GFR increased substantially in transplanted as well as control kidneys following ECF expansion with hypertonic NaCl, hypotonic NaCl or synthetic ECF. ERPF initially decreased in transplanted and increased in control kidneys. Thereafter, values approached pretransplantation levels.

Concentrating ability of transplanted kidneys ( $T_{H_2O}/C_{Cr}$ ) compared favorably with control kidneys although the response to Pitressin was often delayed.

A relative Na-losing state occurred in most transplanted kidneys. However, 1 animal did not manifest this abnormality, and in 2 others it ultimately disappeared. Similar defects were not apparent in nontransplanted denervated kidneys. Following ECF expansion, Na reabsorption increased with GFR in all kidneys, thereby establishing filtration dependence of Na reabsorption in denervated kidneys. During anesthesia, GFR consistently decreased only in control kidneys, and changes in Na excretion correlated with alterations of filtered loads.

Conclusions: (1) Autotransplantation of dog kidneys is associated with impairment of renal hemodynamics, which is reversible despite normal contralateral kidneys. (2) Permanent denervation is not associated with persisting gross defects in Na transport. (3) Anoxia sustained during transplantation may be causally related to the physiologic abnormalities.

## **NERVOUS SYSTEM**

#### **Frenquel: Studies in Dosage and Duration of Action**

By *John T. Ferguson and Thos. G. Allin, Jr.* Department of Medical Research, The Wm. S. Merrell Company, Cincinnati; the Traverse City State Hospital, Traverse City, Michigan.

Patients suitable for treatment with Frenquel are selected on the basis of response to a series of 3 intravenous test doses of 100 mg. given at intervals of 4 hours. In those cases in which behavior is improved, the drug is then administered orally in dosage of 40 mg. 3 times daily with supplemental intravenous Frenquel and other therapeutic measures as indicated.

Therapeutic results with Frenquel have been highly gratifying when patients are selected by this method. On May 1, 1956 a total of 164 patients in

the female wards at the Traverse City State Hospital were receiving maintenance doses of 40 mg. 3 times daily by mouth. In all cases a single daily dose of 100 mg. was substituted. In those cases in which behavior was not as well controlled, supplementary doses of 100 mg. were given later in the day as needed. The experiment was terminated after a period of 14 weeks. At that time, of a total of 164 patients, only 76 were maintained adequately on the single daily dose of 100 mg.; 65 had been switched to 100 mg. twice daily, and 23 to 100 mg. 3 times daily.

At the conclusion of the experiment, all the Frenquel patients were put back on 40 mg. 3 times daily, which dosage appears to be as effective as 100 mg. 3 times daily. It is recommended that prior to initiation of Frenquel therapy, all patients

be given a test series of 3 intravenous doses of 100 mg., each at intervals of 4 hours. Those not responding should then be tested with other types of therapy. Those helped by intravenous Frenquel

should be put on a maintenance dose of at least 40 mg. 3 times daily by mouth. Other drug psychotherapy and shock may and should be used in combination with Frenquel when indicated.

## RESEARCH METHODS

### A Graphic Method for the Evaluation of Percentage Differences

By *Henry S. Bloch*. Department of Internal Medicine, State University of Iowa, Iowa City.

Diagnostic and therapeutic considerations in medicine are based to a large extent on collections of cases in which the incidence of certain signs and symptoms in a disease, or the number of patients succumbing to or recovering from an illness, has been counted. The evaluation of such statistics depends on comparison with allied experience. Analytic methods are available for this purpose, but they are rather complex.

This paper describes a simple graph for the evaluation of percentage differences between 2 series of observations.\* The abscissa  $N_A$  represents the total number of cases in the smaller of the 2 series which are to be compared. The ordinates  $\Delta p$  represent the percentage difference in the incidence of the phenomenon under study between the series. The scales  $p_0$  (or  $q_0 = 100 - p_0$ ) represent the percentage incidence of the phenomenon in both series combined.

The use of the graph may be illustrated by means of a simple example: the mortality in a series of 10,000 cases of *Z* disease was 10%. A physician treats 100 comparable patients with this disease by a new method; the mortality in his series is 4%. Is the success of the new treatment likely to be due to chance alone? To answer this question with the graph one may proceed as follows: (1) Find the value of 100 on the abscissa  $N_A$  and draw a vertical line through this point. (2) On the scale of ordinates  $\Delta p$  marked "1/∞" find the value 6 (=10 - 4) and draw a horizontal line through this point until it intersects the line through  $N_A = 100$ . The intercept gives the point  $\Delta p, N_A$ . (3) Find the value of  $p_0 = (4 + 1000)/(100 + 10,000) \times 100 = 10$  on scales  $A_1$  and  $A_2$  and draw a straight (diagonal) line through these 2 points.

The relation of the point ( $\Delta p, N_A$ ) to the diagonal line determines whether or not the difference between the 2 series is "statistically significant." Points on diagonal lines through scales  $A_1$  and  $A_2$  have a level of significance of  $p = .01$ ; points above

these lines have a higher level of significance ( $p < .01$ ); those below have a lower level of significance ( $p > .01$ ). Points on diagonal lines through  $B_1$  and  $B_2$  have a level of significance of  $p = .05$ ; points above these lines have a greater, those below have a lesser level of significance.

In the example cited, the difference between the 2 series is not significant at a level of  $p = .01$ . To test if the difference is significant at the lower level of  $p = .05$  draw a line through the points  $p_0 = 10$  on scales  $B_1$  and  $B_2$ . The point (6100) lies above this line, indicating that the observed difference is statistically significant at a level higher than  $p = .05$ .

### Description and Applications of New High-Sensitivity Technics for Study of Serum Lipoproteins by Zone Electrophoresis

By *William Q. Wolfson and Brenton H. Penwarden, Jr.* Department of Medicine and the Laboratory Service, U.S. Army Hospital, Fort Riley; Office of the Regimental Surgeon, Headquarters 18th Infantry Regiment, Fort Riley, Kansas.

Available methods for demonstrating lipoproteins on electropherograms by staining are insensitive and tend to give diffuse bands and high interfering background, partially corrected at the expense of quantification by washes with mixtures of water and lipid solvents. Such washes are eliminated by a simple modification of post-run Sudan Black B staining, but new technics were required to overcome insensitivity. Pre-run staining with Nachtblau reveals serum patterns comparable to post-run Sudan Black B, but without background; both are selective for slow-moving  $\beta$  and zero lipoprotein. Intrarun staining with Nilblau or intrarun staining with Sudan Black B by migration over impregnated paper gives similar patterns which selectively demonstrate the faster lipoprotein and  $\alpha$  lipoproteins. Combined use of pre-run Nachtblau and intrarun Nilblau permits demonstration of the full lipoprotein pattern which, under favorable conditions, has included up to 10 discrete bands in normal serum without elevated lipids. Intrarun Nilblau is more reproducible than intrarun Sudan B, and the former's background is removable by tap-water; a further major advantage of Nilblau is that, during the run, bands exhibit color

\* *Editor's Note:* The graph has been omitted because of physical limitations of the Journal.

bright green through electric blue to brilliant red-yellow.

Such double staining with oxazine dyes long has been known to depend on the fatty acid/neutral fat ratio; colors seen for various serum protein bands are consistent with this view. Since lipoprotein lipase (clearing factor) shifts lipoprotein to faster higher-density components and increases fatty acid/neutral fat ratios, these methods offer a simple method for observing both changes, and their applicability to normolipemic sera increases the possibilities for physiologic studies.

#### Can Serum Protein-Bound Carbohydrates Accurately Be Detected on Electropapergrams by Stains Employed for Tissue Carbohydrates?

By William Q. Wolfson and Brenton H. Penwarden, Jr. Laboratory Service and the Department of Medicine, U.S. Army Hospital, Fort Riley; Office of the Regimental Surgeon, Headquarters 18th Infantry Regiment, Fort Riley, Kansas.

Serum electropapergrams of normals and patients were stained for protein with bromphenol blue or amidoschwarz, and compared with duplicates stained with Schiff reagent, toluidine blue, acid crystal violet and/or mucicarmine following no oxidation, periodic acid, bromine water or periodic acid and bromine. Isolation data show about half of serum protein-bound carbohydrate in  $\alpha$  globulins with virtually none in albumin. Reproduction of this pattern was the standard for evaluating staining technics, and none were successful. Schiff is capricious and highly subject to artifacts. Untreated strips with presumably masked aldehydes stain strongly. Oxidation increases are chiefly in low-carbohydrate regions. Peak Schiff/protein ratios usually are not in  $\alpha$  globulin. Toluidine blue stains untreated strips poorly, acid crystal violet well. Both increase intensity and toluidine blue, also metachromasia with periodate, but more strikingly with bromination. However, bromination or periodate virtually abolishes mucicarmine staining. Except for one myeloma component, all fractions showed toluidine/protein ratios between 0.85 and 1.35, indicating nonselectivity.

There exists a demonstrable and real discrepancy, as yet unexplained, between Rice's results with acid crystal violet and ours. Such results suggest that each of these special stains colors a chemically different component. However, if each stain is used under conditions of maximal staining, the pattern always resembles the general protein pattern in locus and relative intensity of bands. These results do not support the view that any of the indicated procedures are reliable indices of serum protein-bound carbohydrate. The simplest, and perhaps strongest objection, however, is that current methods make the implicit assumption that 3

$\mu\text{g.}$  of carbohydrate (about 0.2  $\mu\text{g.}$  of heteropolysaccharide reactive aldehyde) distributed over 1  $\text{cm.}^2$  of paper will give brilliant staining by methods which are not particularly notable for high sensitivity or freedom from background.

#### A Rapid Colorimetric Method for the Determination of Oxygen Saturation of Whole Blood by Reflectance

By William Meltzer and George A. Saxton, Jr. Respiratory Center, Department of Preventive Medicine, University of Illinois College of Medicine.

A simple, inexpensive method for determining oxygen saturation of human blood, unaffected by hematocrit changes, seemed desirable. Therefore, an abridged reflectance spectrophotometer (Color Eye), employing a broad-band red (X) filter (520-700  $\text{m}\mu$ ), was used to compare blood samples of known saturation with a series of color comparators, to establish the latter as standards for future comparisons with bloods of unknown saturation. It was then possible to make visual comparisons in a simple black box using light passed through an X filter, to determine oxygen saturation quickly and inexpensively.

The following facts were established: (1) Fully saturated blood from different normal individuals is the same color as indicated by the Color Eye and visual color comparators. Twenty of 24 bloods from different individuals, when equilibrated with room air, gave identical Color Eye readings. The other 4 (all indicated lower saturations) were found to have elevated hematocrits (52-68). (2) Hematocrit is not a factor affecting reflectance within certain limits. Blood from individuals with normal hematocrits did not show different reflectance when the RBC's were concentrated by centrifugation or diluted by addition of plasma, between 15 to 75 hematocrit. (3) The color of whole blood at a given saturation does not vary as a function of oxygen tension. Equilibrating blood with room air and with 30, 40, 60, 80 and 100% oxygen gave identical Color Eye readings.

On the basis of these studies a simple reflectance method for the determination of oxygen saturation of freshly-drawn arterial blood in a syringe has been established. A blood sample is compared visually with commercially available calibrated color standards to a degree of accuracy of plus or minus 1-2% in the range of 70-100% saturation. The clinical practicability of the method is much broader than those which require a technician and a laboratory instrument, since the cost of a light source, X filter, black box and color comparators does not exceed \$100, and the method can be used without special training.

# RESPIRATORY SYSTEM

## A Simple Inexpensive Method for Determination of Vital Capacity and Maximal Breathing Capacity in Normal Subjects and in Patients with Lung Disease

By *Eugene W. Worton*. Department of Internal Medicine, State University of Iowa College of Medicine, Iowa City.

The purpose of this paper is to present a method for measuring vital capacity and maximal breathing capacity (MBC) in normal people and patients with lung disease utilizing simple and inexpensive equipment, and to compare the accuracy of values obtained with this equipment with those obtained using standard equipment. The apparatus consists of a mouthpiece, an Edison unidirectional valve, a 30-inch piece of corrugated rubber tubing and an American Meter Company gas meter. Values are read from a dial on the face of this meter. No recording apparatus is necessary. Cost of the equipment is less than \$100. To perform the tests the subject inspires room air and expires through the meter.

Vital capacity measurements were made using this equipment and a Benedict Roth spirometer (standard method). Twenty normal subjects and 10 patients with lung disease were studied. Mean values in normal subjects were 4.54 L. by the gas meter method and 4.55 L. by the Benedict Roth method; in patients with lung disease, 3.23 L. by the gas meter and 3.04 L. by the Benedict Roth method.

MBC was measured with the apparatus described and also by the standard method in our laboratory, utilizing a low resistance valve and a Tissot spirometer. The same 30 subjects were studied. Mean values in normal subjects were 121.7 L. by the gas meter method and 141.4 L. by the Tissot method; in patients with lung disease, 41.3 L. by the gas meter method and 49.7 L. by the Tissot method.

Measurement of vital capacity is extremely accurate by this method. MBC values were lower by this method than by the standard method, which is compatible with the known higher resistance in the gas meter system. The method is sufficiently accurate to be used by practicing physicians, and combines economy and simplicity.

## The Inaccuracy of the Water-Filled Spirometer in the Measurement of the Maximum Breathing Capacity

By *William W. Stead, Herbert S. Wells, N. L. Gault and John Ognanovich*. V. A. Hospital, Minneapolis.

Bernstein has shown that the water-filled spirometer may record anywhere from 50-140% of the volume of air that is pumped into it during determination of maximal breathing capacity, de-

pending upon the characteristics of the spirometer and the rate and depth of the respiration. We have studied both the 9 and the 13.5 L. respirometers made by Collins, and have obtained curves of frequency response that are similar in form to that given by Bernstein for the Knipping spirometer. The purpose of this paper is to illustrate some of the causes for the recording errors observed.

At rates of breathing and air flow that are involved in basal breathing the spirometer records accurately (response of 100%). At frequencies of 80-90/min. the spirometer records less than the actual volume (response of 90%). At greater frequencies the spirometer overshoots (response progressively greater than 100%). The inaccuracy of the 9 L. spirometer is greater than that of the 13.5 L. spirometer.

Analysis of the physical reasons for the discrepancies has revealed the following: (1) The early under-response is due to the motion of the water as it is forced up and down by the rapidly changing pressures. This effect can be lessened considerably by the use of a light plastic bell which fits close to the inner drum of the spirometer. (2) The later and progressively greater overshoot of the recording pen is due to a combination of factors, the greatest of which are the inertia associated with the weight of the metal bell and its counterweight, and the snapping and slacking of the chain which connects the moving bell with the recording pen. These defects were mitigated by mounting the writing pen directly on the light plastic bell. We are presently working on other causes of inaccuracy in spirometer recording, and on a design for a better instrument.

## Nitrogen Clearance Rates of Right and Left Lungs in Different Postures

By *Glen A. Lillington, Ward S. Fowler, R. Drew Miller and H. Frederic Helmholtz, Jr.* Mayo Clinic and Mayo Foundation, Rochester, Minnesota.

Study of total expired gases has shown that nonuniformity of alveolar ventilation occurs normally and is increased in many pulmonary diseases, but the responsible mechanisms and spatial locations are uncertain.

Alveolar ventilation of individual lungs was studied by use of bronchospirometric catheter and continuous measurement of concentration of nitrogen and flow rate of gases expired during inhalation of oxygen. Right and left lungs of 5 normal men in the supine and both lateral decubitus positions were studied. Nitrogen clearance curves of multiple exponential form were found, and their analysis showed that uneven alveolar ventilation of similar magnitude was present in all lungs in all postures. In the supine position, tidal volume, dead space and functional residual capacity were greater for the right lung than the left, but turnover rates of al-



veolar gases and the relative magnitude of slowly and rapidly ventilated regions of both lungs were similar. In lateral decubitus positions, the ventilatory pattern of the dependent lung was similar to that of the supine position. The superior lung had an increased functional residual capacity and decreased tidal volume. Alveolar turnover rates of both rapidly and slowly ventilated components of a lung were only about half as great when it was in the superior position as they were in the same lung when the patient assumed the supine position.

Relative alveolar turnover rates of right and left lungs varied with certain postures, an indication of the existence of regionally uneven ventilation of an anatomically variable type. Uneven alveolar ventilation of undetermined nature also occurred within normal single lungs.

#### **The Influence of Plasmin upon Experimental Pulmonary Emboli and Pulmonary Infarcts**

By Paul Rueggesser, Irwin Nydick, John S. LaDue and Eugene E. Clifton. Memorial Center for Cancer and Allied Diseases, New York City.

The effects of plasmin, a fibrinolytic enzyme, were studied during different phases of the evolution of pulmonary infarcts in rabbits. A method was devised whereby pulmonary infarction could be produced consistently following embolization. Plasmin was administered intravenously in varying dosages at different times following embolization, and its influence upon the animals' course was studied.

Polyethylene catheters were threaded into the right heart of rabbits via the jugular vein. Preformed clots of different sizes were injected into these catheters in a group of 17 control rabbits and a group of 15 "treated" rabbits.

Sixteen of the 17 control rabbits revealed pulmonary infarction at autopsy, usually extensive in degree. Four of these rabbits had died within 24

hours after embolization from shock or acute right heart failure.

Plasmin was administered to the treated group in doses of 6 to 9 mg./Kg. body weight. All of the plasmin-treated rabbits survived. None of the 5 rabbits treated within 40 minutes after embolization showed infarction at autopsy. Of 6 rabbits treated within 4 to 24 hours, the lungs were normal in 3, and single small residual infarcts were seen in the other 3. Two animals treated after 40 hours showed somewhat larger areas of infarction. Two animals were treated promptly after 2 separate series of embolization. Both survived, 1 with clear lungs and the other with 2 small infarcts, whereas the control rabbit died promptly after the first embolization.

#### **Endobronchial Involvement in Systemic Sarcoidosis**

By Gordon L. Snider and S. Allen Mackler. Michael Reese Hospital, Chicago.

Sarcoidosis has been reported to involve virtually every organ and tissue of the body. The lung parenchyma is commonly involved in systemic sarcoidosis, but bronchial involvement has been reported infrequently. In 1952 a patient presenting with the clinical picture of bronchial asthma was found to have systemic sarcoidosis with endobronchial infiltration by the disease process.

Since that time, approximately 40 cases of sarcoidosis have been thoroughly studied, including ventilatory function studies and biopsy of enlarged superficial nodes or scalene lymph nodes. Bronchoscopy and routine bronchoscopic biopsy were performed on these patients. Although the mucosa appeared grossly normal in most instances, over half of the biopsy specimens showed granulomatous endobronchitis consistent with sarcoidosis. Ventilatory function studies frequently showed mild degrees of reversible airway obstruction.

No  
Ab

I

S

V

No  
Na

I

S

A

Ab

Ab

Ab

Ac

Ac

Ag

Ag

Al

Al

Al

Al

Al

Al

Al

Al

Al

Al

Al

Al

Al

Al

Al

Al

Al

Al

Al

Al

Al

Al

Al

Al

Al

Al

Al

Al

Al

Al

Al

---

## Clinical Research Proceedings, Vol. IV, 1956

---

### No. 1, JANUARY

#### Notices, page 1

Abstracts Submitted to Sectional Meetings of the  
American Federation for Clinical Research:  
Eastern Section, Philadelphia, December 1955,  
page 3  
Southern Section, New Orleans, January 1956,  
page 24  
Western Section, Carmel, Calif., January 1956,  
page 49

### No. 2, APRIL

#### Notices, page 71

National Meeting of the American Federation for  
Clinical Research:  
Program, page 73  
Subsection Programs, page 75  
Advance Research Reports, page 77

### No. 3, SEPTEMBER

On the Teaching of the Science of Medicine, page 161  
"Lest One Good Custom . . .," page 168  
Correspondence, page 168  
Notices, page 170  
Membership Roster: American Federation for Clin-  
ical Research, page 172  
Abstracts Submitted to the Ninth Annual Meeting,  
Western Society for Clinical Research, page 196

### No. 4, NOVEMBER

Statistics and the Individual Patient, page 225  
Medical Research in the Area of the Southern Section  
of the American Federation for Clinical Re-  
search, page 227  
Advance Reports Submitted to the Annual Meeting  
of the Midwestern Section of the American Fed-  
eration for Clinical Research, page 232  
Annual Author Index, page 259  
Annual Subject Index, page 263

---

## AUTHOR INDEX

---

- Abarbanel, A. R., 214  
Abbott, O. A., 46, 68  
Abelmann, W. H., 147  
Adams, W. S., 212  
Adlersberg, D., 91  
Agnà, J. W., 150  
Agress, C. M., 205  
Aikawa, J. K., 64, 106  
Akeroyd, J. H., 234  
Albright, H., 112  
Albrink, M. J., 121  
Alden, J. A., 65  
Aldrich, R. A., 211  
Alexander, C., 136  
Allin, T. G., Jr., 253  
Almy, T. P., 131  
Alpen, E. L., 65  
Alpert, H. C., 125  
Altland, P. D., 239  
Alzamora, C. C., 104  
Amatruda, T. T., Jr., 124  
Amkraut, A., 197  
Anderson, R., 83, 198  
Anderson, W. H., 113  
Antonowicz, I., 139  
Apt, L., 79  
Arias, I. M., 144  
Arons, W. L., 14, 118  
Atlas, L. T., 38  
Auchincloss, J. H., 18,  
151  
Auerbach, T., 126  
Azen, N. H., 109  
Babcock, E. B., 131  
Bakke, J. L., 58, 207  
Balchum, O. J., 56, 57,  
201, 202  
Balfour, D. C., Jr., 63,  
218  
Ball, R. E., 204  
Ballard, J., 55, 56  
Ballon, J. D., 112  
Baltch, A., 156  
Bane, H. N., 14, 127  
Barger, L. M., 100  
Barnet, H. N., 196  
Barnwell, J. B., 114  
Baronofsky, I. D., 65  
Barrett, J., 56  
Bartlett, G. R., 196  
Bascoy, L. T., 222  
Bashour, F., 96  
Bauer, F. K., 60  
Bauer, H., 40  
Baxter, J. H., 17, 141  
Beard, M. F., 144  
Beckman, E. L., 150  
Bedell, G. N., 235  
Beeson, P. B., 86  
Behnke, R., 238  
Belkin, G. A., 30  
Belt, J. A., 206  
Bender, M., 92  
Benjamin, A., 17  
Berger, E. S., 234  
Berg, G. C., 202  
Berman, L. B., 44, 138  
Bernick, S., 60  
Bernstein, S. H., 133  
Bernstein, W., 152  
Bertles, J. F., 79  
Best, W. R., 235  
Bethell, F. H., 78, 232  
Bierman, H. R., 52, 215,  
200  
Bishop, L. H., 30  
Bishop, R. C., 234  
Black, R. L., 20  
Blahd, W. H., 216  
Blair, E., 59  
Blakemore, A. H., 39  
Bloch, H. S., 254  
Bloom, A. A., 216  
Blount, S. G., Jr., 56, 57,  
95, 201, 202  
Blumenthal, W. S., 6, 81  
Boak, R. A., 218, 219  
Bodi, T., 18  
Bollet, A. J., 92  
Bolt, R., 89  
Bond, W. H., 236, 237  
Bondurani, S., 47  
Borges, W. H., 82  
Boryczka, A., 222  
Bothwell, T., 197  
Bradford, S., 40  
Bradley, H. W., 204, 205  
Bradley, S. E., 139  
Brainerd, H., 66  
Braude, A. I., 40, 143  
Braveman, W. S., 129  
Breit, H. J., 12  
Brewer, S. S., 88  
Bricker, N. S., 138, 253  
Brill, I. C., 204  
Brody, M., 105  
Broida, H. P., 29  
Bross, I. D., 113  
Browder, E. J., 99  
Brown, C. H., 93, 146  
Brown, E. B., Jr., 153,  
232, 239  
Brown, F. R., Jr., 62, 210,  
216  
Brown, H., 213  
Brown, J. F., 104, 135,  
252  
Brubaker, C., 197, 200  
Bruce, R. A., 202  
Bruns, P. D., 64, 68  
Bryant, J. M., 9, 10, 12,  
103  
Buchholz, J. H., 108  
Buhlmann, A., 153  
Bunnell, I. L., 9  
Burch, G. E., 28  
Burgner, P. R., 58, 204  
Burke, J. O., 40  
Burnell, J. M., 127, 215  
Burrows, B. A., 128, 136,  
150  
Burst, A. A., 107  
Burstein, S., 35  
Byers, C., 34  
Byers, S. O., 215, 220  
Calix, A., 100  
Campbell, E. W., 5, 6, 85  
Campbell, J. A., 120  
Canada, R. O., Jr., 68  
Canary, J. J., 16, 33  
Cantrell, C. G., 90  
Capecci, N., 135

- Carbone, J. V., 218  
 Carlisle, R. P., 94  
 Carnes, W. H., 208  
 Carpenter, C. M., 218, 219  
 Carpenter, L. G., 206  
 Carpentier, J., 238  
 Carroll, R. T., 5  
 Carroll, S. K., 129  
 Carson, C. R., 242  
 Cary, A., 196  
 Castillo, C., 135, 252  
 Castle, J. N., 119, 208  
 Cathcart, R. T., 21  
 Cawley, L. P., 238  
 Cecil, L. M., 66  
 Centeno, P. A., 200  
 Chalmers, T. C., 147, 148  
 Chapman, C. B., 47, 71, 152, 161  
 Checchia, C. S., 120  
 Chernish, S. M., 241  
 Chernoff, A. I., 233  
 Childs, A. W., 139  
 Chodos, R. B., 15, 141, 145  
 Chomet, B., 154  
 Christensen, J. M., 12  
 Christensen, R. C., 103  
 Clark, G. M., 63, 157, 237  
 Clark, R., 66  
 Cleland, W. W., 245  
 Clifton, E. E., 257  
 Close, A. S., 241  
 Cobb, L. A., 94, 97  
 Code, C. F., 130  
 Coleman, J., 33  
 Colmore, J. P., 44  
 Colwell, A. R., 123  
 Combes, B., 139  
 Commons, R. R., 208  
 Conn, H. L., Jr., 99  
 Conn, J. W., 242  
 Cook, A. W., 99  
 Coonrad, E. V., 88  
 Cooper, G. R., 90  
 Cordes, F. L., 52  
 Cosby, R. S., 223  
 Costa, F., 222  
 Costiloe, J. P., 45  
 Costley, C., 246  
 Cotsonas, N. J., 115  
 Cox, R. W., 61, 209  
 Craig, J., 139, 246  
 Cramer, L. M., 35  
 Creamer, B., 130  
 Creger, W. P., 83, 197  
 Crevling, V., 218  
 Crispell, K. R., 33, 35, 119  
 Critides, S. D., 8  
 Crosby, W. H., 88  
 Crosley, A. P., Jr., 135, 252  
 Crumpton, C. W., 104  
 Crutcher, J. C., 36  
 Cuajunco, F., Jr., 137  
 Cummings, M. M., 114  
 Cummins, A. J., 39, 131  
 Curtis, R., 211  
 Dameshek, W., 5, 86  
 Daniell, H. W., 84  
 Danielson, E., 91  
 Darvill, F. T., Jr., 58  
 Daugherty, C., 248  
 David, N. A., 58, 204  
 Davidson, C. S., 148  
 Davignon, A., 11  
 Davis, O. F., 240  
 Davis, W. D., Jr., 145  
 Dawson, J. P., 78  
 Dearborn, E. H., 136  
 deBruin, C. H., 211  
 Deiss, W. P., 32  
 deLalla, O., 213  
 de Magalhes, M. N., 89  
 Denny, W. F., 27  
 Desforges, J. F., 78  
 DeVore, J. K., 248  
 deWolfe, V. G., 109  
 Dexter, L., 94, 96, 97  
 Dexter, R. L., 129  
 Dick, H. L., 203, 206  
 Dingman, J. F., 125  
 DiRaimondo, V., 210  
 Dobson, E. L., 53, 58  
 Dobson, H. L., 26  
 Dobson, R. L., 53  
 Dontas, A. S., 109  
 Doolan, P. D., 65, 68  
 Dorris, R. J., 126  
 Doscherholmen, A., 83  
 Dowling, H. F., 115  
 Dowling, J. T., 120  
 Doyle, J. E., 22  
 Doyle, J. T., 111  
 Dreiling, D. A., 132  
 Drell, W. W., 216  
 Dreskin, O. H., 85  
 Drucker, W. R., 246  
 Drury, D. R., 209, 214  
 Drusch, H. E., 219  
 Dubach, R., 232  
 Duchesne, E. R., 106  
 Duff, I. F., 236  
 Duggan, J. J., 112  
 Dunner, E., 114  
 Dunning, M. F., 64  
 Dupee, A. B., 236  
 Durbin, R. P., 217  
 Dutton, R. E., Jr., 102, 145  
 Dyniewicz, J. M., 252  
 Ebner, C. M., 107  
 Ebnother, C. L., 56, 204, 205  
 Eckstein, J. W., 110  
 Edelman, I. S., 217  
 Ehmke, D., 100  
 Eich, R. H., 18, 151  
 Eik-Nes, K., 213  
 Eiseman, B., 63  
 Eisenberg, G. M., 134  
 Eisenstein, A. B., 244  
 Elder, N., 79  
 Eldridge, F. L., 238  
 Eliel, L. P., 245  
 Ellison, R. G., 95  
 Elmlinger, P. J., 79  
 Elster, S. K., 156  
 Emanuel, D. A., 104, 135, 252  
 Engel, F. L., 122, 124  
 Epstein, F. H., 21, 137  
 Epstein, J. A., 16  
 Epstein, J. H., 144  
 Essig, A., 128  
 Estes, E. H., Jr., 30  
 Evans, J. M., 102, 108, 155  
 Evans, R. S., 46, 151  
 Fajans, S. S., 242  
 Faloon, W. W., 18, 147  
 Farber, F. M., 221  
 Farguhar, J. W., 55  
 Favour, C. B., 200  
 Feichtmeier, T. V., 221  
 Fein, S. B., 199  
 Feinstein, A. R., 92  
 Fell, S. C., 32  
 Felton, J. S., 116  
 Ferguson, J. T., 253  
 Ferguson, R. W., 44  
 Feys, J., 44, 138  
 Field, J. B., 60, 222  
 Filler, D. A., 222  
 Finch, C. A., 51, 197  
 Finch, S. C., 8, 19, 86  
 Fine, D., 126  
 Finegold, S. M., 219  
 Finkenstaedt, J. T., 125  
 Finley, P. R., 249  
 Finn, T. O., 27  
 Finnerty, F. A., Jr., 106, 108  
 Firmat, G., 121  
 Fisch, S., 28  
 Fisher, C. J., 147  
 Fisher, J. M., 235  
 Fisher, M. M., 31  
 Fitz, R. H., 106  
 Fitzgerald, W. T., 248  
 Fitzpatrick, H. F., 39  
 Flanagan, J. F., 40  
 Fleishman, M., 252  
 Fleming, W. L., 115  
 Flink, E. B., 153  
 Flink, E. F., 239  
 Flippin, H. F., 134  
 Foley, J., 122  
 Follette, J. H., 211  
 Formel, P. F., 111  
 Forsham, P. H., 210, 218  
 Forster, R. E., 150  
 Fortunato, J., 34  
 Fouts, D., 238  
 Fowler, N. O., 106  
 Fowler, W. S., 256  
 Fox, R., 116  
 Franch, R. H., 106  
 Frank, H., 217  
 Frankland, M., 210  
 Frayser, R., 47  
 Freed, S. C., 213  
 Frei, E., 35  
 Freinkel, N., 120  
 Freis, E. D., 11, 38, 110  
 Fremont-Smith, K., 15  
 Friedman, B., 240  
 Friedman, I. A., 236  
 Friedman, M., 215, 220  
 Friedman, M. M., 39  
 Friend, C., 102  
 Friou, G. J., 157  
 Friskey, R. W., 210, 216  
 Froeb, H. F., 67  
 Frumin, A. M., 7, 130  
 Fudenberg, H. H., 85, 86  
 Fukayama, G., 210  
 Furrer, D., 52, 77  
 Furth, F. W., 79  
 Fyke, F. E., Jr., 130  
 Gardner, L. I., 158  
 Garrett, W., 55, 56  
 Gauer, O. H., 32  
 Gault, N. L., 256  
 Geiger, E., 62  
 Gelhorn, A., 88  
 Geller, H. M., 63  
 Genest, J., 11  
 Gilbert, R., 18, 151  
 Gilbert, R. P., 110  
 Gilbertsen, A. S., 121  
 Glassner, H. F., 205  
 Gleason, D. F., 246  
 Glicksman, A. S., 14, 127  
 Gofman, J. W., 213  
 Gompertz, M. L., 39  
 Gonlubol, F., 100  
 Good, R. A., 156  
 Goodman, E. L., 21  
 Goodman, H. C., 17, 141  
 Gordon, P., 110  
 Gorlin, R., 29  
 Goss, M., 116  
 Gotch, F. A., 217  
 Graettinger, J. S., 120  
 Gray, S. J., 131  
 Grayston, J. T., 250  
 Greene, D. G., 9  
 Greenspan, F. S., 60, 208  
 Greipel, M., 210  
 Gribetz, D., 14  
 Griffith, D. R., 236  
 Griffith, J. R., 21  
 Griggs, R. C., 80, 82  
 Grossman, J., 128  
 Gubner, R., 103  
 Guillaudeu, R. L., 106, 108  
 Gurney, C. W., 89  
 Gyorgy, P., 5  
 Haddy, F. J., 109, 252  
 Haebich, A. T., 46  
 Hagans, J. A., 158, 244  
 Hagen, P. S., 83  
 Hainline, A., Jr., 93, 146  
 Hakim, A. A., 133  
 Halden, E. R., 47, 152  
 Hall, B., 249  
 Hall, B. E., 221, 222  
 Hall, W. H., 249  
 Haller, J. A., Jr., 9, 97  
 Halpern, M., 14  
 Hammond, J. B., 247  
 Handley, C. A., 41, 42  
 Handy, J., 114  
 Hannon, D. W., 65  
 Harbour, J., 107  
 Hardy, J. D., 33  
 Harger, R. N., 247  
 Harman, D., 54, 68  
 Harper, H. A., 65, 68  
 Harris, J. W., 80, 82  
 Harris, R. E., 206  
 Hartoft, P., 244  
 Hartwig, R., 223  
 Havner, N. M., 149  
 Hayden, D. T., 55  
 Haynes, F. W., 94, 96, 97  
 Heath, J., 201  
 Hecht, H. H., 94, 201, 203  
 Hefner, L. L., 28  
 Heider, C., 42  
 Heidorn, G. H., 11  
 Heiman, D. F., 99

- Heinz, R., 57  
 Heiselt, L. R., 211  
 Hellems, H. K., 103  
 Heller, P., 87, 154  
 Helmholtz, H. F., Jr., 256  
 Helwig, H. L., 119, 208  
 Hendrix, T. R., 132  
 Henegar, G. C., 52  
 Henley, E. D., 61, 209  
 Henley, K. S., 245  
 Hennes, A. R., 242  
 Hershenson, L. M., 11  
 Hettig, R. A., 26  
 Hewitt, C., 54  
 Hewitt, W. L., 219  
 Heyman, A., 154  
 Hibbett, L. L., 34  
 Hickam, J., 47  
 Higgins, F. C., 236  
 Highman, B., 239  
 Hill, S. R., Jr., 34  
 Hilton, J. G., 135  
 Hinckley, W. C., 132  
 Hinkle, L. E., Jr., 113  
 Hintz, C. F., Jr., 93  
 Hirschowitz, B. I., 247  
 Hoffman, M. S., 95  
 Holburn, R. R., 5  
 Holden, W., 246  
 Holland, J., 35  
 Hollander, W., 12  
 Holley, H. L., 34, 41  
 Holliday, M., 43  
 Hollifield, G., 35  
 Hollingsworth, J. W., 8, 19, 86  
 Hood, R. M., 94  
 Hornsby, A. T., 32  
 Horsley, J. S., III, 137  
 Hoseli, G., 153  
 Howe, J. S., 139  
 Howie, D. L., 237  
 Huckabee, W. E., 10, 100  
 Hudson, D. G., 219  
 Huestis, R., 83  
 Huff, R. L., 55, 223  
 Hughes, C. W., 147  
 Hultgren, H. N., 10, 57, 100, 205, 238  
 Huratado, A., 197  
 Hutcheson, J. M., Jr., 147  
 Hutchin, M. E., 65, 68  
 Hwang, P., 200  
 Hydovitz, J. D., 14, 118  
 Hystis, R., 198  
 Hyman, A., 30  
 Hyman, C. B., 200  
 Hyman, E. S., 30  
 Hyman, G. A., 88  
  
 Iacono, J. M., 245  
 Iber, F. L., 15, 147, 148  
 Ingbar, S. H., 120  
 Innerfield, I., 23  
 Irwin, G. W., 241  
 Isaacs, M. C., 128  
 Island, D., 210  
  
 Jacobs, H. I., 205, 207  
 Jaques, W. E., 30  
 Jandl, J. H., 81  
 Jankelson, O. M., 144  
 Janowitz, H. D., 132  
  
 Jay, B. E., 46, 151  
 Jelinek, B., 52, 77  
 Jenkins, D., 125  
 Johnson, B. B., 211  
 Johnson, H. I., 119  
 Johnson, J., 63  
 Johnson, J. L., 201  
 Johnson, P. C., 234  
 Johnson, R., 63  
 Johnson, R. H., 37  
 Johnson, R. L., Jr., 47, 67, 152  
 Johnston, P. B., 250  
 Jones, M. H., 39, 131  
 Jones, W. B., 28  
 Jordan, R. T., 65  
 Judson, W. E., 12  
  
 Kachmar, J. F., 130  
 Kahn, K. A., 246  
 Kaiser, R. J., 115  
 Kallman, H., 103  
 Kark, R. M., 123, 124, 140, 143, 250  
 Karler, A., 223  
 Karp, H. R., 154  
 Kattus, A. A., Jr., 67  
 Katz, J., 221  
 Katz, Y. J., 65  
 Kaufman, J. W., 59  
 Kayser, H., 134  
 Keitel, H. G., 7, 17, 141  
 Kelley, V. C., 212  
 Kellow, W. F., 154  
 Kelly, J. J., Jr., 10, 99, 100  
 Kelly, K. H., 52, 200, 215  
 Kennedy, B. J., 121  
 Kenny, J. J., 87  
 Kern, F., Jr., 157  
 Kessler, E., 79  
 Keyes, H. E., 131  
 Killip, T., III, 98, 104, 152  
 Kimura, T., 199  
 Kinsell, L. W., 62, 210, 216  
 Kirby, W. M., 219  
 Kirk, M., 68  
 Kirkendall, W. M., 251  
 Kleeman, C. R., 21, 137  
 Klein, R., 34, 36  
 Kleinerman, J., 151  
 Knapp, P. H., 17  
 Knight, W. A., Jr., 248  
 Knowles, H. C., Jr., 150  
 Knowles, J. H., 29  
 Koiw, E., 11  
 Kolb, F. O., 213  
 Koler, J., 66  
 Korst, D. R., 232  
 Kortzeborn, J., 199  
 Kory, R. C., 241  
 Koster, S., 216  
 Kovach, R. D., 11, 38, 110  
 Krakauer, L. J., 131  
 Krantz, K. E., 142  
 Kregzde, J., 31  
 Kriss, J. P., 60, 208  
 Kruesi, O., 135  
 Kuida, H., 94, 96, 97  
 Kuipers, F., 212  
 Kunin, A. S., 136  
 Kunkle, E. C., 45  
 Kupperman, H. S., 16  
  
 Kurnick, N. B., 54, 77  
 Kyle, L. H., 16, 33  
  
 Labby, D. H., 115  
 LaDue, J. S., 13, 19, 101, 102, 240, 257  
 Laidlaw, J. C., 125  
 Lakis, B. L., 206  
 Lambie, A. T., 128, 150  
 Landaburu, R. H., 236  
 Landy, M., 134  
 Lange, R. D., 88, 234  
 Lange, R. L., 94, 203  
 Langford, G. G., 107  
 Lathem, W., 17, 141  
 Lawrence, J. H., 68  
 Lawrence, N. L., 207  
 Lazaro, E. J., 29  
 Lee, N. D., 39  
 Leff, D., 52  
 Leftwich, C. I., 67  
 Lemieux, G., 11  
 Lemon, H. M., 17  
 Levey, H. A., 60  
 Levine, E. H., 42  
 Levine, G., 116  
 Levitt, M. F., 14, 142  
 Lew, W., 60  
 Lewis, A. J., 156  
 Lewis, B. M., 150  
 Lewis, L. L., 109  
 Ley, A. B., 7, 80  
 Liddle, G. W., 125  
 Lieberman, A. H., 211  
 Lieberman, E., 53  
 Liebowitz, D., 218  
 Lilienfeld, L. S., 11, 38, 110  
 Lillehei, J. P., 47, 152  
 Lillington, G. A., 256  
 Limarzi, L. R., 235  
 Limson, B. M., 135  
 Lindeman, R. D., 102, 145  
 Linman, J. W., 78  
 Lipton, M. A., 129  
 Loeb, H. G., 222  
 Logan, G. A., 202  
 Loosli, C. G., 250  
 Lott, H., 210  
 Louie, C., 119  
 Love, W. D., 28  
 Lowe, I. P., 149  
 Lowell, F. C., 17  
 Lowenfels, A. B., 9  
 Lowenstein, J. M., 197  
 Luchsinger, P., 153  
 Luetscher, J. A. Jr., 211  
 Luhn, N. R., 153  
 Lukas, D. S., 96, 98, 104, 152  
 Lukemeyer, G. T., 241  
 Lukens, J. G., 157  
 Lunseth, J. H., 244  
 Lusk, W., 47  
 Lyons, H. A., 8, 10, 99, 100  
 Lyons, R. H., 145  
  
 McCawley, E. L., 203, 206  
 McClaughry, R. I., 118  
 McCord, M. C., 56, 201  
 McIntosh, H. D., 30, 32  
 McKusick, V. A., 18  
  
 McLaughlin, H. M., 9, 10, 12, 103  
 McMaster, J., 81  
 McPherson, H. T., 122  
  
 Mack, R. E., 242  
 Mackler, D., 126  
 Mackler, S. A., 257  
 Macmanus, J. E., 9  
 MacNeil, A. E., 22  
 Madison, L. L., 43, 137  
 Magalini, S. I., 6, 81, 82, 89  
 Mahaffey, W. C., 30  
 Mahoney, E., 253  
 Mahoney, J. P., 86  
 Mahrer, P. R., 96, 104  
 Maier, E. S., 201  
 Man, E. B., 121  
 Marks, P. A., 11  
 Marmorston, J., 221  
 Martignoni, P., 39  
 Martin, C. J., 66  
 Martires, F. M., 99  
 Martner, J., 139  
 Martz, B. L., 241  
 Mason, H. S., 211  
 Masouredis, S. F., 54  
 Matter, M., 63  
 Maxwell, G. M., 104  
 Mayer, K., 7, 80  
 Mayo, M., 223  
 Meador, R. S., 151  
 Mednicoff, I. B., 6  
 Meehan, J. P., 207  
 Meiselas, L. E., 126  
 Melhado, J., 30  
 Mellinkoff, S. M., 210  
 Melly, A., 53  
 Meltzer, W., 255  
 Merendino, K. A., 202  
 Merrill, A. J., 37  
 Merrill, J. P., 125, 138, 253  
 Metcoff, J., 139  
 Meyer, R. J., 16  
 Michaels, G. D., 62, 210, 216  
 Michelson, A. L., 17  
 Miller, G. E., 117  
 Miller, J. N., 218, 219  
 Miller, M., 246  
 Miller, R. D., 256  
 Miller, W. F., 47, 67, 153  
 Mills, H., 67  
 Mills, L. C., 41  
 Minish, L. T., Jr., 109  
 Molander, D. W., 39, 63  
 Moloney, W. C., 87  
 Molthan, L., 81  
 Moore, C. V., 232  
 Moore, G. E., 92  
 Moorhouse, J. A., 123, 124  
 Morita, Y., 107  
 Morris, G., 42  
 Morrow, A. G., 97  
 Mortimer, R., 51  
 Moschides, E., 89  
 Moscovitz, H. L., 96  
 Moses, L. E., 60  
 Motley, H. L., 67  
 Motulsky, A. G., 83, 198  
 Moyer, J. H., 41, 42, 227



- Muehrcke, R. C., 140, 143, 250  
 Mueller, J. F., 245  
 Muenster, J. J., 120  
 Munyan, E. A., 95  
 Murphy, J. R., 93  
 Murphy, Q. R., 104  
 Murphy, T. J., 112  
 Murtadha, M., 9, 12, 103  
 Myers, J. D., 122  
  
 Nadel, E. M., 35  
 Nadel, J., 134  
 Nadell, J., 217  
 Nakada, H. I., 209  
 Nashelsky, G. M., 237  
 Neal, J. J., Jr., 28  
 Nelson, C. V., 201  
 Nelson, N. A., 234, 238  
 Nelson, S. S., 79  
 Nelson, W. P., III, 79  
 Nettles, J. B., 143  
 Newcomb, T., 53  
 Nichols, N., 122  
 Nickson, J. J., 127  
 Nordyke, R., 66  
 Novack, P., 94, 97  
 Nowaczynski, W. J., 11, 15  
 Noyes, R. W., 214  
 Noyes, W. D., 219  
 Nydick, I., 101, 102, 240, 257  
  
 Oester, Y. T., 240  
 Ognanovich, J., 256  
 Oliver, J., 43  
 Olmstead, E. G., 244  
 Olsen, A. M., 130  
 Orloff, J., 17, 136  
 Orr, C., 60  
 Orvis, H. H., 108  
 Osborne, W., 156  
 O'Shaughnessy, P. J., 32  
 Osmon, K., 62  
 Ostfeld, A. M., 111  
 Ostrow, B. H., 102, 144, 155  
 Owens, J. C., 59  
 Owings, R. H., 90  
 Owren, P. A., 199  
  
 Packard, P., 56  
 Pader, E., 156  
 Palm, L., 245  
 Papper, S., 114, 124  
 Paronetto, F., 91  
 Parrish, A. E., 42, 139  
 Parrish, D., 223  
 Parson, W., 35, 119  
 Paterson, J. C., 26  
 Patterson, J. H., 82  
 Patterson, J. L., Jr., 44  
 Patton, F., 41  
 Payne, R., 87  
 Pearce, M. L., 66  
 Pearson, C. M., 224  
 Penton, G. B., 105  
 Penwarden, B. H., Jr., 254, 255  
 Perkoff, G. T., 220  
 Peters, J. H., 36  
 Petersdorf, R., 92  
 Peterson, R. E., 242  
 Petrakis, N. L., 53  
  
 Phelps, P., 199  
 Pietz, D. G., 247  
 Pigman, W., 41  
 Pilz, C. G., 240  
 Pinsky, R. H., 113, 126  
 Pirani, C. L., 140, 143, 250  
 Pirizio-Biroli, G., 51  
 Platt, D., 41  
 Plitman, G. I., 27  
 Plough, I. C., 15  
 Plum, F., 64  
 Plummer, K., 40  
 Plummer, N., 113  
 Polhemus, J. A., 236  
 Polis, G. N., 155  
 Pollak, V. E., 140, 143, 250  
 Pollard, H. M., 247, 248  
 Pollycove, M., 51, 79  
 Pool, J. G., 198  
 Poppell, J. W., 137  
 Porfido, F. A., 110  
 Portwood, R. M., 43, 137  
 Prasad, A. S., 153, 239  
 Pratt, G., 63  
 Prout, T. E., 125  
 Prunier, J., 121  
 Pyfer, H., 55, 56  
  
 Randall, H. T., 14, 137  
 Rapaport, E., 96  
 Rather, L. J., 198  
 Rawson, R. W., 121  
 Reader, G. G., 116  
 Reardan, J. B., 138  
 Rector, F. C., 43  
 Redeker, A. G., 63  
 Redington, J. C., 248  
 Reeves, T. J., 28  
 Regan, T. J., 103  
 Reichman, S., 145  
 Reifenstein, G. H., 94  
 Reilly, W. A., 119, 208  
 Reiner, L., 112  
 Reinhardt, L., 52, 77  
 Reiss, E., 225  
 Relman, A. S., 128, 136, 150  
 Remenchik, A. P., 252  
 Renold, A., 125  
 Reynafarje, C., 232  
 Reynolds, R., 40  
 Reynolds, T. B., 63  
 Richard, J. E., 125  
 Richardson, D. W., 44  
 Richburg, P. L., 46  
 Rider, J. A., 62  
 Ridolfo, A. S., 241  
 Rivers, S. L., 7  
 Robbins, J. H., 236  
 Roberts, K. E., 14, 121, 129, 137  
 Roberts, T. N., 117  
 Robins, E., 149  
 Rock, W., 240  
 Rodnan, G. P., 11, 20, 90  
 Roe, B. B., 206  
 Rohn, R. J., 236, 237  
 Romansky, M. J., 135  
 Rosano, C. L., 79  
 Rose, J. C., 29  
 Roseman, R. H., 213, 220  
 Rosenak, B. D., 247  
 Rosenberg, C. A., 39  
  
 Rosenberg, L. C., 131  
 Rosenfeld, S., 221  
 Rosenthal, A., 152  
 Rosenthal, R. L., 84  
 Roshe, J., 9, 97, 239  
 Ross, J. F., 79  
 Ross, M., 31  
 Ross, R. S., 13  
 Roth, D. A., 244  
 Roth, K. L., 7  
 Rowe, G. G., 104, 135, 252  
 Roy, A. M., 128, 136, 150  
 Rozenbojm, J., 131  
 Rubin, A. L., 129  
 Rubin, C. E., 199  
 Rudolph, L. A., 102, 145  
 Ruegamer, W. R., 15, 145  
 Rueggeger, P., 101, 102, 240, 257  
 Rukes, J. M., 213  
 Rumel, W. R., 202  
 Rundles, R. W., 88  
 Ruskin, A., 30  
 Ruskin, B., 30  
  
 Sachs, B. A., 91  
 Said, S., 9, 10, 12, 103  
 St. George, S., 213  
 Salisbury, P. F., 221  
 Samet, P., 152  
 Samuels, A. J., 52, 77  
 Samuels, L. T., 213  
 Sancetta, S. M., 151  
 Sandberg, A. A., 92, 213  
 Sanford, J. P., 134  
 Sarks, L. A., 79  
 Saslaw, M. S., 133, 155  
 Saxon, E. I., 132  
 Saxon, L., 125  
 Saxton, A., Jr., 255  
 Scadron, E., 142  
 Scaparone, M., 66  
 Schaaf, M., 16  
 Schaen, R. P., 113  
 Schemm, F. R., 11  
 Schloerb, P. R., 251  
 Schmidt, R. H., Jr., 114  
 Schneider, E. M., 248  
 Schneider, R. A., 45  
 Schoen, E. J., 220  
 Schoenberger, J. A., 252  
 Schottstaedt, W. W., 126  
 Schreiner, G. E., 20, 44, 138  
 Schultz, A. L., 119  
 Schuster, B., 104, 252  
 Schwartz, I. R., 5  
 Schwartz, M. K., 14, 127  
 Schwartz, R., 149  
 Schwartz, W. B., 128  
 Scott, J., 252  
 Scribner, B. H., 127, 215  
 Seaman, A. J., 199  
 Seebohm, P. M., 235  
 Segal, S., 122  
 Seldin, D. W., 36, 43  
 Sellers, A., 221  
 Seltzer, H. S., 243  
 Selzer, A., 56, 204, 205, 238  
 Setna, S. S., 84  
 Shapiro, A. P., 30, 143  
 Shay, H., 130  
 Sharp, J. T., 9  
 Sheldon, W. H., 40  
  
 Shields, D. O., 151  
 Shonnard, C. P., 31  
 Shotton, D., 37  
 Shulman, N. R., 27, 85  
 Shuman, C. R., 105  
 Shwayri, E. I., 138  
 Sieker, H. O., 32, 154  
 Sieminski, J., 143  
 Silver, H. M., 21  
 Silverman, J. L., 233  
 Simkin, B., 215  
 Sims, E. A., 142  
 Siperstein, M. D., 129  
 Sissman, N. J., 36  
 Skoog, W. A., 212  
 Sleisenger, M. H., 131  
 Small, W. J., 5  
 Smith, A. A., 157  
 Smith, D. E., 232  
 Smith, F., 55, 56  
 Smith, G., 233  
 Smith, M. E., 250  
 Smith, R. E., 55  
 Smith, R. R., 35  
 Smith, R. T., 156  
 Smith, W. O., 245  
 Smyth, C. J., 237  
 Smyth, J. D., 221  
 Smythe, C. M., 39  
 Snider, G. L., 257  
 Soberman, R. J., 157  
 Sobin, S. S., 201  
 Sohar, E., 142  
 Sokolow, M., 58, 204, 206  
 Soloff, L. A., 99  
 Solomon, A. K., 217  
 Solomon, D. H., 60, 211  
 Sonkin, L., 117  
 Sothill, J. A., 140  
 Soper, H. A., 241  
 Sortor, A. T., 83  
 Spivack, A., 134  
 Sprague, C. C., 26  
 Starnes, W. R., 34  
 Starr, P., 60  
 Stead, W. W., 170, 256  
 Steel, M., 197  
 Stefanini, M., 6, 81, 82, 89  
 Steiger, W. A., 81  
 Steinberg, H., 131  
 Steinberg, I., 96  
 Steinkamp, R., 233  
 Stevenson, T. D., 144  
 Steyermark, P. R., 11, 15  
 Stone, A. O., 56, 204, 205  
 Stowell, E. C., 223  
 Straffon, R., 253  
 Street, J. P., 246  
 Streeten, D. H., 247  
 Streitfeld, M. M., 155  
 Stults, R., 246  
 Stunkard, A. J., 126  
 Sturgeon, P., 197, 200  
 Summerskill, W. H., 148  
 Sun, D. C., 130  
 Sunshine, A., 9  
 Swader, J., 62  
 Swan, H., 57, 202  
 Sweet, M. L., 211  
 Sweet, A. Y., 14  
 Symon, W. E., 237  
 Szilagyi, D. E., 31  
  
 Talbot, T., 5  
 Talbot, T. R., 196

- Talmers, F. N., 103  
 Tamagna, I. G., 108  
 Taniguchi, L., 199  
 Tarail, R., 92  
 Tascott, H. K., 78  
 Taylor, P., 34  
 Taylor, W. F., 133  
 Test, C. E., 241  
 Thomas, C. L., 220  
 Thompson, D., 7  
 Thomson, G. W., 21  
 Thorn, G. W., 125  
 Tice, A. A., 158  
 Tickton, H. E., 102, 144  
 Tindall, G. T., 45  
 Tocantins, L. M., 5, 18  
 Tolbert, B. M., 68  
 Tomizawa, H. H., 61, 209  
 Tompkins, G. M., 125  
 Towbin, E. J., 28  
 Tuchman, H., 135, 252  
 Turner, M. D., 33  
 Turner, R., 105  
 Tyan, M., 221  
 Tybergheim, J. M., 61, 124, 209  
 Tyler, E. T., 217  
 Tyler, F. H., 213, 220
- Udenfriend, S., 27  
 Ultman, J. E., 88  
 Unger, R. H., 243  
 Unugur, A. B., 85  
 Uyeno, B. T., 127, 215  
 Uzman, L. L., 148
- Valentine, R. J., 60  
 Valentine, W. N., 211  
 van Elk, J., 57, 202  
 Vaname, P., 129  
 Vaughan, J. H., 20, 26  
 Villamil, M., 127, 215  
 Vogel, W. C., 132  
 Voiss, D. V., 203  
 von Kaulla, K. N., 64, 237
- Wada, T., 103  
 Wajchenberg, B. L., 242  
 Walker, W. G., 13  
 Wallace, J. M., 112  
 Waller, M. V., 26  
 Walser, M., 136  
 Walsh, G. W., III, 209  
 Walters, D. H., 38  
 Wang, Chun-I, 91  
 Ware, A. G., 199  
 Warner, G. F., 58  
 Warner, H. R., 202, 203  
 Warren, J. V., 32  
 Watten, R. H., 68, 94  
 Weaver, D., 135  
 Webb, G. N., 18  
 Webster, L. T., Jr., 146  
 Weiger, R. W., 123  
 Weiman, C. G., 117  
 Wein, M., 31  
 Weiner, J., 237  
 Weisman, R., Jr., 82  
 Weiss, A. J., 5  
 Weiss, W., 22, 134  
 Wells, H. S., 256
- Welsh, G. W., III, 61  
 Welt, L. G., 43  
 Wenger, J., 133  
 Wenzel, C., 54  
 Werdein, E. J., 16  
 Werk, E. E., Jr., 122  
 Wessler, S., 112  
 West, K. M., 244  
 Weston, R. E., 128  
 Wharton, G. K., 62  
 Wheeler, H. O., 139  
 Whipple, G. H., 105  
 Whisnant, C. L., 37, 90  
 Whitcomb, J. G., 31  
 White, C., 21  
 White, K. L., 115  
 White, L. P., 221  
 Wiberg, C. A., 207  
 Wick, A. N., 209, 214  
 Wiggins, H. S., 248  
 Wild, J. B., 251  
 Wilder, R. J., 96  
 Wilkins, R. W., 110  
 Willbanks, O. L., Jr., 36  
 Willett, F. M., 221  
 Williams, G. A., 119  
 Williams, R. H., 61, 124, 209  
 Willis, P. W., III, 236  
 Wilson, J. S., 37  
 Wilson, R. H., 46, 151  
 Wilson, T. E., 93, 146  
 Wiltshaw, E., 87  
 Winchell, P., 96  
 Windsor, E., 216  
 Winters, R. W., 43
- Wirts, C. W., 18  
 Wise, R. I., 21  
 Wiskind, H. K., 18  
 Witham, A. C., 95  
 Wohl, M. G., 105  
 Wokalek, F. W., 109  
 Wolf, S., 126, 158, 166  
 Wolfe, S. J., 148  
 Wolff, H. G., 111  
 Wolfson, W. Q., 91, 237, 254, 255  
 Wood, J. E., 110  
 Woodward, H., 246  
 Woolridge, R. L., 250  
 Wotiz, H. H., 17  
 Wright, W. D., 222  
 Wroblewski, F., 13, 19, 101, 102, 240  
 Wu, N., 47, 67, 152, 153  
 Wyngaarden, J. B., 122
- Yakulis, V., 87  
 Yamamoto, M., 242  
 Yamasaki, M., 55  
 Young, A. C., 66  
 Young, B. G., 35  
 Young, I. I., 91, 246
- Zamecheck, N., 144  
 Zarafonitis, C. J., 81  
 Zatuchni, J., 99  
 Zieve, L., 119, 132  
 Zimmerman, H. J., 87, 240  
 Zinn, W., 62  
 Zinsser, H. H., 199

## SUBJECT INDEX

- Abortion**, protein-bound iodine for, 121  
**Acetylsthrophanthidin**, and digitalization, 58  
**Acid**  
 -base balance, and bone, 36  
 -base disorders, and potassium, 215  
 excretion, in alkalosis, 129  
**Acidosis**  
 and anemia, 244  
 calcium in, 153  
 diabetic, adrenocortical activity in, 61  
 respiratory, in emphysema, 67  
 rubidium-induced, 128  
 salicylates and, 152  
**ACTH**  
 and bronchial asthma, 17  
 in differential diagnosis, 210  
 and heart failure, 11  
 in the newborn, 34  
 and pepsinogen excretion, 247  
 in peptic ulcer, 39  
**Acylamid**, 204  
**Adenopathy**, vs. azygous vein, 113  
**Adrenocortical function**  
 measurement of, 213  
 and potassium, 213
- Age**, and creatine and creatinine levels, 36  
**Albumin deficiency**, in hyperlipemia and hypercholesteremia, 220  
**Alcohol**, as liver function test, 247  
**Alcoholism**, and Dupuytren's contracture, 148  
**Aldosterone**  
 and blood volume, 126  
 and hypertension, 11  
 output, 211  
**Alkali therapy**, in hypotension, 109  
**Alkalosis**, acid excretion in, 129  
**Amino acid(s)**  
 and appetite, 210  
 loading, renal response to, 65  
**Aminoaciduria**, in muscular dystrophy and myotonia dystrophica, 216  
**Ammonia**  
 and kidney, 137  
 metabolism  
 in cirrhosis, 18  
 in hemorrhage, 63  
 production, and glutamine, 43  
**Anemia**  
 and acidosis, 244
- hemolytic, 6  
 prednisone for, 82  
 iron deficiency, 78  
 of myelofibrosis-myeloid metaplasia syndrome, 86  
 new syndrome, 234  
 pernicious  
 blood group A in, 83  
 gastric lesion in, 199  
 in renal disease, 141  
 sickle cell, urine concentration in, 7  
**Anesthesia**  
 mechanics of respiration in, 153  
 and pyruvate and lactate metabolism, 246  
**Angiocardiography**, in atrial thrombosis, 99  
**Antibiotics**, anticarcinogenic activity of, 222  
**Antibody**  
 antileukocytic, 87  
 and erythrocyte surfaces, 197  
**Anticoagulant**, from mammalian tissue, 28  
**Apomorphine**, and duodenum, 131  
**Appetite**, and amino acid and glucose, 210

- Archlorethamine**, in lymphatic leukemia, 88
- Arrhythmias**, Pronestyl for, 103
- Arteriosclerosis**, lipoproteins in, 109
- Artery**  
disease  
  lidar in, 31  
  oscillograms in, 109  
  pulmonary, size of, 99  
  substitutes, 31
- Arthritis**  
with peptic ulcer, 157  
rheumatoid  
  adrenocortical function in, 34  
  experimental, 224  
  sera in, 20
- Asolectin**, and proaccelerin, 199
- Asthma**, bronchial, ACTH therapy in, 17
- Atrial septal defect**  
electrocardiogram of, 95  
lesser circulation in, 96
- Azotemia**, glucose tolerance in, 220
- Azygous vein**, recognition of, 113
- Bacteremia**, transfusion in, 19
- Ballistocardiography**  
and calcium, 103  
high-frequency, 28
- Basal ganglia disorders**, reserpine for, 44
- Biopsy**  
of parietal pleura, 154  
renal, 139
- Bladder obstruction**, 251
- Blood**, 5-8, 26-28, 51-54, 77-90, 196-201, 232-238  
bank storage, 196  
and *Candida albicans*, 40  
deficiency syndrome, 197  
dialyzer, new, 22  
disorders  
  cholinesterase in, 52  
  glycoproteins in, 89  
  and neoplastic tissue, 82  
flow  
  coronary, and myocardial hypoxia, 10  
  determination of coronary, 55  
  in hypotension and hemorrhage, 206  
  peripheral, in cirrhosis, 147  
  group A in pernicious anemia, 83  
  hemophilic A, transfusions of, 5  
  levels and insulin and Orinase, 242  
  plasma volume determination, 90  
  pressure and behavior, 30  
  proteins, 91-93  
  separation by Cohn fractionator, 52  
  storage in hypersplenism, 53  
  thyrotropin disappearance in, 60  
  volume  
    and aldosterone, 126  
    determination, 89
- Blood cell(s)**  
red  
  binding capacity of, 33  
  in blood bank storage, 196  
  Cr<sup>51</sup>-labeled, 52  
  destruction of, 81  
  and hydrocortisone, 79  
  life-span, 79  
  and polyvalent cations, 79  
  potassium and rubidium incorporation by, 52  
  production, and iron turnover, 197  
  sensitizers, 26  
  surfaces, 197  
  survival, 80  
    in hemoglobinopathy, 26  
    studies of, 7  
    after transfusion, 196  
  uptake, and cobalt, 232  
white  
  dynamics of, 8  
  and hydroxysteroids, 211  
  effect of temperature on, 53  
  viability of, 86  
  volume in leukemia, 235
- Bone**  
and acid-base balance, 36  
marrow  
  analysis of, 222  
  gelatinous, 238  
  Hodgkin's disease of, 236
- Bromine**, and thyroid function, 242
- Bromsulphalein**, and chlorpromazine, 144
- Bundle branch block**, left, diagnosis of, 103
- Burns**, myocardial alteration in, 58
- Calcium**  
and ballistocardiogram, 103  
in acidosis and tetany, 153
- Calciuria**, and poliomyelitis, 64
- Cancer**, 54-55  
reducing agents in, 54
- Candida albicans***, and blood, 40
- Capillary bed**  
hematocrit of, 110  
in hypertension, 106
- Carbohydrate**  
ingestion, and lipemia, 121  
protein-bound, 255
- Carbon dioxide**  
inhalation, in emphysema and hypercapnia, 21  
patterns, 68
- Carbonic anhydrase inhibition**, renal compensation for, 43
- Carbutamide**, and thyroid function, 241
- Carcinoma**, prostatic, fibrinogen in, 85
- Cardiovascular system**, 9-14, 28-32, 55-60, 94-113, 201-207, 238-241
- Cardiopneumopexy**, in coronary artery disease, 56
- Carotene**, and steatorrhea, 133
- Carotenemia**, 130
- Catheterization**, in aortic stenosis, 97
- "Cerebral embolization,"** 99
- Cheyne-Stokes respiration**, 154
- Chlorpromazine**  
and bromsulphalein, 144  
and gastric secretion, 130  
in hyperkalemia, 37  
-induced water diuresis, 42  
and jaundice, 248
- Cholangiography**, 248
- Cholesterol**  
absorption of, 215  
and eggplant, 216
- Cholinesterase**  
in blood disorders, 52  
in nephrotic syndrome, 140
- Chondroitin determination**, 157
- Chromate<sup>51</sup> technic**, 7
- Circulation**  
capillary, 38  
cerebral, and mephentermine, 44  
mixing volumes in, 99
- Cirrhosis**  
ammonia metabolism in, 18, 146  
Dupuytren's contracture in, 148  
Neomycin in, 147  
peripheral blood flow in, 147  
portocaval shunt in, 147  
venous pressure in, 63
- Citric acid**, and hypercalcemia, 33
- Coagulation**  
defect, and proconvertin, 85  
in hemorrhage, 27  
and platelet morphology, 84
- Cobalt**  
and erythrocyte uptake, 232  
and thyroid function, 208
- Coenzyme A**, in heart failure, 105
- Cohn fractionator**, 52
- Colostrum**, intrinsic factor activity of, 5
- Commissurotomy**, aortic, appraisal of, 202
- Corticosteroids**  
hydroxylation of, 211  
in neoplastic disease, 35
- Cortisone**  
and glucose tolerance, 125  
in Von Gierke's disease, 213
- Creatine and creatinine levels**, and age and sex, 36
- Dead space**, respiratory, measuring of, 46
- Defibrillation**, transesophageal ventricular, 105
- Dehydrogenase activity**, lactic, 13
- Depressants**, CNS, 45
- Dextran sulfate**, 236
- Diabetes**  
fructose feeding in, 123  
glycogenolysis in, 124  
insipidus  
  Pitressin-resistant, 136  
  water and electrolytes in, 136  
  mellitus, and tolbutamide, 243
- Diamox**, 43, 128, 135
- Diet**, and kidney function, 137
- Digitalization**, and acetylcholine, 58
- Digoxin**  
effect of in normals, 205  
in heart failure, 204  
and kidney, 30
- Dihydroxytyrosine**  
in liver disease, 145  
metabolism of, 15
- Diuresis**  
Diamox in, 128  
and factors other than antidiuretic hormone, 21  
osmotic, 138  
water, chlorpromazine-induced, 42

- Duodenum**, apomorphine and, 131  
**Dupuytren's contracture**, 148
- Ebstein's malformation**, 94  
**Ecolid**, 58  
   in hypertension, 107  
**Ecology**, 113-114  
**Edema**, nephrotic, 139  
**Education**, medical, 115-118, 161-167
- Eisenmenger's syndrome**, hemodynamics of, 94
- Electrocardiography**  
   in atrial septal defect, 95  
   in auricular flutter, 9  
   in hypertrophy, 56  
   in paracentesis, 30
- Electrolytes**, and pancreas, 132
- Electrophoresis**  
   of lipids, 62  
   and lipoproteins, 254  
   in myoglobinuria, 90  
   in poliomyelitis, 133  
   of polysaccharides, 91
- Emphysema**  
   CO<sub>2</sub> inhalation in, 21  
   dead space in, 151  
   exercise in, 47  
   respiratory acidosis in, 67  
   salicylates in, 152  
   and smoking, 151  
   vagus nerve in, 46  
   Valsalva maneuver in, 67  
   venous-arterial admixture in, 152
- Endocarditis**, bacterial, prognosis of, 249
- Endocrines and metabolism**, 14-18, 32-38, 60-62, 118-131, 207-217, 241-246
- Endometrium**, secretory, 214
- Endotoxin(s)**  
   and infection, 134  
   shock, 110
- Epinephrine**, metabolic action of, 214
- Erythrocytes**, *see* Blood cells, red
- Erythropoiesis**  
   measurement of, 77  
   stimulation of, 78
- Ethylene glycol kidney**, 44
- Exercise**, 151  
   in emphysema, 47  
   and hypertension, 12
- Fat**  
   absorption, 62  
   and lipid fractions, 245  
   and serum lipids, 216
- Fava bean**, hemolysis and, 7
- Fertility**, 217
- Fever**, rheumatic, 155  
   prednisone in, 156  
   salicylates in, 156
- Fibrillation**, auricular  
   after mitral valvotomy, 57  
   drug screening in, 203  
   quinidine for, 204
- Fibrinogen**, in prostatic carcinoma, 85
- Fibrinolysin**, inhibition of, 199
- Flutter**  
   atrial, hemodynamics of, 104  
   auricular, 9
- Frenquel**, 253
- Fructose**, in diabetes, 123
- Galactose**, and glucose, 209
- Ganglionic blocking drugs**, mechanism of, 107
- Gastrointestinal system**, 18-19, 39-40, 62-64, 130-133, 217-218, 247-249
- Globulin**  
   antihemophilic, 198  
   gamma, measurement of, 93  
   hexosamine content of, 92  
   immune, i.v., 92
- Glomerulonephritis**, renal biopsy in, 139
- Glucagon**  
   in diabetes, 124  
   and insulin, 209  
   metabolism and insulin, 61
- Glucose**  
   and appetite, 210  
   concentration, estimation of, 243  
   and galactose, 209  
   tolerance  
     in azotemia, 220  
     and cortisone, 125
- Glutamine**, and ammonia production, 43
- Glycogen**, megakaryocyte, 84
- Glycolysis**, in thrombocytes, 5
- Glycoproteins**, in blood disorders, 89
- Goiter**, accessory thyroid in, 60
- Granuloma**, and vasculitis, 8
- Gynecology**, 64
- Headache**, 111
- Heart**  
   disease  
     cardiopneumopexy in, 56  
     and posture, 66  
     sitosterol in, 55  
     transaminase in, 102  
   electric dipole in, 201  
   failure  
     and ACTH, 11  
     Acylandid for, 204  
     coenzyme A in, 105  
     complete right, 29  
     Digoxin in, 204  
     left, lung in, 223  
     and norepinephrine, 106  
     potassium during, 106  
     splanchic hematocrit in, 11  
     test for, 29  
   lesions, hemodynamics in, 56, 201  
   murmur, cause of, 238  
   pressure artifact, 201
- Hematocrit**  
   of forearm capillary bed, 110  
   splanchic, in heart failure, 11
- Hemoglobin**  
   D disease, 233  
   molecular diseases of, 26  
   synthesis, iron in, 51
- Hemoglobinopathy**, red cell survival in, 26
- Hemolysis**  
   and fava bean, 7  
   splenic, 6
- Hemophilia**, vascular, 53
- Hemorrhage**  
   and ammonia metabolism, 63  
   gastrointestinal, 18  
   of obscure etiology, 27  
   and steroids, 237
- Hemostasis**, and gastrointestinal hemorrhage, 18
- Heparin**, and dextran, 236
- Heparinization**, arterial, 59
- Hepatitis**  
   and transaminase activity, 19  
   venous pressure in, 145
- Hexamethonium**, for hypertension, 59
- Hexosamine**, in serum globulin, 92
- Hodgkin's disease**, of bone marrow, 236
- Hormone**, thyroid  
   effect of TSH on, 32  
   radiochromatography of, 14
- Hufnagel valve**  
   and aortic insufficiency, 239  
   hemodynamic effects of, 9
- Hyaluronidase**, in renal failure, 221
- Hydrocortisone**  
   disappearance of, 212  
   and electrolyte exchanges of erythrocytes, 79  
   and triiodothyronine, 15  
   in Von Gierke's disease, 213
- Hydroxycorticoids**, in peptic ulcer, 131  
   studies, 210
- Hydroxysteroids**, and leukocytes, 211
- Hypercalcemia**  
   acute, and renal function, 14  
   and citric acid, 33  
   idiopathic, in infancy, 36
- Hypercapnia**  
   CO<sub>2</sub> inhalation in, 21  
   salicylates in, 152  
   sequelae of, 239
- Hypercholesterolemia**  
   albumin deficiency in, 220  
   lipoproteins in, 91
- Hyperglobulinemia**, study of, 92
- Hyperglycemia**  
   and glucocorticoid potency, 244  
   potassium for, 122
- Hyperkalemia**  
   chlorpromazine in, 37  
   resin therapy for, 37
- Hyperlipemia**  
   albumin deficiency in, 220  
   and anemia, 6  
   lipoproteins in, 91
- Hyperplasia**, adrenal, prednisone for, 212
- Hypersplenism**, blood storage in, 53
- Hypertension**  
   and aldosterone, 11  
   capillary bed in, 106  
   Ecolid for, 58, 107  
   and exercise, 12  
   eyeground manifestations of, 107  
   hexamethonium for, 59  
   pentolinium for, 108  
   primary pulmonary, 238  
   psychologic stress in, 206  
   and reserpine, 12, 241
- Hyperthyroidism**  
   adrenocortical function in, 119  
   evaluation of, 119  
   I<sup>131</sup> uptake in, 60
- Hypertrophy**, ventricular, electrocardiogram in, 56

- Hypoglycemia**  
 insulin and ketosis, 122  
 ketosis in, 124  
 and U-2043, 124
- Hypotension**  
 alkali therapy in, 109  
 neurogenic, and blood flow, 206
- Hypoventilation**, 153
- Hypoxia**, myocardial, and increased coronary blood flow, 10
- I<sup>127</sup> concentration and determination**, 119, 208
- I<sup>131</sup>**, in leukemia and myeloma, 200
- Illdar**, in arterial disease, 31
- Infarction, pulmonary**, transaminase in, 205  
*see* Myocardial infarction
- Infection**  
 adenovirus, 250  
 pulmonary, 19
- Infectious diseases**, 19-20, 40-41, 64-65, 133-135, 218-220, 249-251
- Inflammation**, buccal trypsin in, 23
- Inflammatory disease**, nicotinic acid in, 22
- Infusuria, CIBHA**, 234
- Insufficiency**  
 adrenal, treatment of, 16  
 aortic, and endocarditis, 239  
 coronary, and transaminase, 101  
 mitral, and mitral stenosis, 9  
 pancreatic, 40  
 renal, 138
- Insulin**  
 and blood level, 242  
 and gamma globulin, 123  
 and glucagon metabolism, 61, 209  
 hypoglycemia, and ketosis, 122  
 and pentoses, 122  
 plasma-binding of, 61, 209
- Intestinal absorption**, 132
- Ion exchange resins**, in extraction studies, 38
- Iron**  
 absorption, 51  
 deficiency anemia, 78  
 excess, 198  
 in hemoglobin synthesis, 51  
 overload, 232  
 turnover, and erythrocyte production, 197
- Ischemia, renal**, and renal function, 42
- Jaundice**, chlorpromazine and, 248
- Joints**, 20, 41
- Ketosis**, and hypoglycemia, 122, 124
- Kidney**, 20-21, 41-44, 65-66, 135-143, 220-221, 252-253  
 and acidosis, 137  
 and amino acid loading, 65  
 anoxic, 221  
 artificial, 68  
 autotransplanted, 253  
 biopsy, 139  
 and carbonic anhydrase inhibition, 43
- and chlorpromazine, 42  
 and Digoxin, 30
- disease**  
 anemia in, 141  
 protein in, 141
- ethylene glycol, 44
- failure**  
 hyaluronidase in, 221  
 management of, 251
- function**  
 and acute hypercalcemia, 14  
 after occlusion, 65  
 and posture, 66  
 and renal ischemia, 42  
 and temperature, 42
- insufficiency, 138, 252
- osmotic diuresis in, 138
- potassium in, 136
- pre-eclampsia and, 143
- pregnancy and, 142
- rubidium in, 136
- scarring of, 252
- and sickling, 81
- steroids and, 125
- and sympathetic nervous system, 41
- in systemic sclerosis, 20
- and urine concentration, 137
- venous pressure of, 252
- and water-loading, 220
- weight, estimation of, 135
- Klebsiella**, in pulmonary disease, 134
- Korotkoff sound**, 94
- Lesions**, mitral valve, 96
- Leukemia**  
 granulocytic, sex difference in, 88  
 I<sup>131</sup> in, 200  
 leukocyte volume in, 235  
 lymphatic, archlorethamine for, 88  
 myelogenous  
 alkaline phosphatase in, 87  
 mercaptopurine-cortisone for, 88  
 prednisone in, 200  
 and temperature, 53  
 and transfusion, 200  
 uric acid in, 54
- Leukocytes**, *see* Blood cells, white
- Leukopenia**, and leukoagglutinins, 87
- Lipemia**, carbohydrate ingestion and, 121
- Lipid(s)**  
 electrophoretic study of, 62  
 fractions, and fat, 245  
 serum, and fat, 216
- Lipoprotein(s)**  
 in arteriosclerosis, 109  
 electrophoresis of, 254  
 in hyperlipemia and hypercholesteremia, 91  
 and soy bean, 91
- Liver**, 144-149  
 carcinoid, serotonin "crisis" in, 37  
 disease  
 diiodotyrosine and triiodothyronine in, 145  
 and protein, 148  
 transaminase in, 63, 102  
 and vitamin B<sub>12</sub>, 144
- zinc sulfate turbidity test in, 146
- function**  
 and alcohol, 248  
 test, 39  
 alcohol in, 247
- hemodynamics of, 18  
 and nephrectomy, 221
- injury, transaminase levels in, 39
- and transaminase, 144, 145  
*see also* Cirrhosis
- Lung**  
 diffusion capacity, 150  
 disease, *Klebsiella* in, 134  
 function, 67  
 infection, 19  
 in left-sided heart failure, 223  
 and plasmin, 257  
 tests of, 256  
 volume changes in, 66  
 volume and kinetics, determination of, 223
- Lupus erythematosus**, therapy of, 54, 77
- Lysergic acid**, and reserpine, 247
- Magnesium**, distribution and excretion of, 14, 127
- Maximal breathing capacity**, 256
- Menstrual disorders**, x-ray therapy for, 214
- Mephentermine**, and cerebral circulation and metabolism, 44
- Mercaptopurine - cortisone**, in myelogenous leukemia, 88
- Metabolism** (*see also* Endocrines and metabolism)  
 cerebral and mephentermine, 44  
 myocardial  
 during exercise and hypoxia, 100  
 and smoking, 100  
 and *Rhizopus oryzae*, 40  
 platelet, 5  
 and stress, 126
- Metaplasia, myeloid**, alkaline phosphatase in, 87
- Methods**, 223, 254-255
- Microelectrochromatography**, 223
- Mucus, cervical**, study of, 64
- Muscle**  
 cells, cation accumulation by, 150  
 and plasma sodium, 150  
 and potassium deficiency, 149
- Muscular dystrophy**, aminoaciduria in, 216
- Myelofibrosis-myeloid metaplasia syndrome**, 86
- Myeloma**, 237  
 I<sup>131</sup> in, 200
- Myocardial infarction**  
 Q-waves in, 10  
 transaminase in, 30, 101, 240
- Myocardium**, and burns, 58
- Myoglobinuria**, electrophoresis in, 90
- Myotonia dystrophica**, and aminoaciduria, 216
- Myxedema**, adrenocortical function in, 119
- Necrosis**, and norepinephrine, 241
- Neomycin**, in cirrhosis, 147



- Neoplastic disease**, 221-223  
and antibody formation, 83  
corticosteroids in, 35  
treatment of, 221
- Nephrectomy**, and urea synthesis, 221
- Nephron function**, 151
- Nephrotic syndrome**, 250  
cholinesterase levels in, 140  
edema in, 139  
new state associated with, 140  
prednisone for, 17  
steroid therapy in, 141
- Nervous system**, 44-46, 253-254  
central, depressants, 45  
and muscle, 149-150  
sympathetic, and kidney function, 41
- Nicotinic acid**, in inflammatory disease, 22
- Nitrogen clearance rates**, 256
- Norepinephrine**  
large doses of, 106  
and necrosis, 241
- Novobiocin**, in bacterial pneumonia, 135
- Nucleic acid**, analysis of bone marrow, 222
- Nucleotidase**, in serum, 246
- Obesity**  
and physical activity, 126  
and polycythemia, 47
- Orinase**, and blood level, 242
- Osteolytic disease**, 245
- Ostium primum defect**, diagnosis of, 95
- Ovarietomy**, and body weight, 35
- Oxygen**  
poisoning, 68  
saturation, determination of, 255
- Oxyphenonium bromide**, and gastric secretion, 218
- Pain spot densities**, 45
- Pancreas**  
electrolyte secretion of, 132  
insufficiency of, 40
- Pancreatitis**, diagnosis of, 132
- Paracentesis**, electrocardiogram in, 30
- Parathyroid activity**, 121
- Paratoluene sulfonylbutylurea**, 124
- Penicillin resistance**, 249
- Pentolinium**, for hypertension, 108
- Pentoses**, and insulin, 122
- Pepsinogen excretion**, increased, 247
- Pericarditis**, and transaminase, 101, 205
- pH**, and serum potassium, 127
- Phosphate**, and triiodothyronine, 121
- Pitressin-resistant diabetes insipidus**, 136
- Plasma osmolality**, in disease, 129
- Plasmin**, and lung, 257
- Platelet**  
function, in hemorrhage, 27  
metabolism, 5  
morphology, during coagulation, 84
- Plethysmography**, venous occlusive, 111
- Pleura**, biopsy of, 154
- Pneumonia**, bacterial, novobiocin for, 135
- Poliomyelitis**  
and calcicuria, 64  
electrophoresis in, 133
- Polycythemia**, 235  
and obesity, 47  
uric acid in, 54  
venous-arterial admixture in, 47, 152
- Polysaccharides**, electrophoresis of, 91
- Potassium**  
and acid-base disorders, 215  
during congestive failure, 106  
deficiency, 149  
and adrenocortical function, 213  
and extracellular pH, 127  
for hyperglycemia, 122  
renal transport of, 136  
and sickling, 80
- Prednisone**  
in adrenal hyperplasia, 212  
and gastric secretion, 218  
in hemolytic anemia, 82  
in leukemia, 200  
in nephrotic syndrome, 17  
in rheumatic fever, 156
- Pre-eclampsia**, renal lesions of, 143
- Pregnancy**  
kidney in, 142  
protein-bound iodine during, 121
- Pressure(s)**  
heart, artifact, 201  
intraluminal, 130  
venous, 39  
in cirrhosis, 63  
in hand, 112  
in hepatitis, 145  
measurement of, 32
- Proaccelerin**, and Asolectin, 199
- Proconvertin deficiency**, 85
- Prolactin**, bioassay for, 215
- Pronestyl**, and arrhythmias, 103
- Properdin levels**, in disease, 93
- Protein(s)**  
and liver disease, 148  
plasma binding capacity of, 33  
in renal disease, 141  
transcapillary leakage of, 13
- Proteinuria**, orthostasis in, 139
- Psychosomatics**, 114
- PTA deficiency**, 6
- Pulse**  
aortic, 203  
and vasodilators, 206
- Purpura**, hyperglobulinemic, 237
- Pyelonephritis**, 66  
and bacterial species, 143
- Pyrazinamide**, and uric acid, 246
- Quinidine**  
in auricular fibrillation, 204  
hemodynamic effects of, 104
- Q-wave**, in myocardial infarction, 10
- Radiochromatography**, of thyroid hormones, 14
- Reserpine**  
in basal ganglia disorders, 44  
and gastric secretions, 62  
and hypertension, 12, 241  
and serotonin and LSD, 247
- Respiratory system**, 21-22, 46-48, 66-69, 150-155, 223-224, 256-257
- Rheumatism**, 155-158, 224
- Rhizopus oryzae**, and metabolism, 40
- Rose Bengal**, in liver function test, 39
- Rubidium**  
renal transport of, 136  
uptake of, 28
- Salicylates**  
in acidosis, 152  
in emphysema and hypercapnia, 152  
in rheumatic fever, 156
- Sarcoidosis**  
epidemiology of, 114  
systemic, 257
- Schilling test**, evaluation of, 83
- Schizophrenia**, serotonin metabolism in, 149
- Scintigram**, in thyroid disease, 242
- Sclerosis**  
experimental, 240  
systemic, renal involvement in, 20
- Semen**, frozen, 217
- Serotonin**  
"crisis," in carcinoid of liver, 37  
in hemorrhage, 27  
metabolism, in schizophrenia, 149  
and reserpine, 247
- Sex**  
and creatine and creatinine levels, 36  
difference, in granulocytic leukemia, 88
- Shock**  
endotoxin, 110  
hemorrhagic, and blood flow, 206
- Sickle cell(s)**  
disease, diagnosis of, 27  
-hemoglobin D disease, 233  
kidney in, 81  
and potassium, 80
- Sitosterol**, in heart disease, 55
- Skin**, 22, 158  
lesions, and steroids, 237  
pain spots in, 45
- Smoking**  
and emphysema, 151  
and myocardial metabolism, 100  
vasoconstrictor effects of, 110
- Sodium deficiency**, 244
- Soy bean**, and serum lipoproteins, 91
- Spherocytosis**, hereditary, 83, 198
- Spleen**, hemolysis in, 6
- Splenic hemolytic system**, 81
- Staphylococci**, Neomycin-resistant, 249
- Statistics**, 225
- Steatorrhea**, and carotene, 133
- Stenosis**  
aortic  
catheterization in, 97  
hemodynamics in, 202  
arterial, 238  
mitral  
anatomy and physiology of, 96

- Stenosis** (*Cont'd*)  
 blood volume and hematocrit in, 96  
 and mitral insufficiency, 9  
 pulmonic, surgery for, 202  
 surgery for, 57  
 tricuspid  
   clinical and physiologic aspects of, 98  
   diagnosis of, 98, 100  
   recognition of, 10  
   valvular, test for, 29
- Sterilization**, intestinal, 219
- Steroid(s)**  
 absorption spectra of, 15  
 blood, analysis of, 33  
 and skin lesions, 237  
 and sodium and water excretion, 125  
 structure and function of, 125  
 therapy  
   body composition during, 16  
   in nephrotic syndrome, 141
- Stomach secretion**  
 and chlorpromazine, 130  
 and prednisone and oxyphenonium bromide, 218  
 and reserpine, 62
- Streptococci**  
 and age, 155  
 antigenicity of, 157
- Stress**  
 and metabolism, 126  
 psychologic, in hypertension, 206
- Sugar**, spinal fluid, 156
- Sympathectomy**, 109
- Synovial fluids**, sources of, 41
- Syphilis**, diagnosis of, 218, 219
- Temperature**  
 and leukocytes, 53  
 maintenance, 207  
 and peripheral veins, 13  
 and renal function, 42
- Testosterone administration**, and uropepsin excretion, 218
- Tetany**, calcium in, 153
- Therapeutics**, 22-23, 158
- Thrombocytes**, glycolysis in, 5
- Thrombocythemia**, coagulation in, 236
- Thromboplastin-thrombin generation test**, 85
- Thrombosis**  
 atrial, angiocardigraphic diagnosis of, 99  
 venous, mechanisms of, 112
- Thyroid**  
 accessory, in goiter, 60  
 disease  
   clinical and hemodynamic studies in, 120  
   diagnosis of, 242  
 function  
   and bromine, 242  
   and carbutoamide, 241  
   and cobalt, 208  
   hormones, serum pattern of, 118
- Thyrotropin**  
 assay for, new, 207  
 disappearance, 60  
 and thyroid hormones, 32
- Tolbutamide**, and diabetes, 243
- Transaminase**  
 in coronary insufficiency and pericarditis, 101  
 in hepatitis, 19  
 and liver, 144, 145  
 in liver disease, 63  
 in liver injury, 39  
 in liver and heart disease, 102  
 in myocardial infarction, 30, 101, 240  
 in pulmonary embolization, 155  
 in pulmonary infarction and pericarditis, 205  
 in trauma, 102
- Transfusion(s)**  
 in bacteremia, 19  
 erythrocyte survival after, 196  
 of hemophilic A blood, 5  
 and leukemia, 200  
 and leukoagglutinins, 87
- Treponema pallidum test for syphilis**, 218, 219
- Trilodothyronine**  
 and hydrocortisone, 15  
 in liver disease, 145  
 metabolism of, 15  
 and phosphate, 121
- Tritium**, in lung volume and kinetics, 223
- Trypsin**, buccal, in inflammation, 23
- Tumor**, and antibiotics, 222
- Ulcer**  
 duodenal, and pepsinogen excretion, 247  
 peptic  
   ACTH in, 39  
   adrenocortical activity in, 131  
   with arthritis, 157  
   hydrocorticoids in, 131
- Uric acid**  
 metabolism, in leukemia and polycythemia, 54  
 and pyrazinamide, 246
- Urine**  
 concentration, in sickle cell anemia, 7  
 thyrotropic activity of, 60
- Uropepsin excretion**, and testosterone administration, 218
- Urticaria pigmentosa**, 158
- Vagus nerve**, in emphysema, 46
- Valsalva maneuver**, in emphysema, 67
- Valve**, aortic, disease, pressure pulses in, 97
- Valvotomy**, mitral, auricular fibrillation after, 57
- Vascular sounds**, 94
- Vasculitis**, and granuloma, 8
- Venography**, evaluation of, 32
- Venous tone**, measurement of, 112
- Viruses**, inactivation of, 65
- Vital capacity**, 256
- Vitamin B<sub>12</sub>**, absorption, 83, 234  
 and liver disease, 144
- Von Gierke's disease**, cortisone and hydrocortisone in, 213
- Waldenstrom's syndrome**, 237
- Water**  
 body, distribution of, 217  
 -loaded man, 220  
 transport, 217
- X-ray therapy**, in menstrual disorders, 214
- Zinc sulfate turbidity test**, in liver disease, 146

